MD Anderson IND Sponsor Cover Sheet  
Protocol ID  2017 -0339  
Protocol Title  A phase Ib/II trial of M7824 in solid tumors with microsatellite 
instability, with Consensus Molecular Subtype 4 metastatic colorectal 
cancer in combination with radiation, or in colorectal cancer patients with 
detectable circulating tumor DNA following definitive therapy  
Phase  Ib/II 
Protocol Version  9.0 
Version Date  June 25, 2020  
Protocol PI  Van Morris, MD  
Department  GI Medical Oncology  
IND Sponsor  MD Anderson Cancer Center  
IND #  137789  
Proprietary of MD Anderson Cancer Center
  1/106 
   
Clinical Trial Protocol  
Clinical Trial Protocol Number  MDA # 2017 -0339  
Title  A phase Ib/II trial of M7824 in solid tumors with 
microsatellite instability, with Consensus Molecular 
Subtype 4 metastatic colorectal cancer  in 
combination with radiation, or in colorectal cancer 
patients with detectable circulating tumor DNA 
following definitive therapy  
Phase  Ib/II 
IND Number  137789 
Principal  Investigator Van Morris, MD  
The University of Texas – MD Anderson Cancer 
Center  
Houston, TX USA 
  
Sponsor  MD Anderson Cancer Center , Houston, TX USA  
 
Clinical Trial Protocol Version   June 25, 2020/ Version 9.0  
Replaces Version  May 23, 2019/Version 8.0  
Proprietary of MD Anderson Cancer Center
  2/106 
  Protocol T able of Contents   
Protocol Table of Contents ..................................................................................................2  
List of Abbreviations ...........................................................................................................6  
1 Sponsor, Investigators and Trial Administrative Structure  ................27  
2 Background Information .....................................................................27  
2.1 Investigational Product .......................................................................27  
2.1.1  Safety  ..................................................................................................28  
2.2 Non-Clinical Findings for M7824 ......................................................32  
2.2.1  In Vitro and in Vivo Pharmacology Findings .....................................32  
2.2.2  Pharmacokinetics / Immunogenicity Findings ...................................34  
2.2.3  Toxicology ..........................................................................................35  
2.2.4  Brief Summary of the Clinical Findings for M7824 ..........................35  
2.2.5  Rationale for Cohorts ..........................................................................36  
2.2.6  Summary of the Overall Benefit and Risk  ..........................................39  
3 Trial Objectives  ..................................................................................42  
3.1 Primary Objective  ...............................................................................42  
3.2 Secondary Objectives  .........................................................................42  
3.3 Exploratory Objectives  .......................................................................43  
4 Investigational Plan  ............................................................................44  
4.1 Overall Trial Design and Plan  ............................................................44  
4.1.2  Planned number of subjects ................................................................45  
4.1.3  Planned treatment duration .................................................................46  
4.1.4  Dose Modification and ADRs Requiring Treatment 
Discontinuation ...................................................................................46  
4.1.5  Analysis Cut -Off Dates  .......................................................................48  
4.2 Discussion of Trial Design  .................................................................48  
4.2.2  Inclusion of Special Populations ........................................................50  
4.3 Selection of Trial Population  ..............................................................50  
4.3.1  Inclusion criteria  .................................................................................50  
4.3.2  Exclusion criteria  ................................................................................51  
4.4 Criteria for Initiation of Trial Treatment  ............................................53  
4.5 Criteria for Subject Withdrawal  ..........................................................53  
4.5.1  Withdrawal from Trial Treatment ......................................................53  
Proprietary of MD Anderson Cancer Center
  3/106 
  4.5.2  Withdrawal from the Trial  ..................................................................54  
4.6 Premature Termination of the Trial  ....................................................54  
4.7 Definition of End of Trial ...................................................................55  
5 Investigational Medicinal Product and Other Drugs Used in the 
Trial  .....................................................................................................55  
5.1 Description of the Investigational Medicinal Product ........................55  
5.2 Dosage and Administration ................................................................55  
5.3 Assignment to Treatment Groups .......................................................56  
5.4 Noninvestigational Medicinal Products to be Used ............................56  
5.5 Concomitant Medications and Therapies  ...........................................57  
5.5.1  Permitted Medicines  ...........................................................................57  
5.5.2  Prohibited Medicines  ..........................................................................57  
5.5.3  Special Precautions  .............................................................................59  
5.6 Packaging and Labeling of the Investigational Medicinal Product ....64  
5.7 Preparation, Handling, and Storage of the Investigational Medicinal Product ...............................................................................64
 
5.8 Investigational Medicinal Product Accountability  .............................65  
5.9 Assessment of Investigational Medicinal Product Compliance .........66  
5.10  Medical Care of Subjects after End of Trial  .......................................67  
6 Trial Procedures and Assessments ......................................................67  
6.1 Schedule of Assessments ....................................................................67  
6.1.1  Screening and Baseline Procedures and Assessments  ........................67  
6.1.2  Treatment period  .................................................................................68  
6.1.3  End of Treatment ................................................................................70  
6.1.4  Post Treatment Follow Up  ..................................................................71  
6.1.5  Blood Consumption for Clinical Assessments ...................................72  
6.2 Demographic and Other Baseline Characteristics  ..............................72  
6.2.1  Demographic Data ..............................................................................72  
6.2.2  Diagnosis of Tumor ............................................................................73  
6.2.3  Medical History  ..................................................................................73  
6.2.4  Vital Signs and Physical Examination ................................................73  
6.2.5  CT or MRI Scans for Tumor Assessment at Baseline  ........................74  
6.2.6  Cardiac Assessments ..........................................................................74  
Proprietary of MD Anderson Cancer Center
  4/106 
  6.2.7  Clinical Laboratory Tests  ...................................................................74  
6.3 Efficacy Assessments .........................................................................77  
6.4 Assessment of Safety  ..........................................................................78  
6.4.1  Adverse Events ...................................................................................79  
6.4.2  Pregnancy and In Utero Drug Exposure .............................................86  
6.4.3  Clinical Laboratory Assessments  .......................................................86  
6.4.4  Vital Signs, Physical Examinations, and Other Assessments .............88  
6.4.5  Biomarkers  ..........................................................................................89  
7 Statistics  ..............................................................................................95  
7.1 Sample Size Calculations  ...................................................................95  
7.1.1  Cohort A-C .........................................................................................95  
7.1.2  Cohort B ..............................................................................................95  
7.1.3  Cohort C .............................................. Error! Bookmark not defined.  
7.2 Randomization ....................................................................................95  
7.3 Endpoints ............................................................................................96  
7.3.1  Primary Endpoints ..............................................................................96  
7.3.2  Secondary Endpoints ..........................................................................96  
7.3.3  Exploratory Endpoints  ........................................................................96  
7.4 Analysis sets .......................................................................................96  
7.5 Descri ption of Statistical Analyses .....................................................96  
7.5.1  General Considerations  .......................................................................96  
7.5.2  Analysis of Primary Endpoint ............................................................97  
7.5.3  Analysis of Endpoints .........................................................................97  
7.6 Interim safety monitoring  ...................................................................99  
8 References Cited in the Text  .............................................................101  
 
  
 
  
Proprietary of MD Anderson Cancer Center
  5/106 
  Table of In-Text T ables  
 
Table 1: Schedule of Assessments (Cohort A -C) ................................................................8 
Table 2: Schedule of Assessments (Cohort B)  ..................................................................16 
Table 3: Schedule of Assessments (Cohort D ) ..................................................................22 
Table 4: Overview of TEAEs for the Dose Escalation Cohorts of M7824 .......................31 
Table 5: Adverse Events in Dose Expansion Cohort for CRC of M7824………………..33 
Table 6: Treatment Modification for Symptoms of Infusion- related Reactions Caused 
by M7824 ............................................................................................61 
Table 7 : Required Laboratory Panel Tests  .........................................................................92 
Table 8 : Toxicity stopping boundaries for Cohort A-C ...................................................103 
Table 9 : Operating Characteristics for Toxicity Monitoring in Cohort A -C ...................104 
Table 1 0: Toxicity stopping boundaries for Cohort B .....................................................104 
Table 1 1: Operating Characteristics for Toxicity Monitoring in Cohort B .....................104 
 
 
 
   
Proprietary of MD Anderson Cancer Center
  6/106 
  List of Abbreviations 
 
ADR  Adverse Drug Reaction  
AE Adverse Event  
ALT  Alanine Aminot ransferase  
AST  Aspartate Aminotransferase  
CIMP  CpG Island Methylator  Phenotype   
CMS  Consensus Molecular Subtype  
CRF  Case Report Form  
CR Complete Response  
CTCAE  Common Terminology Criteria for Adverse Events  
ctDNA  Circulating Tumor DNA  
DFS Disease -Free Survival  
DLT  Dose Limiting Toxicity  
EKG Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
GCP  Good Clinical Practice  
Hgb Hemoglobin  
IB Investigator’s Brochure  
ICH International Conference on Harmonization  
iCPD  Immune Confirmed Progressive Disease  
IEC Independent Ethics Committee  
IHC Immunohistochemistry  
IMP Investigational Medicinal Product  
INR International Normalized Ratio  
IRB Institutional Review Board  
ITT Intention To Treat  
iUPD  Immune Unconfirmed Progressive Disease  
IV Intravenous  
IVRS  Interactive Voice Response System  
LA Locally advanced  
mCRC  Metastatic Colorectal Cancer  
Proprietary of MD Anderson Cancer Center
  7/106 
  MoA  Mechanism of Action  
MSI Microsatellite Instability  
MSI-L Microsatellite In stability – Low 
MSI-H Microsatellite Instability  - High  
MSS  Microsatellite Stable  
NCI National Cancer Institute  
NFkB  Nuclear Factor Kappa Light Chain Enhanced of Activated B cells  
NK Natural Killer  
OS Overall Survival  
ORR  Objective Response Rate  
PCR  Polymerase Chain Reaction  
PD Progressive Disease  
PD-1 Programmed Death - 1 
PD-L1 Programmed Death Ligand 1  
PDx Pharmacodynamics  
PGx Pharmacogenetics/Pharmacogenomics  
PFS Progression Free Survival  
PK Pharmacokinetics  
PO Per Os  
PR Partial Response  
PS Performance Status  
RECIST  Response Evaluation Criteria in Solid Tumors  
ROS  Reactive oxygen species  
RR Response Rate  
SAE  Serious Adverse Event  
SBRT  Stereotactic Body Radiation Therapy  
Treg T-regulatory  
TGF -β Transforming Growth Factor β 
WBC  White Blood Cell  
ULN  Upper Limit of Normal  
UR Unresectable 
 
Proprietary of MD Anderson Cancer Center
8/106 Table 1: Schedule of Assessments ( Cohort A-C) 
Test Cycle  1  Cycle  2  Cycle  3 (and all 
subsequent cycles)  End-of-
Treatment 28-day
follow up
after 
progression Long 
term 
follow up  
Measure  Day -28 to 
treatment Day 1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation 
or within 7 
days after  Every 3 
months 
after 28 
day 
follow up  
Inclusion/exclusion 
criteria X X 
Demographic data  X 
Medical history  X 
Cancer disease history  X 
Prior anticancer drug/ radiotherapy/ 
procedures X 
Concurrent medications  X 
Written informed 
consent  X 
Enrollment (if eligible)a X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
9/106 Test Cycle  1  Cycle  2  Cycle  3(and all 
subsequent cycles)  End of 
Treatment 28day 
follow-up 
after 
progression Long-
term 
follow-up  
Measure  
Day -28 
to 
treatment Day 
1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of 
discontinuati
on or within 
7 days after  Every 3 
months 
after 28 -
day 
follow up  
Physical examinationb,p X X X X  X X X X X 
Vital signs including 
weightp and height 
(latest height on record 
acceptable ; height is 
only performed at 
screening) X X X X
 X X X X X X 
ECOG PSp X X X X  X X X X X X 
Toxicity assessmentp X X X X  X X X X X Xr 
12-lead EKGc,d, pX X X 
Full serum chemistrye, p X X X X X X X X X 
Complete blood counte,
pX X
 X X
 X X X X X 
Free T4, TSHe, f, p X X X 
ANA, RFe,  X X 
Urinalysis (dipstick)e, p X X X X X X  
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
10/106 β-HCG pregnancy test, 
FSH e, f,p X X X X Xo 
Test Cycle  1  Cycle  2  Cycle  3 (and all 
subsequent cycles)  End of 
treatment 28 day 
follow up 
after 
progression Long-
term 
follow-up  
Measure  Day -28 
to 
treatment Day 
1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of 
discontinuati
on or within 
7 days after  Every 3 
months 
after 28 -
day 
follow up  
HIV, HBV, HCV 
testing   X 
Documentation of AEs, 
concomitant medications, and 
procedures  q X X X X X X X Xq Xq X 
M7824 Administration  p Xt Xt X X X X 
Patient-reported outcomes 
p X X
 X X X X X 
Tumor biopsy  g,p X X X 
MSI testing  h X 
Tumor evaluation by imaging (w/collection of available staging 
imaging prior to study 
enrollment)
  l,j,p X X Xu Xq 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
11/106 Verification of available 
specimen for m utation 
profiling k X 
Test Cycle  1  Cycle  2  Cycle  3 (and all 
subsequent cycles)  End of 
Treatment 28 day 
follow up 
after 
progression Long-
term 
follow-
upr 
Measure  Day -28 
to 
treatment Day 
1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of 
discontinuati
on or within 
7 days after  Every 3 
months 
after 28 -
day 
follow up  
Verification of available 
specimen for TGFβ 
1,2,3 analysis  p X X X X
 Xs X 
Blood biomarkers (including circulating 
cytokines)   l,p X X X X  X X 
Collection of buccal 
and fecal swabs  for 
microbiome testingp X X Xs X 
Verification of available 
specimen for PD -L1 
expression m X X 
Collection of specimens 
for analysis of pharmacokinetics of 
M7824 
 n,p X X
 X X 
aEnrollment will be done after the confirmation of fulfilling all screening inclusion criteria without matching any exclusion criterion . 
bPhysical examination should include a dermatological examination.  If abnormal skin findings are observed, patient should be 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
12/106 referred to a dermatologist for biopsy of suspicious lesions. An ophthalmology examination including slit lamp evaluation inclusive of 
the anterior segment and with visual acuity should be conducted at Screening. At subsequent visits, eye signs and symptoms should be 
checked. If there are any clinically relevant findings then an appropriate ophthalmology examination including slit lamp evaluation 
inclusive of the anterior segment and with visual acuity should be obtained within 2 days. Starting with C1D15, a focused examination 
may be performed centered around patient’s symptoms at an assigned visit.  
c12-lead EKG  should be performed as soon after completion of infusion as possible.   
dEKGs are to be performed every 6 weeks.  
eLaboratory draws may be performed up to 72 hours before a scheduled treatment.  
fFor women of child-bearing potential.  FSH should be drawn if clarification of post- menopausal state is warranted.   Refer to 
Appendix 2 for further details. 
gMandatory fr esh tumor biopsies will be collected prior to treatment and prior to dose 3.  An optional tumor biopsy following 
progression may be offered to the patient. 
hPerformed on archival tissue or fresh biopsy. MSI testing performed in a CLIA certified laboratory is acceptable and does not need to 
be repeated (see section 6.4.5) 
iTumor me asurements should occur with CT imaging or MRI.  Ideally the same methodology would be used over the course of the 
study for a given patient. Bone scan should be done at screening if clinically indicated.  For collection of those prior imaging studies 
prior to informed consent, readily available imaging studies since the onset of metastatic/unresectable disease are to be prioritized for 
collection.   If the results of a CT scan or MRI performed within 4 weeks prior to first treatment are available, the screen ing CT and/or 
MRI does not need to be performed. 
jTumor measurements are to be assessed every 8 weeks (+/ - 5 days).  For subjects continuing treatment beyond 12 months, tumor 
evaluations should take place every 12 weeks (+/ - 5 days). 
kTo be performed on archival tissue or fresh biopsy either via hotspot next general sequencing panel in CLIA certified molecular 
diagnostics laboratory at MD Anderson.  
lPlasma will be sent for markers including, but not limited to, interleukin (IL) IL -1α, IL-1β, IL-2, IL -5, IL-6, IL-8, IL- 13, TNF -α, 
MCP, MIP -1β, G-CSF, GM -CSF, IFN -γ via a cytokine assay  ((Meso Scale Discovery (MSD), 40 Plex) . Leukocyte subpopulations and 
immune activation status will be assessed by flow cytometry (fluorescence -activated cell sorter [FACS]) on PBMC from hepariniz ed 
blood samples (10 mL, tubes). Additional time points to include for collection after cycle 3, day 1 include C4D1, C5D1, and C6D1.  No additional biomarker samples for this analysis will b e collected while the patient is receiving treatment on study. 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
13/106 mPD-L1 expression by immunohistochemistry on fresh biopsy. Repeat IHC on FRESH biopsy prior to dose 3 of  M7824 
nOne 10 mL vial of blood will be drawn prior to M7824 infusion and immediately following completion of M7824 infusion for doses 
1 and 3 (cycle 1 day 1 and cycle 2 day 1) for analysis of pharmacokinetics.  One 10 mL vial of blood will be drawn prior to M7824 
infusion of M7824 infusion for doses 2 (cycle 1 day 15) and dose 6/end of treatm ent (whichever comes first).  Refer to Section 6.4.3 
for details on processing of PK samples.  
oβ-hCG (no FSH) at post-progression follow-up visit 
pWindow of +/ - 7 days is allowed 
qAdverse events are recorded and assessed continuously throughout the trial (see Section 6.4.1.3) and are assessed for final outcome at 
the End of Treatment  visit. After the End of Treatment visit only AEs that are deemed attributable to trial drug by the Investigator 
should be documented until the Safety Follow-up visit. 
rFor up to one year following discontinuation of treatment on study.  
sCycle 3, Day 1 collection only.  
tPatients must remain at the CTRC for two hours of observation following the first two doses of therapy.   
uOnly to be performed if no disease progression was documented previously. 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
14/106 Table 2: Schedule of Assessments (Cohort B)  
Test Cycle  1  Cycle  2  Cycle 3 (and all 
subsequent cycles)  End-of-
Treatment 28 day 
follow up 
after 
progression  Long 
term 
follow up  
Measure  Day -28 to 
treatment Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation 
or within 7 
days after  Every 3 
months 
after 28 
day 
follow up  
Inclusion/exclusion 
criteria X X 
Demographic data  X 
Medical history  X 
Cancer disease history  X 
Prior anticancer drug/ radiotherapy/ 
procedures X 
Concurrent medications  X 
Written informed 
consent X 
Enrollment (if eligible)a X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
15/106 Test Cycle  1  Cycle  2  Cycle  3 (and all 
subsequent cycles)  End of 
Treatment 28 day 
follow-up 
after 
progression Long-
term 
follow-up  
Measure  
Day -28 
to 
treatment Day 
1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of 
discontinuati
on or within 
7 days after  Every 3 
months 
after 28 -
day 
follow up  
Physical examinationb,q X X X X  X X X X X 
Vital signs including 
weight and height 
(latest height on record acceptable)
q X X X X
 X X X X X X 
ECOG PSq X X X X X X X X X X 
Toxicity assessmentq X X X X  X X X Xs Xs X 
12-lead EKGc,d, qX X X 
Full serum chemistrye, q X X X X  X X X X X 
Complete blood counte,
qX X
 X X
 X X X X X 
Free T4, TSHe, f, q X X X 
ANA, RFe, X X 
Urinalysis (dipstick)e, q X X X X X X  
β-HCG pregnancy test, 
FSH e,  f,q X X X X Xp 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
16/106 Test Cycle  1  Cycle  2  Cycle  3 (and all 
subsequent cycles)  End of 
treatment 28 day 
follow up 
after 
progression Long-
term 
follow-up  
Measure  Day -28 
to 
treatment Day 
1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of 
discontinuati
on or within 
7 days after  Every 3 
months 
after 28 -
day 
follow up  
HIV, HBV, HCV 
testing   X 
Documentation of AEs, concomitant medications, and 
procedures 
q X X X X X X X Xr Xr X 
M7824 Administration q Xu Xu X X X X 
SBRT Adm inistrationw X 
Patient-reported 
outcomes q X X
 X X X X X 
Tumor collection g,q X Xx X X 
MSI testing h X 
Confirmation of CMS 
statusi X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
17/106 Test Cycle  1  Cycle  2  Cycle  3 (and all 
subsequent cycles)  End of 
Treatment 28 day 
follow up 
after 
progression Long-
term 
follow-ups 
Measure  Day -28 
to 
treatment Day 1 Day 15  Day 1  Day 15  Day 1  Day 15  Day of 
discontinuati
on or within 
7 days after  Every 3 
months 
after 28 -
day 
follow up  
Verification of available 
specimen for analysis of 
TGFβ 1,2,3 q X X X X
 Xt X 
Tumor evaluation by imaging (w/collection of available staging 
imaging prior to study 
enrollment)
 j,k,q X X Xv Xr 
Verification of available specimen for mutation  
profiling 
l X 
Blood biomarkers 
(including circulating 
cytokines)  m,q X X X X
 X X 
Collection of buccal and fecal swabs  for 
microbiome testingq X X Xt X 
Verification of available specimen for PD -L1 
expression 
n X X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
18/106 Collection of samples 
for pharmacokinetics of 
M7824o,q X X
 X X 
aEnrollment will be done after the confirmation of fulfilling all screening inclusion criteria without matching any exclusion criterion.  
bPhysical examination should include a dermatological examination.  If abnormal skin findings are observed, patient should be 
referred to a dermatologist for biopsy of suspicious lesions. An ophthalmology examination including slit lamp evaluation inclusive of 
the anterior segment and with visual acuity should be conducted at Screening. At subsequent visits, eye signs and symptoms should be 
checked. If there are any clinically relevant f indings then an appropriate ophthalmology examination including slit lamp evaluation 
inclusive of the anterior segment and with visual acuity should be obtained within 2 weeks, unless an urgent necessity is determined by the treating provider that requires a sooner evaluation . Starting with C1D15, a focused examination may be performed centered 
around patient’s symptoms at an assigned visit.  
c12-lead EKG should be performed as soon after completion of infusion as possible.   
dEKGs are to be performed every  6 weeks.  
eLaboratory draws may be performed up to 72 hours before a scheduled treatment. 
fFor women of child-bearing potential.  FSH should be drawn if clarification of post- menopausal state is warranted.  Refer to 
Appendix 2 for further details. 
gMandatory fresh tumor biopsies will be collected prior to treatment and prior to dose 2 (i.e., on cycle 1, day 15) and prior to dose 3.  
An optional tumor biopsy following progression may be offered to the patient. 
hMSI testing performed in a CLIA certifie d laboratory is acceptable and does not need to be repeated (see section 6.4.5) 
iCMS on FFPE at CLIA testing laboratory on archival primary tissue or fresh biopsy. 
jTumor measurements should occur with CT imaging or MRI.  Ideally the same methodology would be used over the course of the 
study for a given patient. Bone scan should be done at screening if clinically indicated. For collection of those prior imaging studies prior to informed consent, readily available imaging studies since the onset of metastat ic/unresectable disease are to be prioritized for 
collection.  If the results of a CT scan or MRI performed within 4 weeks prior to first treatment are available, the screenin g CT and/or 
MRI does not need to be performed. 
kTumor measurements are to be assessed every 8 weeks (+/ - 5 days).  For subjects continuing treatment beyond 12 months, tumor 
evaluations should take place every 12 weeks (+/ - 5 days). 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
19/106 lTo be performed on archival tissue or fresh biopsy either via hotspot next general sequencing panel in C LIA certified molecular 
diagnostics laboratory at MD Anderson.  
mPlasma will be sent for markers including, but not limited to, interleukin (IL) IL -1α, IL-1β, IL-2, IL -5, IL-6, IL-8, IL- 13, TNF -α, 
MCP, MIP -1β, G-CSF, GM -CSF, IFN -γ via a cytokine assay ( (Meso Scale Discovery (MSD), 40 Plex) . Leukocyte subpopulations and 
immune activation status will be assessed by flow cytometry (fluorescence -activated cell sorter [FACS]) on PBMC from heparinized 
blood samples (10 mL, tubes).  Additional time points to in clude for collection after cycle 3, day 1 include C4D1, C5D1, and C6D1.  
No additional biomarker samples for this analysis will be collected while the patient is receiving treatment on study. 
nPD-L1 expression by immunohistochemistry on fresh biopsy. Repeat IHC on FRESH biopsy prior to dose 3 of M7824 
oOne 10 mL vial of blood will be drawn prior to M7824 infusion and immediately following completion of M7824 infusion for dose s 
1 and 3 (cycle 1 day 1 and cycle 2 day 1) for analysis of pharmacokinetics.  One 10 mL vial of blood will be drawn prior to M7824 
infusion of M7824 infusion for doses 2 (cycle 1 day 15) and  dose 6/end of treatment (whichever comes first).  Refer to Section 6.4.3 
for details on processing of PK samples.  
pβ-hCG (no FSH) at post-progression follow-up visit 
qWindow of +/- 7 days is allowed 
rAdverse events are recorded and assessed continuously throughout the trial (see Section 6.4.1.3) and are assessed for final outcome at 
the End of Treatment  visit. After the End of Treatment visit only A Es that are deemed attributable to trial drug by the Investigator 
should be documented until the Safety Follow- up visit.  
sFor up to one year following discontinuation of treatment on study.  
tCycle 3, Day 1 collection only.  
uPatients must remain at the CT RC for two hours of observation following the first two doses of therapy.   
vOnly to be performed if no disease progression was documented previously. 
wSBRT administration (total 24 Gy over 3 consecutive business days at a daily fraction of 8Gy to start within 7 days following cycle 
1, day 15 and completed prior to cycle 2, day 1).  While SBRT is preferred, Intensity -modulated radiation therapy ( IMRT ) or 3D 
conformal techniques may be utilized at the discretion of the treating radiation oncologist depending on the dose to surrounding 
normal tissues.   Patient will receive a total dose of 24Gy over three days with one of the following modalities, at the discretion of the 
treating radiation oncologist: SBRT, IMRT and 3D conformal.     
xBiopsy to be performed cycle 1, day 15   
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
20/106 Ta
ble 3: Schedule of Assessments (Cohort D)  
Test Cycle  1  Cycle  2  Cycle  3  Cycle 4x (and all 
subsequent cycles)  End of 
treatment  Long term 
follow up  
Measure  Day -28 
to 
treatmen
t Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation or 
within 7 days 
after 28 
day 
follow 
up 
after 
progr
ession  Every 
3 
months 
after 
28 day 
follow 
up 
Inclusion/exclusion 
criteria X X 
Demographic data  X 
Cancer disease history  X 
Prior anticancer drug/ radiotherapy/ 
procedures  X 
Medical history  X 
Concurrent medications  X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
21/106 Vital signs including 
weightq and height 
(latest height on record 
acceptable ; height is 
only performed at 
screening ) X X X X  X X X X X X X 
Test Cycle  1  Cycle  2  Cycle  3  Cycle 4x (and all 
subsequent cycles)  End of 
treatment Long term 
follow up  
Measure  Day -28 
to 
treatmen
t Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation or 
within 7 days 
after 28 
day 
follow 
up 
after 
progr
ession  Every 
3 
months 
after 
28 day 
follow 
up 
Written informed consent X 
Enrollment (if eligible)a X 
Physical examinationb,q X X X X  X X X X X X X 
ECOG PSq X X X X  X X X X X X X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
22/106 Toxicity assessmentq X X X X  X X X X X Xs Xs 
Test Cycle  1  Cycle  2  Cycle  3  Cycle 4y (and all 
subsequent cycles)  End of 
treatment  Long term 
follow up  
Measure  Day -28 
to 
treatmen
t Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation or 
within 7 days 
after 28 
day 
follow 
up 
after 
progr
ession  Every 
3 
months 
after 
28 day 
follow 
up 
Documentation of AEs, 
concomitant 
medications, and 
procedures q X X X X X X X X X X X Xs 
12-lead EKGc,d, qX X X X X 
Full serum chemistrye, q X X X X  X X X X X X 
Complete blood counte,
qX X X X  X X X X X X 
Free T4, TSHe, f, q X X 
ANA, RFe, X 
Urinalysis (dipstick)e, q X X X X X X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
23/106 β-HCG pregnancy test, 
FSH e, t,q X X X X X 
HIV, HBV, HCV 
testing   X 
Test Cycle  1  Cycle  2  Cycle  3  Cycle 4x (and all 
subsequent cycles)  End of 
treatment  Long 
term 
follow 
up 
Measure  Day -28 
to 
treatmen
t Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation or 
within 7 days 
after  28 day 
follow 
up 
after 
progr
ession  Every 
3 
months 
after 
28 day 
follow 
up 
M7824 Administration 
qXu Xu X X X X X X 
Tumor biopsy g Xn 
Patient-reported 
outcomes q X X
 X X X X X X X 
MSI testing h X 
Verification of available specimen for mutation profiling 
m X 
Tumor evaluation by imaging (w/collection 
of available staging X 
X Xv Xs 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
24/106 imaging prior to study 
enrollment) j,k,q 
Verification of 
available specimen for 
TGFβ 1,2,3 q X X X X
 X X Xt X 
Test Cycle  1  Cycle  2  Cycle  3  Cycle 4x (and all 
subsequent cycles)  End of 
treatment  Long term 
follow up  
Measure  Day -28 
to 
treatmen
t Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day of dis -
continuation or 
within 7 days 
after 28 
day 
follow 
up 
after 
progr
ession  Every 
3 
months 
after 
28 day 
follow 
up 
Verification of available specimen for 
PD-L1 expression 
n X 
Collection of buccal and fecal swabs  for 
microbiome testingq X X X X 
Verification of 
available specimen for testing of 
pharmacokinetics of 
M7824  o,q X X  X X X 
Blood for collection of 
ctDNA X Xy X 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
25/106 aEnrollment will be done after the confirmation of fulfilling all screening inclusion criteria without matching any exclusion criterion. 
bPhysical examination should include a dermatological examination.  If abnormal skin findings are observed, patient should be 
referred to a dermatologist for biopsy of suspicious lesions. An ophthalmology examination including slit lamp evaluation inclusive of 
the anterior segment and with visual acuity should be conducted at Screening. At subsequent visits, eye signs and symptoms should be 
checked. If there are any clinically relevant findings then an appropriate ophthalmology examination including slit lamp evaluation 
inclusive of the anterior segment and with visual acuity should be obtained within 2 days. Starting with C1D15, a focused examination 
may be performed centered around patient’s symptoms at an assigned visit.  
c12-lead EKGs should be performed as soon after completion of infusion as possible.   
dEKGs are to be performed every 6 weeks.  
eLaboratory draws may be performed +/- 7 days of  a scheduled treatment.  
fFor women of child-bearing potential.  FSH should be drawn if clarification of post- menopausal state is warranted.  Refer to 
Appendix 2 for further details. 
gAn optional tumor biopsy following progression may be offered to the patient. 
hPerformed on archival tissue or fresh biopsy. MSI testing performed in a CLIA -certified laboratory is acceptable and does not need to 
be repeated (see section 6.4.5)  
iBlood for ctDNA collection to be dr awn after 14 days of completion of standard treatment. 
jTumor measurements should occur with CT imaging or MRI.  Ideally the same methodology would be used over the course of the 
study for a given patient. Bone scan should be done at screening if clinically indicated. For collection of those prior imaging studies 
prior to informed consent, readily available imaging studies since the onset of metastatic/unresectable disease are to be pri oritized for 
collection.  If the results of a CT scan or MRI performed within 4 weeks prior to first treatment are available, the screening CT and/or MRI does not need to be performed. 
kTumor measurements are to be assessed every 12 weeks (+/ - 5 days).  For subjects continuing treatment beyond 12 months, tumor 
evaluations shoul d take place every 12 weeks (+/ - 5 days). 
lTo be performed on archival tissue or fresh biopsy either via hotspot next general sequencing panel in CLIA certified molecul ar 
diagnostics laboratory at MD Anderson. TGFβR2, ACVR2A, SMAD2 and SMAD4 will need to be performed if not done previously. 
mPlasma will be sent for markers including, but not limited to, interleukin (IL) IL -1α, IL-1β, IL-2, IL -5, IL-6, IL-8, IL- 13, TNF -α, 
MCP, MIP -1β, G-CSF, GM -CSF, IFN -γ via a cytokine assay ( (Meso Scale Discovery (MSD), 40  Plex) . Leukocyte subpopulations and 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
26/106 immune activation status will be assessed by flow cytometry (fluorescence -activated cell sorter [FACS]) on PBMC from heparinized 
blood samples (10 mL, tubes). 
nPD-L1 expression by immunohistochemistry on archival tumor specimen or fresh tumor tissue (if available).  
oOne 10 mL vial of blood will be drawn prior to M7824 infusion and immediately following completion of M7824 infusion for dose s 
1 and 3 (cycle 1 day 1 and cycle 2 day 1) for analysis of pharmacokinetics.  One 10 mL vial of blood will be drawn prior to M7824 
infusion of M7824 infusion for doses 2 (cycle 1 day 15) and dose 6/end of treatment (whichever comes first).  Refer to Section 6.4.3 
for details on processing of PK samples.  
pβ-hCG (no FSH) a t post-progression follow-up visit 
qWindow of +/- 7 days is allowed 
rAdverse events are recorded and assessed continuously throughout the trial (see Section 6.4.1.3) and are assessed for final outcome at 
the End of Treatment  visit. After the End of Treatme nt visit only AEs that are deemed attributable to trial drug by the Investigator 
should be documented until the Safety Follow- up visit.  
sFor up to one year following discontinuation of treatment on study.  
tCycle 4, Day 1 collection only.  
uPatients must r emain at the CTRC for two hours of observation following the first two doses of therapy.   
vOnly to be performed if no disease progression was documented previously. 
wIncluding confirmation of R0 resection of metastatic disease 
xAt the discretion of the treating provider and patient in the absence of recurrence or progression 
yCycle 4 Day 1, and every 12 weeks (+/1 14 days) thereafter as long as the patient continues study treatment. 
Proprietary of MD Anderson Cancer CenterProprietary of MD Anderson Cancer Center
27/106 1 Sponsor, Investigators and Trial Administrative Structure 
This clinical trial will be sponsored by: 
The University of Texas - MD Anderson Cancer Center. 
The trial will be conducted within the Department of Gastrointestinal Medical Oncology at the 
University of Texas  - MD Anderson Cancer Center in Houston, TX.  All clinical assessments will 
be performed in the outpatient clinic setting.  Study drug will be administered in the Cancer Therapy and Research Center (CTRC), an outpatient infusion center at MD Anderson.   
The Principal Investigato r represent s all Investigators for decisions and discussions regarding this 
trial, consistent with the International Conference on Harmonisation (ICH)  Topic E6 G ood C linical 
Practice (GCP; hereafter refe rred to as ICH GCP) . The Coordinating Investigator will provide 
expert medical input and advice relating to trial design and execution and is responsible for the 
review and signoff of the clinical trial report.   The trial will appear in the following clinical trial registry : www.clinicaltrials.gov  
2 Background Information  
2.1 Investigational Product 
The Investigational Medicinal Product (IMP) for the present trial is   M7824. 
M7824 is a bifunctional fusion protein that combines an anti -programmed death ligand 1 (PD -
L1) antibody and the soluble extracellular  domain  of transforming growth factor  beta (TGFβ 
receptor type II as a TGFβ neutralizing  “trap,” into a single molecule. This an ti-PD-L1 / TGFβ -
Trap molecule is designed to target 2 major mechanisms of immunosuppression in the tumor 
microenvironment. The anti -PD-L1 moiety of  M7824 is identical to avelumab, except  for three  
amino  acid substitutions in the heavy  chain  constant  regions, which result in a different human 
IgG1 allotype, and one amino acid substitution in the heavy chain for antibody stability. As of 
June 2017, FDA has granted accelerated approval to avelumab for metastatic Merkel cell 
carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy. 
Combining these pathways, PD -1 / PD -L1 and TGFβ, is attractive as an antitumor approach. A 
recent report found that blockade of TGFβ signaling in T cells or deletion of TGFβ1 from T  cells 
in a mouse model led to diminished PD -1 expression in tumor -infiltrating CD8 + T cells
1. 
Concomitant PD -1 and TGFβ blockade can restore pro- inflammatory  cytokines2. In a murine 
model of hepatocellular carcinoma, TGFβ appeared to increase the expression  of PD-L1 in 
dendritic cells,  which  in turn promoted T- cell apoptosis and increased  percentage of CD25+,  
Foxp3+ T regulatory  cells3. Higher levels  of circulating myeloid -derived suppressor cells 
(MDSCs),  a significant source of TGFβ,  are associated  with failure to respond to anti -PD-1 
therapy4. 
Proprietary of MD Anderson Cancer Center
  28/106 
  Experiments demonstrate that M7824 strongly enhances antitumor activity and prolongs survival 
in mouse tumor models above the effect of either the anti -PD-L1 antibody, avelumab, or 
TGFβRII control alone. Tumor rechallenge experiments in cured mice show durable  protecti ve 
immunity. In vivo studies showed that the antitumor effects were mediated by CD8+ T cells  and 
NK cells.  CD8+  T-cell tumor infiltrates  were  observed  and, overall, the CD8+  response was 
associated with long term protective immunity. Importantly, in the MC38 model, M7824 showed 
significantly better efficacy than the combination of avelumab plus TGFβ Trap control, 
supporting the rationale  of combining the 2 active moieties  in 1 molecule.  
M7824, is comprised of an extracellular domain of  the human TGFβ receptor  TGFβRII 
covalently  joined via a glycine / serine linker to the C terminus of each heavy chain  of the fully 
human  IgG1  anti- PD-L1 antibody, avelumab.  Given  the emerging  picture  for PD-1 / PD-L1 class, 
in which  responses are apparent  but with room for increase  in effect  size, it is assumed  that 
cotargeting a complementary immune modulation step will improve tumor response. A  similar 
TGF -targeting agent, fresolimumab, which is a monoclonal antibody targeting TGF β1, 2, and 3, 
showed initial evidence of tumor response in a Phase I trial in subjects with melanoma.  The 
objective response was observed in 1 of 28 subjects with 6 subjects showing stable  disease5. 
Internal data shows that the TGFβRII portion of M7824 has dose dependent antitumor activity  
in a mouse pharyngeal carcinoma xenograft model, similar  to antitumor findings with soluble 
receptor  reported  elsewhere6. Given  the preclinical  and clinical  evidence of both pathways, it is 
anticipated  that M7824 may have enhanced antitumor activity compared with avelumab. 
2.1.1 Safety  
A reasonable safety profile is anticipated when targeting these pathways. The safety  of the PD-1 
/ PD-L1 class continues to emerge  but appears to be substantially  less adverse compared  with 
the CTLA -4 class  of T cell checkpoint inhibitors7,8. Two TGFβ  inhibiting  biologics have been  
administered  in clinical  trials  and showed an acceptable  human safety profile in humans. 
Fresolimumab was studied in Phase I trial in subjects with cancer  (28 with melanoma,  1 with renal  
cell carcinoma).  No DLTs were  observed and 15 mg/kg, the highest dose tested,  was determined  
to be safe5. The  major  AE was emergent skin tumors and hyperkeratosis.  In a small  trial of 
idiopathic pulmonary fibrosis, the most common AE was fatigue9. In a study of 16 subjects with 
focal segmental glomerulosclerosis, the only  AE was  pustular rash in 2 subjects10. TβM1, an 
antibody inhibiting the TGF βII receptor, was well tolerated  when studied at doses as high as 240 
mg with diarrhea as the only DLT event11. Notably, one  event of low hemoglobin (Hgb) was 
observed in the high dose group. Importantly, the precli nical  profile  of M7824 is 
predominantly benign and highly comparable to that of avelumab. Overall, evidence suggests 
non-overlapping toxicity profiles for anti -PD-L1 and anti -TGFβ  agent classes.  There  is a 
theoretical potential of immune -related  adverse events (irAEs) that would be the consequence of 
a double blockade of negative regulatory loops of the immune system; however, taken together, the preclinical profile of M7824 and clinical  evidence of each pathway suggests a low risk of 
synergistic toxicity stemming from the dual-functionality of M7824. 
An irAE is  def
 ined as off target side effects associated with exposure of immunogenic drug and is 
consistent with an immune mechanism. In the process of identification of irAEs, any possible 
etiology of neoplastic, infectious, metabolic, toxin, or any other factor should be ruled out. 
Serological, histological (biopsy), immunological data should be obtained to support immune 
Proprietary of MD Anderson Cancer Center
  29/106 
  mediation of occurrence of adverse event. Immune -related A Es are AESIs for M7824 and 
important identified risks (adverse reactions) for M7824, and the precautions and management are 
discussed in Section  5.5.3.3. 
Important identified irAE risks for M7824 include colitis, pneumonitis/interstitial lung disease, 
endocrinopathies, hyperthyroidism, hypothyroidism, autoimmune thryroiditis, adrenal insufficiency, Type 1 diabetes mellitus), nephritis, hepatitis, retinal microvasculitis, uveitis, myositis, and skin reactions like rash (generalized, maculo- papula, erythemato us, bullous 
pemphigoid). Management  algorithms include steroids,  other immune- suppressants,  study drug 
interruption  / discontinuation, and supportive management.  Anti-PDL1  has shown an overall 
rate of infusion reactions  of approximately 10% (Grade  3 / 4 approximately 0.4% [fell to 0.2% 
with mandatory premedication]; no Grade  5. 
A brief summary of safety experience with the PD -1 inhibitors nivolumab (Opdivo®)  and 
pembrolizumab (Keytruda®) is given  here,  based  on prescribing  information (refer  to current label 
information for updated information). For pembrolizumab the section on Warnings and Precautions includes adverse reactions of immune -mediated pneumonitis  (2.9%), immune-
mediated colitis (1%), immune -mediated hepatitis (0.5%), immune -mediated hypophysitis 
(0.5%), renal failure (0.5%) and immune -mediated nephritis  (0.7%), immune -mediated 
hyperthyroidism (1.2%) and hypothyroidism (8.3%), and a variety of  other immune -mediated 
adverse reactions occurring in less than 1% of patients. In addition, a  warning for  embryofetal 
toxicity  is provided. For nivolumab the section  on Warning and Precautions includes adverse 
reactions of immune -mediated pneumonitis (2.2%) with fatal immune- mediated pneumonitis in 
0.9% (5/574), immune -medicated colitis (2.2%), immune -mediated  hepatitis (1.1%), immune -
mediated nephritis and renal dysfunction (0.7%),  immune- mediated hyperthyroidism (3%) and 
hypothyroidism (8%) and a variety of other immune -mediated  adverse reactions occurring in less 
than 1% of patients. I n addition, a warning for embryofetal toxicity is provided. 
Safety  experience with various TGF β targeting  agents described  in the literature  suggests no 
overlapping immune -related profile with compounds of the anti -PD-1 / anti -PD-L1 class.  In 
Phase I  trials,  the experience with a molecule with a highly similar mechanism  to the M7824 
TGFβ  trap moiety, the anti- TGF β-1 and 3 antibody fresolimumab,  showed  no dose limiting 
toxicity up to 15 mg/kg and no immune related events
5. There  were no  DLTs  and the only major  
AEs were  skin lesions, mainly  keratoacanthomas,  some  with atypical features, one event of 
squamous cell carcinoma, plus hyperkeratosis of the skin.  Immune events were  not reported. A 
syndrome known as Ferguson- Smith  disease is caused  by mutations in TGF β is associated with 
the formation of keratoacanthomas , similar to the findings described  for fresolimumab12. 
Therefore, it is plausible that skin tumors observed during fresolimumab  treatment  may be 
related  to TGF β inhibition. A neutralizing antibody  against TGF β-1, TβM1,  was well tolerated  
when  studied as high as 240 mg with diarrhea  as the only DLT  event. Notably, one event of low 
Hgb was observed in the high dose group. This is notable  since the only preclinical finding 
associated with M7824 was decreased Hgb. Trabedersen,  an antisense oligonucelotide that 
inhibits TGFβ2 expression, was associated with  thrombocytopenia that was moderate13. Finally, 
TGFβ is known to play a role in wound repair14. 
In the recently released initial phase I dose escalation cohort of M7824 (MSB0011359C), 19 subj
ects had enrolled in the dose -escalation part of the study with 3 subjects treated at each dose 
Proprietary of MD Anderson Cancer Center
  30/106 
  level of M7824 (MSB0011359C): 1, 3, 10, and 20 mg/kg, once every 2 weeks.  Median age was 
56 years (range: 34 to 78).  All had ECOG PS 0 or 1, with a median of 4 prior therapies (range: 
2 to 7).  
As of the data cutoff date (Oct 3rd, 2016), the overview of t reatment emergent adverse events 
(TEAEs) for the M7824 dose escalation cohort is provided in Table 4. 
Table 4: Overview of TEAEs for the Dose Escalation Cohorts of M7824  
 Dose Level  
0.3 mg/kg  
N = 3  
(%) Dose Level  
1 mg/kg  
N = 3  
(%) Dose Level  
3 mg/kg  
N = 3  
(%) Dose Level  
10 mg/kg  
N = 3  
 (%) Dose Level  
20 mg/kg  
N = 7  
(%) Overall  
N = 19 
(%) 
Any TEAE  2 (66.7)  3 (100.0)  3 (100.0)  3 ( 100)  7 (100.0)  18 ( 94.7)  
TEAE, Grade ≥ 3  2 (66.7)  3 (100.0)  1 ( 33.3)  0 (  0.0)  4 ( 57.1)  10 ( 52.6)  
Related TEAE  1 (33.3)  0 ( 0.0)  2 ( 66.7)  1 (  33.3)  5 ( 71.4)  9 ( 47.4)  
Related TEAE, 
Grade ≥ 3 0 (0.0)  0 (  0.0)  1 ( 33.3)  0 (  0.0)  2 ( 28.6)  3 ( 15.8)  
TEAE Leading to 
Treatment 
Discontinuation 0 (0.0)  1 ( 33.3)  1 ( 33.3)  0 (  0.0)  2 ( 28.6)  4 (  21.1) 
Any TEAE leading 
to Infusion Rate 
Reduction 0 (0.0)  0 (  0.0)  0 (  0.0)  0 (  0.0)  1 (  14.3)  1 (  5.3)  
Serious TEAE  1 (33.3)  2 ( 66.7)  1 ( 33.3)  0 (  0.0)  5 ( 71.4)  9 ( 47.4)  
Related Serious 
TEAE  0 (0.0)  0 (  0.0)  1 ( 33.3)  0 (  0.0)  3 (  42.9) 4 (  21.1)  
TEAE Leading to 
Death  0 (0.0)  0 (  0.0)  0 (  0.0)  0 (  0.0)  0 (  0.0)  0 (  0.0)  
Any TEAE of 
Special Interest: 
Infusion-Related 
Reaction 0 (0.0)  0 (  0.0)  0 (  0.0)  0 (  0.0)  1 (  14.3)  1 (  5.3)  
Any TEAE of 
Special Interest: 
Immune-Related  1 (33.3)  0 (  0.0)  0 (  0.0)  1 (  33.3)  2 (  28.6)  4 (  21.1)  
Note: Reporting of infusion-related reactions is being amended at the time this document was being prepared.  
TEAE: treatment emergent adverse events.  
18 out of 19 subjects experienced at least one TEAE of any grade. The most frequently observed 
TEAEs in more than 3 subjects were gastrointestinal disorders reported in 14 subjects (nausea in 9 subjects, vomiting in 7 subjects and abdominal pain in 4 subjects), followed by general disorders and administration site conditions in 8 subjects (fatigue in 5 subjects, localized edema in 4 subjects and fever in 4 subjects), skin and subcutaneous tissue disorders in 7 subjects, anemia in 6 subjects, infections and infestations in 5 subjects, metabolism and nutrition disorders in 5 subjects, musculoskeletal and connective tissue disorders in 4 subjects and respiratory, thoracic and mediastinal disorders in 4 subjects.  
Proprietary of MD Anderson Cancer Center
  31/106 
  Most of the TEAEs are of Grade 1 or 2. Ten subjects experience d at least 1 Grade ≥ 3 TEAE, 
including Grade 4 cerebrovascular accident (CVA) in 1 subject, Grade 4 anemia in 1 subject, Grade 
3 anemia in 4 subjects, cerebrovascular accident (CVA) in 1 subject, nausea in 3 subjects, vomiting in 2 subjects, abdominal pain in 2 subjects, colitis in 1 subject, rectal bleeding in 1 subject, 
hematuria in 1 subject, decreased urine output in 1 subject, skin infection in 1 subject, soft tissue infection in 1 subject, hypertension in 1 subject, dehydration in 1 subject, back pain in 1 subject, 
skin squamous cell carcinoma in 1 subject. Grade 3 laboratory abnormalities include decreased lymphocyte counts in 2 subjects, prolonged APTT in 1 subject, acidosis in 1 subject, hypokalemia in 1 subject. 
9 out of 19 subjects experienced at least one trial drug related TEAE. 3 subjects experienced at 
least 1 Grade ≥ 3 trial drug related TEAE, including grade 3 anemia in 1 subject, grade 3 colitis in 1 subject, grade 3 skin infection in 1 subject, grade 3 skin squamous cell carcinoma in 1 subj ect. 
All of the other trial drug related TEAEs are of Grade 1 or 2, including hyperthyroidism in 2 subjects, hypothyroidism in 2 subjects, maculopapular rashes in 2 subjects, bullous dermatitis in 1 subject, acneiform dermatitis in 1 subject, pruritus in 1  subject, infusion related reaction in 1 
subject, nausea in 1 subject, vomiting in 1 subject, dry mouth in 1 subject, exertional dyspnea in 1 subject. 
At the 20 mg/kg dose level, 2 subjects experienced TEAE leading to treatment discontinuation. 
The maximum  tolerated dose (MTD) level was not reached at the highest so far at investigated 
dose of 20 mg/kg. One subject had a dose limiting toxicity (DLT) with colitis with subsequent bleeding and anemia at the 20 mg/kg dose level. Overall, the TEAE profile was si milar across 
different dose escalation cohorts and the incidences of TEAEs by TEAE category did not increase significantly with increasing dose.  
The safety summary of the M7824 expansion cohort in colorectal patients is listed as below. As of April 21 2017, 32 patients with a diagnosis of colorectal cancer have received at least one, or more, 
doses of 1,200mg of M7824. Table 5 list both drug- related and not -related AEs for items in which 
> 10% of patients experience the event, or if the events was recurrent Grade 3 or any Grade 4 or 
higher. Overall, the drug was well tolerated at the 1,200mg dose level with a typical AE profile for 
an advanced cancer patient cohort. Of note, the grade 3 toxicities occurring in more than 10 percent of study subjects were anem ia (4 out of 32, 12.5%), hyponatremia (4 out of 32, 12.5%) and dyspnea 
(4 out of 32, 12.5%).  There were 4 subjects with Grade 3 events listed as related to M7824. These include anemia (1 event), blood bilirubin increased (1 event), enteritis (1 event) and adrenal insufficiency (1 event). No Grade 4 or Grade 5 events have been reported as related to M7824.  
Table 5. Adverse Events (AEs) in Dose Expansion cohort of colorectal cancer patients on 
EMR200647- 001 dosed with 1,200mg M7824 (cut -off date 21 April 2017; n=32). Both drug-
related and not drug -related AEs for items in which > 10% of patients experience the event, or if 
the event was recurrent Grade 3 or any Grade 4 or higher, are listed. 
 
Primary System Organ Class  Any Grade  Grade 
>=3 Grade 
>=4 Grade 
5 
Preferred Term  n (%)  n (%)  n (%)  n (%)       
Proprietary of MD Anderson Cancer Center
  32/106 
  Anemia  8 (25.0)  4 (12.5)  1 (3.1)  0 
Abdominal Pain  10 (31.3)  1 (3.1)  0 0 
Constipation  12 (37.5)  0 0 0 
Diarrhea  8 (25.0)  0 0 0 
Nausea  11 (34.4)  3 (9.4)  0 0 
Vomiting  7 (19.4)  2 (6.3)  0 0 
Fatigue  10 (31.3)  2 (6.3)  0 0 
Pyrexia  8 (25.0)  1 (3.1)  0 0 
Cholangitis  1 (3.1)  1 (3.1)  1 (3.1)  0 
Sepsis  3 (9.4)  3 (9.4)  2 (6.3)  1 (3.1)  
UTI 7 (21.9)  1 (3.1)  0 0 
Infusion related reaction  5 (15.6)  0 0 0 
Blood bilirubin increased  2 (6.3)  2 (6.3)  0 0 
GGT increased  3 (9.4)  3 (9.4)  0 0 
Weight decreased  4 (12.5)  0 0 0 
Decreased Appetite  10 (31.3)  1 (3.1)  0 0 
Dehydration  4 (12.5)  0 0 0 
Hyperglycemia  3 (9.4)  3 (9.4)  1 (3.1)  0 
Hyperkalemia  1 (3.1)  1 (3.1)  1 (3.1)  0 
Hyponatremia  6 (18.8)  4 (12.5)  0 0 
Back pain  7 (21.9)  0 0 0 
Myalgia  5 (15.6)  0 0 0 
Headache  4 (12.5)  1 (3.1)  0 0 
Anxiety  4 (12.5)  0 0 0 
Cough  5 (15.6)  0 0 0 
Dyspnea  9 (28.1)  4 (12.5)  1 (3.1)  0 
Pleural Effusion  5 (15.6)  0 0 0 
Respiratory Failure  1 (3.1)  1 (3.1)  1 (3.1)  0 
Hypotension  2 (6.3)  1 (3.1)  1 (3.1)  0 
 
 
2.2 Non-Clinical Findings for M7824  
2.2.1 In Vitro and in Vivo Pharmacology Findings  
Avelumab, a fully human anti -PD-L1 IgG1 antibody, recently entered Phase III  clinical 
development by EMD  Serono R&D,  Billerica,  MA. Preclinical  pharmacology investigations  have 
shown that avelumab functionally  enhances T cell activation  in vitro  and significantly  inhibits the 
growth of PD-L1 expressing  tumors in vivo; thus avelumab  serves as a benchmark for the 
preclinical  proof of principle  studies of the anti- PD-L1 / TGFβ  Trap  (M7824).  In addition, M7824, 
Proprietary of MD Anderson Cancer Center
  33/106 
  which  consists of the TGFβ  trap covalently linked  to an inactive  anti-PD-L1, was generated to 
evaluate the effect of inhibition of TGFβ  only. 
M7824 binds recombinant and cell surface expressed PD -L1 with an affinity similar to that of 
the parental anti -PD-L1 antibody (avelumab), and binds recombinant human TGFβ1 with high 
affinity. Importantly, M7824 can bind simultaneously to PD -L1 and TGFβ1  as demonstrated by 
a two -step binding assay. M7824 potently attenuated TGFβ signaling in cell assays and enhanced  
interleukin -2 production by T cells stimulated  with a super antigen, Staphylococcal enterotoxin 
A. M7824 is capable of mediating  antibody-depe ndent cell -mediated  cytotoxicity (ADCC)  in 
vitro,  but at a significantly  reduced  level  compared  with the parental  avelumab antibody. M7824 
was shown to be internalized by PD-L1-expressing cells in vitro with kinetics similar to those of 
the parental avelumab antibody. In summary, the dual  functionalities  of M7824 were  confirmed 
by in vitro  studies:  the fusion protein retains the biological activities of the parental anti- PD-L1 
avelumab antibody, but possesses  the added modality of effective TGFβ binding and  
neutralization.  
M7824 is cross- reactive with murine PD -L1 and TGFβ1; therefore, its in vivo antitumor  efficacy  
and the immunological response during the course of treatment  can be evaluated  in syngeneic  
models; however, since  this therapeutic  agent  is a recombinant human protein  with two 
mechanisms  of action  aimed  at blocking immunosuppression, it caused  an augmented  mouse 
antibody against human antibody (MAHA) response in immunocompetent mice, which limits  the 
dosing to a 3- or 6-day window, depending on the strain  of mice.  To avoid a MAHA response, 
2 B cell deficient  strains of mice  were  employed in a series of studies designed to assess  the optimal 
antitumor efficacy of M7824 treatment in cancer models. Homozygous Jh mice  (Igh-Jtm1Dhu; 
Balb/C) lack normal B lymphocyte numbers and have no detectable IgM or  IgG antibody titers 
due to the absence of the Jh gene segments responsible for genetic  recombination of the Ig heavy 
chain. Likewise, B6.129S2- Ighmtm1Cgn/J mice (C57BL/6) lack mature B  cells due to a 
targeted  Ighmtm1Cgn mutation. The use of Jh and B6.129S mice  allowed  clinically -relevant 
repeat dosing schedules of the M7824 treatment in the in  vivo pharmacology studies. To ensure 
the results obtained were not artifacts due to the B  cell deficiency,  efficacy  and associated  
immunological responses of M7824 in wild type mice  were also demonstrated, although to a 
lesser extent for efficacy due to the limited dosing window and interference by MAHA.  
M7824 possesses superior a ntitumor  activities  relative  to monotherapy with either  PD-L1 
blockade or TGFβ  sequestration, resulting  in complete tumor  regression  and long- term survival 
in the EMT-6 breast  cancer  model and MC38  colorectal  cancer  model. Dose -dependent efficacy  
was observed in multiple models, and the effective dose range was between 25 to 492 μg per  
mouse (approximately 1.25 to 25 mg/kg) depending on the model. Importantly, M7824 therapy 
induced antitumor  activities that conferred a durable,  protective immunity  in those mice  eradicated 
of their primary tumor. Moreover, the antitumor effect of M7824 was associated  with 
modulations in T cell and NK cell phenotypes, increase in dendritic  cell maturation, and reduction 
in MDSCs  in the tumor microenvironment.  M7824 was also shown to be capable  of activating 
both adaptive and innate immune responses that included favorable changes in  tumor immune 
infiltrates. Furthermore, tumor antigen -specific CD 8+ T cell responses were enhanced with 
M7824 therapy. 
Proprietary of MD Anderson Cancer Center
  34/106 
  In a trial to further elucidate the mechanisms of action, tumor- bearing mice were systemically 
depleted of CD4+ T cells, CD8+ T cells or NK cells during treatment. The therapeutic efficacy 
of M7824 was completely abrogated by the depletion of either CD8+ T  cells or NK cells, but not 
by the depletion of CD4+ T cells. Consistent with the reduced ADCC in vitro, the effector function of M7824 did not play an important role in the antitumor effect in vivo. Furthermore, 
the dominant role of CD8+ T cells in maintaining long- term protective immunity following 
M7824 induced tumor eradication has been demonstrated. 
The therapeutic potential of M7824 was explored in combination with various standard -of-care 
therapies. In combination with the core components of the  FOLFOX chemotherapy regimen 
(oxaliplatin, 5 -fluorouracil and oxaliplatin), an additive enhancement  in efficacy was 
demonstrated against MC38 colorectal carcinoma. In combination with fractionated, localized 
radiotherapy, a highly synergistic antitumor effect w as achieved with only a single  low dose  of 
M7824 in the MC38  tumor  model. An augmented antitumor  effect  was also observed  when  
M7824 was combined with pazopanib in a mouse  renal  cell carcinoma model, and with anti -
CTLA -4 in a B16 melanoma model. Immunological readouts from  these combination studies 
consistently showed additive immunomodulatory effects that correlated with antitumor response. 
These data suggest that M7824 can be explored as a  combination partner in different clinical 
settings for t he treatment of cancer  patients.  
Refer to the Investigator’s Brochure for full details of the preclinical pharmacology of M7824. 
2.2.2 Pharmacokinetics / Immunogenicity Findings  
Preclinical PK data and PK / PharmDyn analysis for M7824 is available from mice and 
cynomolgus monkeys. The single- dose data in monkey shows non- linearity  between  the low doses 
of 0.8 and 4 mg/kg versus the high dose of 20 mg/kg, which had reduced clearance, suggesting  
a saturable component. The TGF β1 binding was assessed and showed suppression for  prolonged 
periods beyond drug exposure at all dose levels;  however, baseline data contained  data below 
lower limit of quantification and therefore these data were not considered relevant  for 
PK/PharmDyn  projections. The fusion protein  appeared  stable since there  was no evidence of 
intralinker cleavage.  Mouse PK / PharmDyn models for tumor  and peripheral blood (CD3+ 
splenic) PD -L1 occupancy were also  generated. 
 
A brief summary of PK and PK / PharmDyn is as follows: 
• The predicted human terminal half- life (t 1/2) for M7824 is approximately 6  days  
• Simulations  predict that a 1 mg/kg dose will provide an average exposure of 
approximately 7 μg/mL in humans 
• Based on PK / PharmDyn modeling and human projections: 
o At a human dose of 0.1 mg/kg, 95% PD -L1 total occupancy at maximum  serum  
concentration  observed post-dose (Cmax) is expected  in PBMCs,  providing 
approximately 60% total occupancy in tumor 
o At a human dose of 1.0 mg/kg, more  than 95% of PD-L1 total occupancy  at Cmax is 
expected  in PBMCs and tumor 
Proprietary of MD Anderson Cancer Center
  35/106 
  o At a human dose  of  1.0  mg/kg,  20%  effect  is  projected  in  tumor  regression  in  the 
PK / PharmDyn model compared with 95% at 7.5 mg/kg 
• Human  projections indicate a dose of 7.5 mg/kg  and higher (range 4 to 20 mg/kg), on a 
biweekly schedule is needed to achieve full efficacy based on a mouse tumor model in which 
complete tumor regressions were observed.  
Anti-drug  antibodies  were  observed  in  some  animals;  however,  the  impact  on  PK  or PK / 
PharmDyn is not known. Preclinical  antidrug  antibody formation  is not predictive  of human  
antibodies. 
2.2.3 Toxicology 
The toxicological profile  of M7824 was investigated  in vivo in mice  and cynomolgus 
monkeys. In addition, an optimized in vitro cytokine release assay in human PBMCs as well  as 
tissue cross- reactivity studies in normal human and cynomolgus monkey tissues were  performed. 
Investigations of local tolerance were integrated in the repeat -dose toxicity studies. The 
investigation of safety pharmacology relevant parameters (CNS, respiratory, cardiovascular) was 
included in the pivotal 4- week intravenous (IV) repeat -dose toxicity study in  cynomolgus 
monkeys. Please refer to the investigator brochure for M7824 for further details.  
2.2.4 Brief Summary of the Clinical Findings for M7824 
As of October 2016, 19 subjects had enrolled in the dose- escalation  part of the dose escalation  
study with M7824. Ple ase see T able 4 for further det ails. 
No subject experienced a DLT and no subject was discontinued from treatment for drug- related 
TEAEs.  No subject was reported with a TEAE with a Preferred  Term  of infusion- related  reaction; 
however using a post -reporting analysis according to criteria outlined in the Statistical Analysis 
Plan,  3 subjects were  reported  with TEAEs  that were  classified  as “infusion- related  reactions,” 
with the Preferred  Terms  of abdominal pain, pyrexia, and back  pain (Note: these  events are 
undergoing further  review).  
The safety summary of the M7824 expansion cohort in colorectal patients is listed in Table 5. As 
of April 21 2017, 32 patients with a diagnosis have received at least one, or more, doses of 1,200mg 
of M7824. Table 5 list both drug- related and not -related AEs for items in which > 10% of patients 
experience the event, or if the events was recurrent  Grade 3 or any Grade 4 or higher. Overall, the 
drug was well tolerated at the 1,200mg dose level with a typical AE profile for an advanced cancer patient cohort. Of note, the grade 3 toxicities occurring in more than 10 percent of study subjects were anem ia (4 out of 32, 12.5%), hyponatremia (4 out of 32, 12.5%) and dyspnea (4 out of 32, 
12.5%). There were 4 subjects with Grade 3 events listed as related to M7824. These include anemia (1 event), blood bilirubin increased (1 event), enteritis (1 event) and adrenal insufficiency (1 event). No Grade 4 and Grade 5  events have been reported as related to M7824. Please see 
Table 5 for further details . 
 
Proprietary of MD Anderson Cancer Center
  36/106 
  2.2.5 Rationale for Cohorts  
The programmed death 1 (PD -1) protein/ PD ligand -1 (PD -L1) interaction is important for im mune 
evasion. PD -L1 is expressed on many cells including tumor cells. The PD -1/PD -L1 interaction 
results in peripheral T effector cell exhaustion and promotes conversion of T cells towards a T -
regulatory (T reg) phenotype. Other cell types express PD -L1 suc h as natural killer (NK) cells, 
myeloid cells and dendritic cells. These cells all contribute to the tumor microenvironment (TME) 
and have the potential to upregulate PD -L1. Evidence for disrupting this interaction via checkpoint 
inhibitors has been shown in melanoma and non- small cell lung cancer. PD1 antibodies, nivolumab 
and pembrolizumab tested in phase III trials versus standard of care chemotherapy have demonstrated better clinical outcomes in melanoma
4,15,16, non- small cell lung cancer17-19. Initial 
data suggests anti -PD-1 therapy may have efficacy in MSI -H mCRC20.  
TGFβ is a cytokine with multiple functions21. It is produced by various cell types including 
platelets22, various myeloid populations, fibroblasts and T regulatory (T reg) cells23. TGFβ has dual 
roles in cancer24. In early stage disease, TGFβ promotes differentiation and apoptosis acting as a 
tumor suppressor . In late stage cancer, TGFβ has a tumor promoter function. TGFβ enhances 
epithelial mesenchymal transition (EMT) by the control of genes like ZEB1,2, TWIST, SNAIL and SLUG that control expression of cell surface markers that mediate epithelial cell -cell contacts 
such as E -cadherin
25. TGFβ has autocrine and paracrine functions in fibroblasts, macrophages and 
myeloid derived suppressor cells (MDSC)26. These cells have direct and indirect effects on the 
overall inflammatory/immune state of the tumor microenvironment (TME).  
TGFβ also contributes to an immunosuppression within the TME. Cancer s secrete various 
cytokines and chemokines that stimulate myelopoiesis and attract immature my eloid cells towards 
the tumor. Granulocyte (PMN -MDSC) and monocyte (M -MDSC) can be recruited and under TME 
specific conditions such as hypoxia, cause differentiat ion of these precursors into tumor associated 
macrophages and neutrophils (TAM s and TANs)26-28. TGFβ forms one of the many cytokines that 
forms autocrine feedback to sustain immunosuppressive signaling at the TME level29. In addition, 
these immature precursor s are highly immunosuppressive while the TAMs are polarized towards 
alternatively activated forms such as the  immunosuppressive M2 phenotype. Together, MDSC and 
M2 macrophages promote downregulation of tumor immunity through direct mechanisms on 
cytotoxic T cells. These include substrate metabolism (arginine) or sequestration (L -cystine), 
direct effects  of reactive oxygen species (ROS) or reactive nitrogen species on T -cell receptor 
subunits and through the secretion of cytokines that promote Treg differentiation. TGFβ has downregulatory effects on cytotoxic T cells and natural killer (NK) cells
26. In the bloodstream , 
TGFβ released from platelets after contact with circulating tumor cells downregulates NK tumorilytic activity in vitro
30,31 and downregulates NKG2D receptors on NK cells32, providing 
another immune escape mechanism.   
TGFβ has pleotropic effects extend beyond the immune regulation. Through effects on local innate immune cells, endothelial cells  and activated fibroblasts, TGFβ is a central component of the 
cytokine milieu that also promotes angiogenesis
25.  TGFβ also mediates an environment of matrix 
remodeling via cancer associated fibroblasts (CAFs) and immune cells. The induction of these cells results secretion of matricellular proteins.  
Proprietary of MD Anderson Cancer Center
  37/106 
  Modulation of the extracellular matrix (ECM) is a dy namic process. The ECM forms the structural 
components holding cells together in a tissue architecture but it has several functions beyond the 
cytoskeletal capacity. It serves as a reservoir for growth factors such as TGFβ, provides survival signals and inhibition signals via cell surface molecules such as integrins. TGFβ is secreted and bound to latent factors that are bound to the ECM until activated and liberated
33. Integrins may 
also modulate TGFβ release34. Active signaling in this way is crucial in embryonic development, 
morphogenesis and wound healing35.  
In cancer, the extracellular signals that result in apoptosis or growth suppression from the  ECM 
are perturbed. Growing tumors resist inhibitory growth signals and the local ECM is disrupted. Liberated factors and danger signals now available for recognition by innate immune cells cause a cascade of events analogous to wound healing
23. Infl ammation via activated macrophages set off 
a cascade inflammatory molecules that recruit further infiltration of neutrophils and immature myeloid cells to the area. Fibroblasts are also activated in this process and secrete TGFβ through autocrine and parac rine pathways. TGFβ induces production of ECM related genes including 
metalloproteinases (MMPs)
36. Chronic remodeling without removal of the cancer trigger results 
in a perpetual cycle of remodeling. TGFβ secretion begets further TGFβ production and as a result, the TME is primed for angiogenesis, invasion, ECM breakdown and immune escape. 
The relationship between immune infiltrates and MSI -H in CRC is well established
37. 
Immunotherapy with anti -PD1 therapy may have efficacy in this population38. Nivolumab and 
ipilumumab was well tolerated with a response rate of 33%  in metastatic MSI -H CRC39. TGFβ, 
being a central determinant of an immune suppressive TME may be a key resistance mechanism 
in PDL1 therapy strategies40. It does so both directly on T cells to differentiate into T regs or 
indirectly via attraction of immunosuppressive immature myeloid and MDSCs into the TME. Upregulation of TGF -β signaling has been associated with de novo resistance to anti -PD-1 
treatment in patients with metastatic melanoma and following development of acquired resistance 
to these agents following an initial response to therapy.  Given the ability of M7824 to sequester 
TGF -β in the circulation away from the TME, we hypothesize that M7824 may promote T cell 
effector function via disruption of PD -1/PD -L1 axis to enhance anti -tumor response following 
resistance to anti -PD-1/PD -L1 therapy in patients with MSI- H mCRC.  
The consensus molecular subtypes (CMS) are the best representation of the variation seen within CRC on the basis of ge ne expression
41. Briefly, CMS1 is characterized by hypermutated  tumors 
with immune infiltrates and often associated with MSI- H. Notably, MSI -H is a subset of CMS1 
and there is a proportion within this group that current biomarkers do not capture. CMS4 is a mesenchymal phenotype and is associated with a number of features associated with poor prognosis. Hallmark features of CMS4 include TGFβ activation, immune infiltration, EMT, matrix remodeling, and angiogenesis
41. In contrast to CMS1, the immune infiltration displays a relative 
absence of cytotoxic T cells but a high proportion of tumor associated macrophages (TAMs)42. 
TGFβ signaling and immune suppression in the microenvironment are contributory factors to the aggressive biology that is reflected in the poor overall survival within this group. TGFβ activation conditions stroma at other sites to form metastatic n iches that promote a receptive environment for 
circulating tumor cells or increases tumor initiating cell capacity in conjunction with fibroblast activation
43. TGFβ inhibition with LY215299 in the TME prevented metastasis formation in 
patient derived tumor organoids44. Blocking TGFβ signaling may help reverse a number of key 
processes in the CMS4 poor prognosis group which include: reversing fibroblast activation, 
Proprietary of MD Anderson Cancer Center
  38/106 
  removing tumor initiating capacity, reversing immature myeloid and MDSC infiltration and 
downregulating EM T. Given the role of inflammatory cells and TGFβ, M7824 may reprogram an 
inflammatory response that is immune suppressive to an immunogenic response.  
In a recent pilot study of patients with mCRC treated with M7824 monotherapy45, there were 22 
patients with adequate tumor tissue avai lable for CMS subtyping.  Patients here had been permitted 
to enroll without prior knowledge of CMS status.  In this cohort, there were 10 patients with CMS4 
mCRC.  Only one of these ten patients demonstrated a radiographic response, which remained > 6 months in duration.  Conclusions from this CMS4 cohort however were limited by the lack of available fresh paired tissue biopsies in order to understand better the intratumoral pharmacodynamics activity of M7824. 
Given the lack of activity noted with single -agent M7824 in the CMS4 CRC setting, additional 
interventions may boost the immunogenicity of these tumors in order to improve the anti -tumor 
responses.  Radiotherapy has been shown to induce tumor cell damage through apoptosis - and 
necrosis- induced mechani sms
46-48, and augment exposure of more tumor -associated antigens for 
recognition by antigen -presenting cells and tumor attack by effector T cells49.  Radiated tumor 
cells promote release of danger -associated molecular patterns50, which likewise recruit more 
activated T cells to the tumor microenvironment.  In preclinical MC38 and CT26 models of 
colorectal cancer using immunocompetent mice, concomitant stimulation by immune checkpoint 
blockade agents  may render these tumors more susceptible to disrupting the PD -1:PD -L1 axis in 
combination with radiotherapy51-54. 
TGF -β activation within the tumor microenvironment by cancer- associated fibroblasts promotes 
T cell exclusion in preclinical models of CRC akin to the CMS4 subtype55.  This may render 
immunotherapy agents ineffective in certain patients with MSS CRC if activated T cells are unable to penetrate intratumorally.  Indeed, knockdown of TGF -β activity microscopically in these 
preclinical models did not eradicate established MSS tumors, although T cells reflexively 
increased PD -L1 expression on the surface in response to TGF -β inhibition.  However, treatment 
with anti - TGF -β agents in the pre -metastatic setting (i.e., prior to development of exclusionary 
TGF -β activated stroma) decreased the onset of metastatic tumors for these models.  Recently, 
identification of micrometastases in patients with CRC has become more feasible due to the advent 
of circulating tumor DNA (ctDNA) technology.  Series of patients with non- meta static and 
metastatic CRC alike have demonstrated resoundingly the strong association between CRC 
recurrence and the presence of ctDNA fo llowing curative resection
56-58, with  (+) ctDNA bearing a 
90-100% positive predictive value for the event of recurrent CRC, a surrogate for the presence of 
micromet astatic disease.  Applying these findings, it is possible then to treat patients with (+) 
ctDNA following resection of oligometastatic CRC and completion of standard-of- care 
chemotherapy in the absence of clinically/radiographically macroscopic disease elsewhere, who may have remnant microscopic disease that can be eradicated by dual PD -L1: TGF- β targeted 
therapies.  
Following on from the high response rates seen with PD -1 blockade in MSI -H mCRC, subsequent 
phase 2 studies have demonstrated impressive response rates in MSI -H tumors, irrespective of site 
of origin. A tumor agnostic phase 2 study enrolling patients with MSI -H metastatic tumors 
demonstrated an ORR of 53% and disease control rate of 77% with median PFS and OS not yet 
reached
59. The cohort of 86 patients included CRC, neuroendocrine, ampulla of Vater, gastric, 
Proprietary of MD Anderson Cancer Center
  39/106 
  pancreatic, prostate and cholangiocarcinomas. Predictive analysis using NGS from known 
databases across 32 different tumors suggests that the most common adenocarcinomas wit h a MSI -
H signature include endometrial, gastric, small intestinal, colon, rectum, cervical, pros tate and 
neuroendocrine tumors. Ovarian and uterine sarcomas are the non- epithelial tumors expected to 
contain subsets of MSI -H. While only 4% of these tumors are stage IV, the number of tumors that 
display the MSI -H phenotype has led to an estimation of 20,000 patients in the US who would 
derive benefit in the advanced setting with PD -1 and immunotherapy treatments59.  
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH GCP and 
any additional applicable regulatory requirements.  Based on the available nonclinical and clinical data to date, the conduct of the trial specified in this protocol i s considered justifiable.  
2.2.6 Summary of the Overall Benefit and Risk  
The risk-benefit ratio has been  carefully  considered  in the planning of the trial. Based  on the 
preclinical  data available  to date,  the conduct of the trial is considered  justifiable  using the dose 
and schedule of M7824 as specified in this protocol. The trial will be discontinued in  the event 
of any new findings that indicate a relevant deterioration of the risk -benefit ratio and would render 
continuation of the trial unjustifiable. The following are considered potential risks  of exposure 
to M7824: 
• Infusion- related reactions including  hypersensitivity 
• irAEs / autoimmune  disorders  
• Anemia  
• Rash with hyperkeratosis, keratoacanthoma, and squamous cell carcinoma of the skin 
• Alterations in wound healing or repair of tissue damage  
• Embryofetal toxicities  
Respective safety  measures that comprise inclusion  / exclusion criteria  for participation  in clinical  
trials  with M7824, guidance for prevention, monitoring, and medical  management of potential 
risks, as well as guidance on study treatment interruption or  discontinuation.  See  Section  2.2.4  
for a summary  of clinical  safety  findings. 
2.2.6.1  Infusion-related Reactions / Hypersensitivity  
Infusion- related reactions hypersensitivity are a risk inherent to the administration of  any 
recombinant protein to humans. Incidence of immunogenicity and character or severity of 
immunogenicity- induced side effects cannot be predicted by animal models because humanized 
or fully  human  proteins  usually provoke a much  stronger immune -response in rodents or non- 
human  primates  than in humans. The parent antibody (avelumab) caused  lethal immune- mediated 
anaphylactic hypersensitivity reactions  in mice  after repeated  application,  while  a control antibody 
lacking pharmacological activity only triggered a moderate immune reaction. However, in 
primates  (cynomolgus monkeys), as a species closer  to human, neither  in the pilot 4-week  IV 
repeat -dose toxicity tr ial nor in the pivotal 13- week IV infusion repeat -dose toxicity trial,  clinical 
signs of hypersensitivity have been seen at dose levels of 20, 60, and 140 mg/kg, respectively.  
Proprietary of MD Anderson Cancer Center
  40/106 
   
As of 05 November 2014, from the EMR100070-001 trial with the parent avelumab  antibody, 
1 subject  (2.0%) in the dose-escalation  cohort reported  an infusion- related  reaction  event (Grade  2) 
and 49 (10.2%) of the 480 subjects in the expansion cohorts experienced at least 1 episode of  an 
infusion- related  reaction  when  receivin g avelumab  monotherapy. Most  of the events were  Grade  
1 (8 subjects, 1.7%) or Grade 2 (36 subjects, 7.5%) in intensity, and Grade 3 (3 subjects, 0.6%)  
or Grade  4 events (2 subjects,  0.4%) were  less frequent. No Grade  5 events have been  reported. 
Most  of the infusion- related  reaction  events had an onset after the first (30 subjects,  6.3%) or 
second (16 subjects, 3.3%) avelumab infusion. In 8 subjects (1.7%), avelumab treatment  was 
discontinued because of infusion- related reaction  events. 
2.2.6.2  Immune- related Adverse Events / Autoimmune Disorders  
Since inhibition of PD -L1 and TGFβ signaling stimulates the immune system, irAEs may occur.  
Treatment of irAEs is mainly dependent upon severity (NCI- CTCAE grade):  
• Grade 1 to 2:  treat symptomatically o r with moderate dose steroids, more frequent monitoring 
• Grade 1 to 2 (persistent):  manage similar to high grade AE (Grade 3 to 4) 
• Grade 3 to 4:  treat with high dose corticosteroids 
Treatment of irAEs should follow guidelines set forth in Section 5.5.3.3:  
• Instructions for trial treatment discontinuation or interruption in case of irAEs /  autoimmune 
disorders (see Section  5.5.3.3).  
 
• Guidance for the medical  management of irAEs  / autoimmune disorders  including specific 
guidance with regard to the affected organ / body system (see Section  5.5.3.3).  
• irAEs / autoimmune disorders (any grade) are considered as AESIs requiring  expedited 
reporting from the Investigator to Merck/EMD Serono . For non- serious AESIs, an AESI 
Report Form has to be completed; for serious events, an SAE Report Form has to be used. 
• Regular laboratory tests on parameters indicative for autoimmune disorders will be  
performed as detailed in the Schedules of Assessments (see Tables  1-3).  
• To help monitor for autoimmune effects, baseline ophthalmology examination including slit 
lamp inclusive of the anterior segment and including visual acuity. If clinically relevant eye 
signs or symptoms  during the study, appropriate ophthalmology examination within  2 
days including slit lamp inclusive of the anterior segment and including visual acuity. 
2.2.6.3  Anemia  
As the 4 -week toxicology studies in cynomolgus monkeys demonstrated reversible decreases  in 
red blood cell counts, as well as corresponding Hgb and hematocrit,  anemia is considered  a 
potential risk. Inclusion criteria for the study will require adequate entry Hgb value. Risk 
management measures are provided in Section  5.5.3.4. Th e  amount of blood drawn during the 
study for non- essential  biomarkers will be carefully  considered, especially  given the preclinical 
finding of reduced Hgb levels.  
Proprietary of MD Anderson Cancer Center
  41/106 
  2.2.6.4  Alterations in Wound Healing or Repair of Tissue Damage 
Alternations of wound healing and tissue damage repair are considered a potential risk given the 
TGFβ mechanism. Management should be discussed with the principal investigator  on a case-
by-case basis.  
2.2.6.5  Rash with Hyperkeratosis / Keratoacanthoma / Squamous 
Cell Carcinoma of the Skin  
Phase I information from  a TGF  antibody showed excess acanthomas,  some  with atypical  features,  
and one confirmed  squamous cell carcinoma5. A genetic disorder in the TGF pathway is also 
known to be associated with skin tumors12. Based on  this information, skin tumors are considered 
a potential risk. Monitoring will include skin assessments as defined in the schedule of 
assessments (see Tables  1-3). Management should  be discussed with the on  a case-by- case basis. 
Dermatological consults should be requested as needed. Rash with hyperkeratosis / 
keratoacanthoma / squamous cell carcinoma of the  skin are considered as AESIs  requiring  
expedited reporting from the Investigator to the Merck/EMD Serono . Any suspicious lesion  
should be biopsied. For non-serious AESIs,  an AESI  Report Form has  to be completed; for serious 
events,  an SAE  Report Form  has to be used (see Section  6.4.1.2).  
2.2.6.6  Embryofetal Toxicity 
Embryofetal toxicities are a known risk of the PD -1 / PD -L1 targeting class. Animal models  link 
the PD-1 / PD-L1 signaling pathway with maintenance of pregnancy through induction of maternal 
immune tolerance to fetal tissue. Based on its mechanism of action (MoA), M7824 may cause 
fetal harm when administered to a pregnant female. An appropriate contraception  warning is 
provided in this clinical protocol. Subjects with pregnancy or in lactation period are  prohibited 
from being enrolled in clinical trials.  
2.2.6.7  Potential Benefit 
In cohort A -C, patients will be selected based on MSI -H status and progression on prior immune 
checkpoint therapy on trial entry. Single agent  responses to nivolumab in MSI -H mCRC have 
been updated in early key studies and range from 31%60 and 50%38. In a population in whom the 
anticipated response rate is high  but who have progressed on  therapy, M7824, which targets a 
possible immunotherapy resistance mechanism in the form of TGFβ  upregulation, appears 
promising.  Beyond CRC, patients with MSI -H tumors who have progressed on prior 
immunotherapy will be enrolled. ORR and DCR to single agent pembrolizumab was 52% and 
77% respectively in a population that contained ampulla of Vater, duodenal, pancreatic, neuroendocri ne, cholangiocarcinoma, gastric, ovarian cancers and uterine sarcomas
59. Many of 
the these tumors lack effective salvage treatments and when considered in context of the response rates to single agent PD -1 blockade, targeti ng a potential resistance mechanism for potential 
durable responses with M7824 is a promising option. 
 
Proprietary of MD Anderson Cancer Center
  42/106 
  In cohort B, patients  with treatment -refractory CMS4  mCRC who have progressed on at least 
two standard-of- care options  will be studied . M7824 has limited benefit as monotherapy in this 
setting. SBRT will be administered after a one dose  lead-in of M7824.  Given the paucity of 
effective available therapies for patients with mCRC who hav e progressed on prior oxaliplati n-
based and irinotecan- based chemotherapy, the risk-benefit ratio in this population for M7824 is 
also favorable given t he prognosis in this population and studies showing that SBRT to metastatic 
tumors have  demonstrated ability to increase tumor- associated antigens and augment 
immunogenicity.  While SBRT is preferred, IMRT or 3D conformal techniques may be utilized 
at the discretion of the treating radiation oncologist depending on the dose to surrounding normal tissues.   Patient will receive a total dose of 24Gy over three days  with one of the following 
modalities, at the discretion of the treating radiation oncologist: SBRT, IMRT and 3D conformal.  
In Cohort D, patients with MSS mCRC who have completed therapy following R0 resection with 
or without chemotherapy for removal of al l clinically and radiographically evident macroscopic 
disease will be tested for the presence of ctDNA.  Given the correlation between detectable ctDNA and the presence of minimal residual disease, patients in this cohort are at high risk for recurrence.  
This clinical  trial will be conducted in compliance with the clinical trial protocol, GCP  (ICH  Topic 
E6), and the applicable national regulatory requirements.  
3 Trial Objectives  
3.1 Primary  Objective 
The primary objectives of this study are to estimate efficacy of M7824 with : 
o Objective response rate (ORR) in m icrosatellite instability -high (MSI -H) patients  who 
have progressed on immune checkpoint blockade therapy (Cohort A-C ). 
OR 
o ORR in patients with t reatment -refractory, consensus molecular subtype 4 (CMS4) mCRC  
patients coadmnistered SBRT (Cohort B). While SBRT is preferred, IMRT or 3D 
conformal techniques may be utilized at the discretion of the treating radiation oncologist depending on the dose to surrounding normal tissues.  Patient will receive a total dose of 
24Gy over three days with one of the following modalities, at the discretion of the treating radiation oncologist: SBRT, IMRT and 3D conformal. 
OR 
o Clearance of ctDNA in ctDNA(+) patients with resected mCRC following completion of standard -of-care therapy  (Cohort D). 
 
3.2 Secondary Objectives  
To estimate progression -free survival (PFS) for M7824 in patients with:  
Proprietary of MD Anderson Cancer Center
  43/106 
  o MSI-H solid tumors  whose disease has progressed on prior immune checkpoint 
blockade therapy (Cohort A-C ). 
OR 
o Treatment- refractory, CMS4 mCRC  coadministered SBRT  (Cohort B).  While SBRT 
is preferred, IMRT or 3D conformal techniques may be utilized at the discretion of the 
treating radiation oncologist depending on the dose to surrounding normal tissues.  Patient will rec eive a total dose of 24Gy over three days with one of the following 
modalities, at the discretion of the treating radiation oncologist: SBRT, IMRT and 3D conformal. 
To estimate overall survival (OS) for M7824 in patients with:  
o MSI-H solid tumors  who are refractory to prior immune checkpoint blockade therapy 
(Cohort A-C ). 
OR 
o Treatment -refractory, CMS4 mCRC coadministered SBRT (Cohort B).  While SBRT 
is preferred, IMRT or 3D conformal techniques may be utilized at the discretion of the treating radiation onco logist depending on the dose to surrounding normal tissues.  
Patient will receive a total dose of 24Gy over three days with one of the following modalities, at the discretion of the treating radiation oncologist: SBRT, IMRT and 3D conformal. 
OR 
o ctDNA(+) re sected mCRC following completion of standard-of- care therapy (Cohort 
D). 
To estimate disease -free survival (DFS) in patients with resected mCRC following standard -of-
care treatment  (cohort D). 
To evaluate safety and tolerability of treatment with M7824 in patients with: 
o MSI-H mCRC who are refractory to prior immune checkpoint blockade therapy 
(Cohort A-C ). 
OR 
o Treatment -refractory, CMS4 mCRC (Cohort B) 
OR 
o ctDNA(+) resected mCRC following completion of standard -of-care therapy (Cohort 
D). 
. 
3.3 Exploratory Objectives  
 1.  To evaluate intratumoral pharmacodynamic changes in immune populations using paired 
biopsies from patients with MSI- H solid tumors (Cohort A -C) or CMS4 mCRC treated with 
Proprietary of MD Anderson Cancer Center
  44/106 
  M7824 and SBRT  (Cohort B).  While SBRT is preferred, IMRT or 3D conformal techniques may be 
utilized at the discretion of the treating radiation oncologist depending on the dose to surrounding normal 
tissues.   Patient will receive a total dose of 24Gy over three days with one of the following modalities, at 
the d iscretion of the treating radiation oncologist: SBRT, IMRT and 3D conformal.  
2.  To characterize circulating immune cell populations and cytokine profiles in tumor and 
circulation following treatment with M7824.  
3.  To describe changes in levels of TGF -β following treatment with M7824. 
4.  To correlate the presence of microsatellite instability with CMS1 profile.  
5.  To correlate MSI -H and CMS4 to CpG island methylator phenotype (CIMP) status, KRAS and 
BRAF mutation status. 
6.  To quantify correlation with CMS4 and immune populations within tumor infiltrate. 7.  To correlate anti -tumor response to M7824 with PD-L1 expression. 
8.  To conduct RNAseq, RNA Scope, WES targeted sequencing and tissue IO gene expression by 
Nanostring.   
9.  To evaluate novel markers in blood by liquid biopsy including, but not limited to, circulating -
free DNA (cfDNA), exosomes, and circulating tumor cells (CTC).   
10. To describe changes in microbiome profiling upon treatment with M7824 (with or without radiation).  
4 Investigati onal Plan  
4.1 Overall Trial Design and Plan 
4.1.1.1  Cohort A -C – MSI- H solid tumors  
This is a phase Ib expansion study to assess efficacy of M7824 in patients with MSI- H solid tumors 
who have progressed on prior anti -PD-1/PD -L1 therapy. The hypothesis is that  these  patients will 
demonstrate anti -tumor response upon treatment with M7824.  Patients successfully enrolled will 
have had at least two doses of prior immune checkpoint therapy (anti -PD1, anti -PDL1 or anti -
CTLA4) with documented progression on CT or MRI imaging.  
M7824 will be administered intravenously at a dose of 1200mg every 14 days ( -3/+1 day). M7824 
will be administered until documented PD, unacceptable toxicity, or withdrawal of informed 
consent. Tumor assessments will be performed every 8 weeks. Progressive disease, stable disease, 
partial response, and complete response will be defined by iRECIST 1.1.  Patients who discontinue 
due to toxicity will continue to be assessed via imaging until documented PD.  
4.1.1.2  Cohort B  – CMS4 mCRC  
This is a phase 2, si ngle arm, Simon’s optimal two- stage design to assess ORR in treatment-
refractory CMS4 mCRC receiving M7824  with SBRT . The hypothesis is that efficacy of M7824 
coadministered with SBRT will be demonstrated in patients with CMS4  mCRC   
Proprietary of MD Anderson Cancer Center
  45/106 
  Patients successfully enrolled will have had CMS4 classification after characterization of their pre-
treatment primary tissue biopsy.  M7824 will be administered intravenously at a  dose of 1200mg 
every 14 days (+/ - 7 days).  The first dose of M7824 will be  administered alone.  After the second 
dose of M7824, patients will receive SBRT for a total dose of 24Gy over three days, with first treatment of radiotherapy administered within 7 days of completion of the second dose of M7824 
(cycle 1, day 15) .  Radioth erapy must be completed prior to the third dose of M7824.  While SBRT 
is preferred, IMRT or 3D conformal techniques may be utilized at the discretion of the treating radiation oncologist depending on the dose to surrounding normal tissues.  Patient will re ceive a 
total dose of 24Gy over three days with one of the following modalities, at the discretion of the treating radiation oncologist: SBRT, IMRT and 3D conformal.  
M7824 will be continued until documented PD or unacceptable toxicity. Tumor assessments will 
be performed every 8 weeks. Progressive disease, stable disease, partial response, and complete 
response will be  defined by i RECIST 1.1 . Patients who discontinue due to toxicity will cont inue 
to be assessed via imaging until documented PD.  
4.1.1.3  Cohort D – ctDNA(+) MSS mCRC following resection of 
metastatic disease 
This is a pilot study to assess the clearance of ctDNA with M7824 following R0 resection of metastatic disease in patients with MSS  mCRC.  Patients with oligometastatic colorectal cancer 
must have undergone an R0 resection with no remnant clinically or radiographically evident disease.  The primary tumor must have also been resected, and patients must have completed all standard -of-care treatment for the primary tumor (e.g., chemoradiation for primary rectal cancer, 
adjuvant chemotherapy, etc) at the discretion of the treating physician. 
Following at least 14 days of completion of standard therapy, patients will be tested for the 
presence or absence of ctDNA.  Patients with a confirmed (+) ctDNA result will be allowed to 
proceed with M7824 treatment.   M7824 will be administered intravenously at a dose  of 1200 mg every 14 days (+/ - 7 days).  ctDNA 
and CT scans will be repeated at 12 weeks .  Patients without evidence of clinical or radiographic 
progression will have the option to continue on treatment every 2 weeks with M7824, until the 
time of disease recurrence and/or progression, either radiographically or clinically .  Radiographic 
assessments will occur every 12 weeks thereafter , until disease progression or patient 
discontinuation on study. 
 
4.1.2 Planned number of subjects 
4.1.2.1  Cohort A -C – MSI- H solid tumors  
The planned number of subjects for this trial is 15 patients with MSI -H metastatic solid tumors. 
Proprietary of MD Anderson Cancer Center
  46/106 
  4.1.2.2  Cohort B  – CMS4 mCRC  
In this Simon two -stage design, t he planned number of subject s is 15 in the first stage . Should at 
least 2 patients demonstrate radiographic response (i.e. CR + PR) , then 14 additional pati ents will 
be treated in the second stage, for a total of 29 patients .  If there is an anti -tumor signal in the 29 
patients with CMS4 metastatic CRC who are treated with this combination, then the study may be 
amended to expand patient selection across all CMS subgroups. 
. 
4.1.2.3  Cohort D -- ctDNA(+) MSS mCRC following resection of 
metastatic disease  
The planned number of subjects for this cohort is 15 patients. 
4.1.3 Planned treatment duration  
The trial duration for a subject is estimated to be up to 2 years. This includes an 28- day s creening 
period (decision will be made in this period for subject ’s trial inclusion if all eligibility criteria are 
met), a treatment duration until confirmed PD, unacceptable toxicity, or any criterion for 
withdrawal from the trial or IMP occurs (see Section 4.5) and an 28-Day Safety Follow-up visit 4 weeks after the last dose of M7824 administration.  
Subjects who have experienced a durable, confirmed PR or CR may conti nue treatment for a 
maximum of 12 months, although additional treatment is possible. If the Investigator believes that 
a subject may benefit from treatment beyond 12 months, it may be permissible after discussion 
with the principal investigator. In the case of pseudoprogression, subjects should continue treatment through one additional  tumor assessment, if they meet the criteria described in Section 
4.5.1. 
Adverse events ( AEs) and adverse drug reactions (ADRs) should be followed until they resolve, 
return to b aseline, or are irreversible (see Section 6.1.4 for details). 
In both cohorts, it  is anticipated to enroll the first p lanned subject by October  2017, and the final 
subject enrolled by October  2018.  
4.1.4 Dose Modification and ADRs Requiring Treatment 
Discontinuation  
4.1.4.1  Dose Modification  
The dose of M7824 is 1200mg. Further details about discontinuation, withholding and restarting 
M7824 based on ADRs and AEs are presented in further detail in Section  5.5.3. 
Proprietary of MD Anderson Cancer Center
  47/106 
  4.1.4.2  Adverse Drug Reactions Requiring Treatment 
Discontinuation  
The following ADRs, defined as any AE assessed as related to M7824 by the Investigator and 
/ or Merck/EMD Serono, require permanent treatment discontinuation:  
Any Grade 4 ADRs  require treatment discontinuation except for single laboratory values out of 
normal range that do not have any clinical correlate, and resolve to Grade ≤ 1 or Baseline grade within 14 days with adequate medical management.  
Any Grade 3 ADRs require treatment discontinuation except  for any of the following:  
• Transient (≤ 6 hours) Grade 3 flu- like symptoms or fever, which is controlled with medical 
management. 
• Transient (≤ 24 hours) Grade 3 fatigue, local reactions, headache, nausea, emesis that resolves to ≤ Grade 1 or Baseline grade.  
• Tumor flare phenomenon defined as local pain, irritation, or rash localized at sites of known or suspected tumor. 
• Any Grade ≥ 3 drug -related amylase or lipase abnormality that is not associated with 
symptoms or clinical manifestations of pancreatitis. The study principal investigator  should 
be consulted for such Grade ≥ 3 amylase or lipase abnormalities. If the amylase or lipase abnormality not associated with symptoms or clinical manifestations of pancreatitis has not resolved to  Grade ≤ 1 within the subsequent 2 doses (28 days), the subject should 
permanently discontinue treatment with M7824. 
• Grade 3 Hgb decrease (< 8.0 g/dL) that is clinically manageable with blood transfusions or erythroid growth factor use does not require treatment discontinuation.  
• Increases in Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 3 that resolves to ≤  2 by Day 1 of the next cycle (infusions should not be given if the ECOG PS 
is ≥ 3 on the day of IMP administration and should be delayed until ECOG PS ≤ 2). 
Any Grade 2 ADR should be managed as follows:  
• If a Grade 2 ADR resolves to Grade ≤ 1 by the last day of the current cycle, treatment may 
continue. 
• If a Grade 2 ADR does not resolve to Grade ≤ 1 by the last day of the current cycl e but it 
is manageable and / or not clinically relevant, the ADR should be discussed with the 
principal investigator  and based upon discussion it is possible the infusion will be given on 
the following cycle. If at the end of the following cycle, the event  has not resolved to Grade 
1, discussion should be had with the principal investigator about permanently discontinuing 
treatment with M7824. 
Proprietary of MD Anderson Cancer Center
  48/106 
  • Upon the second occurrence of the same Grade 2 ADR in the same subject (except for 
fatigue and hormone insufficienc ies that can be managed by replacement therapy), 
continuation of treatment with M7824 has to be discussed with the principal investigator  
and might be permanently discontinued. 
• Infusion- related reactions and hypersensitivity reactions (Grades 1 to 4) should be handled 
according to the guidelines provided in Sections 5.5.3.1 and 5.5.3.2, respectively.  
• Anemia should be handled according to the guidelines provided in Section 5.5.3.4. 
4.1.5 Analysis Cut -Off Dates 
4.1.5.1  Cohort A -C 
The primary data cut -off for the analysis will be  after 24 weeks after the last subject received 
M7824. 
The final data cut -off will be 1 year after the last subject has received the last dose of M7824.  
4.1.5.2  Cohort B  
The first data cut -off for the interim analysis will be 12 weeks after the 15th subject enrolled has 
received study treatment. A decision to continue on to the target 29 patients will be based on the 
number of responses observed. If 2 or more confirmed responses are observed, the primary data 
cut-off for the analysis will be 24 weeks after the last subject (n=29) received study treatment. 
The final data cut -off will be 1 year after the last subject has received the last dose of M7824.  
4.1.5.3  Cohort D  
The primary data cut -off for the analysis will be after 24 weeks after the last subject rec eived 
M7824. The final data cut -off will be 1 year after the last subject has received the last dose of M7824.  
4.2 Discussion of Trial Design  
4.2.1.1  Cohort A -C 
This is a Phase Ib , open- label trial in patients with MSI- H metastatic solid tumors  who have 
progressed on prior checkpoint inhibitor treatment.  
The study focuses on the subset of patients with metastatic solid tumors  that has displayed higher 
responses rates to immune checkpoint blockade. Microsatellite instability  is associated with higher 
immune infiltration61-63 .  One early study demonstrated that responders to the anti -PD-1 antibody, 
pembrolizumab, were restricted to MSI -H mCRC patients  in comparison to non- MSI-H CRC38. 
Updated results from this study demonstrated RR of 50% and disease- control rate (DCR) of 89% 
Proprietary of MD Anderson Cancer Center
  49/106 
  seen in MSI -H, compared  to 0% and 16% in non- MSI-H mCRC patients, respectively59. 
Pembrolizumab has since received breakthrough designation by the FDA for approval in MSI -H 
solid tumors (including mCRC ). In addition, PD -L1 expression was not associated with OS in this 
study and preliminary results from the Checkmate -142 trial , in which patients with mCRC were 
treated with the anti -PD-1 antibody nivolumab60. Therefore, using MSI- H as the current selection 
biomarker for this study  is appropriate.  
MSI-H non-CRC tumors have demonstrated impr essive ORR of 53% with PD -1 blockade in a 
variety of tumors was 53% and DCR of 77% with median PFS and OS not being met59. Given the 
mechanism of M7824, use of MSI -H as a biomarker as already demonstrated is appropriate to 
enrich for likely responders while selection based on prior progression following checkpoint 
immunotherapy approaches ensures targeting of a potential resistance mechanism.   
 
4.2.1.2  Cohort B  
This is a phase II, single arm, Simon two- stage design to assess efficacy of M7824 as an abscopal 
phenomenon with radiation to a single metastatic lesion in patients with  treatment -refractory , 
CMS4 mCRC receiving M7824. Tumors ≥ 7.0 cm in largest diameter should be excluded from 
receiving radiation as part of this study. As previously described, TGFβ represents an immune resistance mechanism via recruitment of immunosuppressive cells and downregulation of existing anti-tumoral responses within the TME. TGF -β signaling may also promote resistance to an 
abscopal phenomenon in patients with mCRC administered  immunotherapy with radiation.  The 
trial design is also justified based on pre -clinical evidence that CMS4  mCRC demonstrate an 
intrinsically  inflamed , immunosuppress ive phenotype mediated by upregulation of TGF -β 
signaling.  
Restriction in this study to CMS4 comes from a number of preclinical studies implicating it with 
upregulation of TGF -β activation
43,64,65. Several of the hallmark features i ncluding EMT, stromal 
infiltration, angiogenesis and matrix remodeling are explained by some of the pleotropic effects of TGF -β. TGFβ represents an immune resistance mechanism via recruitment of immunosuppressive 
cells and downregulation of existing anti -tumoral responses within the TME
26,66. CMS4  is 
associated with poorer cancer specific outcomes and non- benefit to current adjuvant chemotherapy 
strategies3, and therefore novel effective therapies ae needed for this subpopulation of mCRC.   
4.2.1.3  Cohort D  
This is a pilot study of M7824 in patients with MSS mCRC who have detectable ctDNA following R0 resection of metastatic disease.  The inevitability of disease recurrence for patients with 
colorectal cancer, as seen in the presence of ctDNA following resection of CRC ,suggests existenc e 
of micrometastatic minimal residual disease in these cases.  Given that macroscopic metastases 
may use TGF -β signaling to exclude anti -tumor immune cells from the microenvironment, limiting 
selection of patients with micrometastatic disease may identify a subpopulation of mCRC patients that selectively benefit from immunotherapy.  
 
Proprietary of MD Anderson Cancer Center
  50/106 
  4.2.2 Inclusion of Special Populations 
Not applicable. 
4.3 Selection of Trial Population  
4.3.1 Inclusion criteria   
 
1. Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum that 
is metastatic or unresectable (cohort B); or histologically or cytologically confirmed 
adenocarcinoma of the colon or the rectum following resection of the primary tumor and 
metastatic disease, following completion of standard -of-care perioperative therapy at the 
discretion of the treating provider (cohort D). 
2. Confirmation of: 
a. Cohort A-C : microsatellite instability  
b. Cohort B: CMS4 CRC classification on pretreatment primary tumor. 
c. Cohort D: microsatellite stability  
3. Age >18 years at time of study entry. 
4. Ability to provide written informed consent. 
5. Documented progression to prior therapies (Cohorts A -C and  B): 
a. Cohort A-C: Disease progression following prior immune checkpoint blockade 
therapy  
b. Cohort B: Progression or intolerance to at least 2 prior lines of standard therapy 
for unresectable or metastatic CRC 
6. Available primary tumor tissue for CMS4 biomarker assessment (cohort B) 
7. Life expectancy ≥12 weeks as judged by the treating physician. 
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 
9. Measurable disease according to i RECIST  v1.1 (Cohorts A- C and  B). For cohort B, 
measureable lesions must be identified apart from the irradiated tumor lesion.   Patients in 
cohort D must have no evidence of radiographically evident disease at the time of study entry. 
10. Adequate hematological funct ion, defined by ANC ≥ 1.0 × 10
9/L, lymphocyte count ≥ 
0.5 × 109/L, platelet count ≥100 × 109/L, and Hgb ≥ 9 g/dL (in absence of blood 
transfusion).  
11. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN), an AST level ≤ 2.5 × ULN, and an ALT level ≤ 2.5 × ULN.  If liver 
metastases are present, then it is acceptable for AST level ≤ 5.0 × ULN, and an ALT level 
≤ 5.0 × ULN. 
12. International normalized ratio (INR) < 1.5  
13. Adequate renal function defined by an estimated cr eatinine clearance >30 mL/min 
according to the Cockcroft- Gault formula or be measure for creatinine clearance from 24 
hour urine collection.  
Proprietary of MD Anderson Cancer Center
  51/106 
  14. Highly effective contraception for both male and female subjects if the risk of conception 
exists. Highly  effective contraception must be used 30 days prior to first trial 
administration, for the duration of trial treatment, and at least for 4 months after stopping 
trial treatment (see Appendix 2 for further details). Should a woman become pregnant or 
suspect  she is pregnant while she or her partner is participating in this trial, the treating 
physician should be informed immediately. 
15. Ability to tolerate receipt of radiotherapy to a metastasis not adjacent to a normal dose-limiting structure, at the discretion  of the treating radiation oncologist (cohort B). 
16. Presence of detectable ctDNA following completion of R0 resection with or without perioperative therapy (cohort D only). 
17. Completion of all standard -of-care adjuvant therapy (cohort D). 
4.3.2 Exclusion criteria  
1. Concurrent treatment with non-permitted drugs and other interventions. 
2. Anticancer treatment within 14 days before the start of trial treatment [e.g., cytoreductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ -sparing technique), immune therapy, or cytokine therapy]. 
3. Major surgery as determined by the investigator within 28 days before the start of trial 
treatment (prior diagnostic biopsy is permitted).  
4. Systemic therapy with immunosuppressive agents within 7 days before the start of treatment; or use of any investigational drug within 28 days before the start of trial treatment.  
5. Cohort A- C only: Intolerance or serious adverse immune related adverse events (irAEs) 
[refer to section 5.5.3.3] that were symptomatic or required or continues to require ongoing immunosuppression to previous immune checkpoint therapy. 
6. Cohorts B and D: prior exposure to any immune checkpoint blockade agent or any other immunomodulatory agent used for antineoplastic therapy for mCRC. 
7. Previous malignant disease (other than the target malignancy to be investigated in this 
trial) within 3 years prior to study treatment initiation. Other Lynch syndrome cancers do not exclude patients from participating on study, at the discretion of the Principal 
Investigator.  Subjects with a history of cervical carcinoma in situ, superficial or non -
invasive bladder cancer, or basal cell or squamous cell carcinoma in situ, previously 
treated with curative intent are NOT excluded. Subjects with other localize d malignancies 
treated with curative intent need to be discussed with the Principal investigator.  
8. Subjects with active central nervous system (CNS) metastases are excluded. Subjects 
with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible 
unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy. 
9. Receipt of any organ transplantation, including allogeneic stem- cell transplantation, but 
with the exception of transplants that do not require immunosuppression (e.g., corneal 
transplant, hair transplant).  
10. Significant acute or chronic infections including, among others:  
Proprietary of MD Anderson Cancer Center
  52/106 
  a. Known history of testing positive test for human immunodeficiency virus (HI V) 
or known acquired immunodeficiency syndrome. 
b. HBV or HCV infection (HBV surface antigen positive and HBV core antibody 
positive with reflex to positive HBV DNA or HBV core antibody positive alone 
with reflex to positive HBV DNA or positive HCV antibody w ith reflex to 
positive HCV RNA).  
c. Subjects with active tuberculosis (history of exposure or history of positive tuberculosis test plus presence of clinical symptoms, physical or radiographic 
findings). 
11. Active autoimmune disease that might deteriorate when r eceiving an immunostimulatory 
agent: 
a. Subjects with type I diabetes, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid 
disease not requiring immunosuppressive treatment are eligible 
b. Subjects requiring hormone replacement with corticosteroids are eligible if the 
steroids are administered only for the purpose of hormonal replacement and at 
doses ≤ 10mg of prednisone or equivalent per day. 
c. Administration of steroids for other conditions through a route known to result in a minimal  systemic exposure (topical, intranasal, intro -ocular, or inhalation) is 
acceptable.  
12. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI -
CTCAE v4.03), any history of anaphylaxis, or recent (within 5 months) history of uncontroll ed asthma.  
13. Persisting toxicity (except alopecia and vitiligo) related to prior oncologic therapy Grade >1 NCI -CTCAE v4.03, however, sensory neuropathy Grade ≤ 2 is acceptable.  
14. Clinically significant cardiovascular/ cerebrovascular disease as follows: cereb ral 
vascular accident / stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class >II), or serious cardiac arrhythmia.  
15. Clinically relevant diseases (for example, inflammatory bowel disease) and / or uncontrolled medical conditions, which, in the opinion of the Investigator, might impair 
the subject’s tolerance or ability to participate in the trial.  
16. Vaccine administration within 4 weeks of M7824 administration. Vaccination with live 
vaccines while on trial is prohibited. Administration of inactivated vaccines is allowed (for example, inactivated influenza vaccines). 
17. Cohort D: peritoneal carcinomatosis. 
 
4.3.3 Screening Eligibility (cohort B) 
Patients are eligible for screening for CMS subtyping prior to enrollment on cohort B provided 
that the following elibility criteria are met:  
• Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum that is metastatic or unre sectable.  
Proprietary of MD Anderson Cancer Center
  53/106 
  • Progression on at least one prior line of systemic therapy for metastatic disease.  
• Prior tissue sampling of primary tumor with core biopsy, endoscopic biopsy, or surgical 
resection to be used for CMS subtype testing. 
4.4 Criteria for  Initiation of Trial Treatment  
The inclusion and exclusion criteria will be checked at the Screening visit. Eligible subjects will 
be enrolled before treatment start after verification of fulfilling all inclusion criteria and satisfy no exclusion criteria.  Documentation of satisfaction of eligibility criteria for each patient will be 
performed within C ORe.  
4.5 Criteria for Subject Withdrawal  
4.5.1 Withdrawal from Trial T reatment  
 Subjects will be withdrawn from trial treatment for any of the following reasons:  
• PD as defined by i RECIST 1.1  
o Patients may continue on M7824 until immune confirmed PD (iCPD) provided they 
meet the criteria  for pseudoprogression (see 5.5.1.1 below) 
• Therapeutic failure requiring urgent additional cancer therapy  
• Occurrence of any  Grade ≥ 3 ADRs or repetitive Grade 2 ADRs as defined in Section 
5.5.3.3. 
• Occurrence of AEs, at the Investigator’s discretion  
• Pregnancy 
• Use of prohibited concomitant drug, as defined in Section 5 .5.2, where the predefined 
consequence is withdrawal from the IMP  
• Non-adherence / non -compliance to the trial protocol or trial requirements (see Section 5.9) 
• Withdrawal of consent 
• Participation in any other trial  
4.5.1.1  Pseudoprogression  
Pseudoprogression is defined as an initial disease flare followed by a delayed disease response. At the time of progression, there is no  definitive way to distinguish this from true progressive disease 
without a confirmatory scan.  To account f or pseudoprogression, patients will  have PD, SD, PR or CR recorded as defined by 
iRECIST 1.1. However, PD will require a subsequent scan at the next planned tumor assessment 
in 8 weeks or earlier if clinically indicated. Patients will be allowed to continue on M7824 despite first document ation of PD if:  
o No new Grade 2 or greater  severity of  symptoms or significant worsening of existing 
symptoms  
o No decrease in ECOG PS  
o In the opinion of the Investigator, the subject does not require new anticancer therapy. 
 Failure to sa tisfy all  of these conditions results in discontinuation of M7824.  
Proprietary of MD Anderson Cancer Center
  54/106 
   
Confirmed PD on the subsequent scan also results in study discontinuation.   The time point for PD will be taken from the first noted date and not the time of the confirmation scan.  
 
4.5.2 Withdrawal from the Trial  
Subjects may withdraw from the trial at any time without giving a reason. Withdrawal of consent will be considered withdrawal from the trial.  If a subject withdraws  participation while on study, 
survival information may still be collected via phone calls, electronic communication, letters or publically available records.  
A subject must be withdrawn if any of the following occur during the trial: 
• Withdrawal of the subject’s consent 
• Participation in any other therapeutic trial during the treatment duration of this trial; 
however, subjects will continue to be followed for survival 
If a subject fails to attend scheduled trial assessments, the Investigator must determine the reasons 
and the circumstances as completely and accurately as possible. 
In case of withdrawal from the trial, the assessments scheduled for the last visit (28 -Day Safety 
Follow- up visit) should be performed (see Section 6.1.3), if possible, with focus on the most 
relevant assessments. In any case, the appropriate 28 -Day Safety Follow -up electronic case report 
form (eCRF) in the Prometheus database visit must be completed. In case of withdrawal, subjects 
will be asked to continue safety and survival follow -up, which includes the collection of data on 
survival and subsequent anticancer therapy. After completion of the Follow-up period or after the End of Treatment visit, whatever is applicable, the appropriate eCRF section for Trial Termination must be completed  in the Prometheus database. 
If a subject is withdrawn prio r to PD for any reason the subject will not be replaced.  
4.6 Premature Termination of the Trial  
For either cohort, the trial may be discontinued prematurely in the event of any of the following: 
New information leading to unfavorable risk-benefit judgment of the IMP, for example, due to 
1. Evidence of inefficacy  of the IMP,  
2. Occurrence of significant previously unknown adverse reactions or unexpectedly high 
intensity or incidence of known adverse reactions, or  
3. Other unfavorable safety  findings. 
(Note: Evidence of inefficacy may arise from this trial or from other trials; unfavorable 
safety findings may arise from clinical or non -clinical examinations, for  example, 
toxicology.) 
Proprietary of MD Anderson Cancer Center
  55/106 
  • Merck/EMD Serono or the IND Office’s decision that continuation of the trial is 
unjustifiable for medical or ethical reasons . 
• Poor enrollment of subjects making completion of the trial within an acceptable time frame 
unlikely. 
• Discontinuation of development of the Merck/EMD Serono’s IMP . 
Health Authorities and Independent Ethics Committees (IECs) / Institutional Review Boards 
(IRBs) will be informed about the discontinuation of the trial in accordance with applicable 
regulations. 
The whole trial may be terminated or suspended upon request of Health Authorities. 
4.7 Definition of End of Trial  
If the trial is not terminated for a reason  given in Section 4.6, the end of the trial is defined as 1 
year after the last subject receives the last dose of M7824. 
5 Investigational Medicinal Product and Other Drugs Used in 
the Trial  
The term “Investigational Medicinal Product” (IMP) refers to an active substance or a placebo 
being tested or used as a reference therapy in a clinical trial, including products that have a marketing authorization but are formulated, packaged, or administered differently from the authorized form, used for an unauthorized indication, or used to gain further information about the authorized form. The only IMP used in this trial is M7824. 
5.1 Description of the Investigational Medicinal Product 
M7824 drug product is a sterile , freeze- dried formulation presented at a concentration of 600 
mg/vial in United States Pharmacopeia (USP) type I glass vial closed with a rubber stopper and sealed with an aluminum plastic crimping cap.  
Each vial contains 600 mg of M7824 as a preservative -free histidine -buffered solution ( pH=5.5) 
containing trehalose dihydrate, sodium chloride, L -methionine and polysorbate 20 (Tween 20). 
Only excipients that conform to the current USP are used for M7824 drug product. 
5.2 Dosage and Administration  
5.2.1 M7824 Administration 
Subjects will receive IV infusion of M7824 over 1 hour (-10 minutes / +20 minutes ) once every 2 
weeks as detailed in the Schedules of Assessments (see Tables  1-3) . Modifications of the infusion 
rate due to infusion- related reactions are described in Section 5.5.3.1.  
The dose for M7824 is 1200mg. In cohorts A -C and  B, subjects will receive M7824 once every 2 
weeks until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or IMP oc curs (see Section 4.5). Subjects who have experienced a persistent, confirmed PR 
Proprietary of MD Anderson Cancer Center
  56/106 
  or CR may continue treatment through the end of 12 months, although additional treatment is 
possible. If the Investigator believes that a subject may benefit from treatment beyond 12 months, 
it may be permissible after discussion with the p rincipal investigator.  In cohort D, patients will 
receive M7824 for 6 doses.  After 6 doses, the patient will have blood checked for ctDNA clearance.  If there is no evidence of radiographic or clinical progression, then the patient may continue on study at the discretion of the investigator. 
For subjects who achieve a PR or CR on M7824 therapy and then subsequently develop disease 
progression after stopping therapy, but prior to the end of the trial, a re-initiation course of 
treatment at the same dose and schedule and treatment duration up to 12 months is allowed at the 
discretion of the Investigator and agreement of the trial p rincipal investigator. Subjects re -initiating 
treatment should be assessed according to the Schedules of Assessment of the trial starting at Week 1, Day 1 (see Table s 1-3). 
5.2.2 Radiotherapy (cohort B only)  
Radiation therapy will be delivered to a single metastatic lesion, with total dose of 24 Gy in 3 daily fractions of 8 Gy each.  Radiation therapy will be delivered on consecutive business days.  All 3 fractions will be administered after the second dose of M7824 and prior to the administration of 
the third dose of M7824. 
Patients will undergo CT simulation, with or without IV contrast.   The gross tumor volume (GTV) 
will include a single metastatic lesion.  The metastati c lesion to be irradiated must not be adjacent 
to a dose -limiting normal structure (e.g., heart, bowel) at the discretion of the treating radiation 
oncologist.  The planning target volume (PTV) will include the GTV with a 5 -7 mm margin in all 
directions.  For lesions affected by respiratory motion, appropriate motion management techniques 
should be used, such as inspiratory breathhold.  Daily volumetric imaging with cone beam CT (CBCT) or CT on rails (CTOR) will be used for image guidance.   
 
5.3 Assignment to Treatment Groups  
Not applicable 
5.4 Noninvestigational Medicinal Products to be Used  
In order to mitigate potential infusion -related reactions, premedication with an antihistamine (e.g., 
25-50 mg PO at the discretion of the investigator) and with acetaminophen (e.g., 325-650 mg PO 
at the discretion of the investigator) approximately 30 to 60 minutes prior to each dose of M7824 
is mandatory for the first 2 infusions and is optional and at the discretion of the Investigator starting with the third  infusion. If Grade ≥ 2 infusion reactions are seen during the first two infusions, then 
premedic ations should not be stopped. Steroids as premedication are not permitted . Special 
precautions for monitoring of subjects and management of infusion- related reactions / 
hypersensitivity including modifications of the infusion rate and stopping of trial drug are described in Section 5.5.3 and subsections. As  with all monoclonal antibody therapies, there is a 
risk of allergic reaction including anaphylactic shock. M 7824 should be administered in a setting 
Proprietary of MD Anderson Cancer Center
  57/106 
  that allows for immediate access to an intensive care unit or equivalent environment and 
administration of therapy for anaphyla xis, such as the ability to implement immediate resuscitation 
measures. Steroids (dexamethasone 10 mg  IV), epinephrine (1:1,000 dilution), allergy medications 
(IV antihistamines), bronchodilators, or equivalents, and oxygen should be available for immediat e 
access  in the event of an anaphylactic reaction. Infusion of M 7824 will be stopped in case of Grade 
≥ 2 infusion- related, allergic, or anaphylactic reactions. Following M 7824 infusions, subjects must 
be observed for a minimum of 2 hours post end of infusion for potential infusion- related reactions. 
Please see the guidelines for handling of infusion- related reaction in Section 5.5.3.1. 
If an allergic reaction occurs, the subject must be treated according to the best available medical practice. Guidelines f or management of infusion- related reactions and severe hypersensitivity 
reaction according to the National Cancer Institute are found in Section 5.5. 3. 
Further precautions are provided in Section 5.5.3.2. For prophylaxis of flu- like symptoms, a non-
steroid al anti -inflammatory drug (NSAID) for example, ibuprofen 400 mg or comparable NSAID 
dose, may be administered 2 hours before and 8 hours after the start of each dose of M 7824 IV 
infusion. 
5.5 Concomitant Medications and Therapies  
All concomitant medications ta ken by the subject during the trial, from the date of signature of 
informed consent are to be recorded in the appropriate section of the eCRF  (Prometheus ) and 
medical record , noting the name, dose, duration and indication of each drug. Nondrug interventions 
(other than vitamins) and any changes to a concomitant medication or other intervention should also be recorded in the eCRF (Prometheus ) and medical record . 
5.5.1 Permitted Medicines  
Any medications (other than those excluded by the clinical trial protocol) th at are considered 
necessary to protect subject welfare and will not interfere with the trial medication may be given at the Investigator’s discretion.  
Other drugs to be used for prophylaxis, treatment of anaphylactic reactions, infusion- related 
reactions, and severe hypersensitivity reactions / flu- like symptoms and irAEs are described in 
Section 5.5.3. 
Palliative radiotherapy  delivered in a normal organ- sparing technique may be administered during 
the trial. The assessment of PD will not be based on the necessity for palliative radiotherapy.  
5.5.2 Prohibited Medicines  
As stated for the exclusion criteria in Section 4.3.2, subjects must not have had chemotherapy, 
radiotherapy (other than palliative radiotherapy delivered in a normal organ- spearing technique as 
described in Section 5.5.1), major surgery, or received another investigational agent within 28 days 
before the start of trial treatment.  
The following treatments must not be administered during the trial: 
Proprietary of MD Anderson Cancer Center
  58/106 
  • Immunotherapy including interferon, immunosuppressive drugs (for example, 
chemotherapy or systemic corticosteroids except for short term treatment of allergic 
reactions, endocrine replacement therapy at low dose prednisone [≤ 10 mg daily] or 
equivalent, or for the treatment of irAEs or other appropriate short term steroid use), or other experimental pharmaceutical products. Short term administration of systemic steroid or other immunosuppressant such as infliximab or mycophenolate (that is, for allergic reactions or the management of irAEs) is  allowed. Steroids with no or minimal systemic 
effect (topical, inhalation) are allowed. Note: for subjects with glioblasto ma, steroid use is 
allowed. 
• Adefovir. 
• Prophylactic use of corticosteroids for infusion related reactions is prohibited. 
• Any live vaccine therapies for the prevention of infectious disease. Administration of inactivated vaccines is allowed (for example, inactivated influenza vaccines).  
• Blood transfusions and erythroid growth factors are permitted for Hgb ≤ less 7 g/dL and/or 
for life threatening bleeding  
If the administration of a non- permitted concomitant drug becomes necessary during the trial, the 
subject will be withdrawn from trial treatment (the Principal investigator  may be contacted to 
discuss whether the IMP must be discontinued). 
Medications other than those specifically excluded in this trial (as outlined in this section) may be 
administered for th e management of symptoms associated with the administration of M7824 as 
required. These might include analgesics, anti -emetics, antihistamines, diuretics, anti -anxiety 
medications, and medication for pain management, including narcotic agents. 
Any additional concomitant therapy that becomes necessary during the trial and any change to 
concomitant drugs must be recorded in the corresponding section of the eCRF  (Prometheus ) and 
medical record , noting the name, dose, duration, and indication of each drug. 
The following non- drug therapies must not be administered during the trial (and within 28 days 
before the start of trial treatment):  
• Major surgery (excluding prior diagnostic biopsy).  
• Herbal remedies with immunostimulating properties (for example, mistletoe extract) or 
known 
• to potentially interfere with major organ function (for example, hypericin) 
• Subjects should not abuse alcohol or other illicit drugs during the trial 
Proprietary of MD Anderson Cancer Center
  59/106 
  5.5.3 Special Precautions  
As a routine precaution, subjects all enrolled in this trial must be observed for 2 hours in the CTRC 
post end of infusion, in an area with resuscitation equipment and emergency agents  at least for the 
first two doses of treatment with M7824. If no medical problems arise during the first tw o 
treatments, then the 2 hour observation period does not need to continue starting with the third 
dose of treatment. At all times during M7824 treatment, immediate emergency treatment of an 
infusion- related reaction or a severe hypersensitivity reaction according to institution al standards 
must be assured. In order to treat possible anaphylactic reactions, for instance, dexamethasone 10 mg and epinephrine in a 1:1000 dilution or equivalents should always be available along with equipment for assisted ventilation. 
Infusion of M7824 will be stopped in case of Grade ≥ 2 hypersensitivity, inflammatory response, 
or anaphylactic reaction. The treatment recommendations for infusion- related reactions and severe 
hypersensitivity reactions according to the NCI are outlined in Sections 5.5.3.1 and 5.5.3.2, respectively.  
Investigators should also monitor subjects closely for potential irAEs  (described in Section 
5.5.3.3) , which may become manifest after several weeks of treatment. Such events may consist 
of persistent rash, diarrhea and colitis, autoimmune hepatitis, arthritis,  glomerulonephritis, 
cardiomyopathy, or uveitis and other inflammatory eye conditions. 
5.5.3.1  Infusion-related reactions  
IRRs are defined as any signs or symptoms experienced by participants  during the infusion of 
pharmaco logic or biologic agents or any event occurring during or within 1 day of drug 
administration. IRRs are common ADRs with monoclonal antibodies timely related to drug administration and have been reported as anaphylaxis, anaphylactoid reactions , and cytokine 
release syndrome, among other terms used. IRRs are important identified risks (adverse reactions) for M7824, and the precautions and management are  provided in Table 46 
A. Signs and symptoms of infusion related reactions (IRRs) including hypersensitivity include but not limited to pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria, were reclassified as important identified risks (adverse reactions).  
B. Management  
Table 6: Treatment Modification for Symptoms o f Infusion- related Reactions Caused by 
M7824 
NCI-CTCAE Grade  Treatment Modification for M7824  
Grade 1 – mild  
• Mild transient reaction; infusion interruption 
not indicated intervention not indicated.  • Decrease the M 7824  infusion rate by 50% and 
monitor closely for any worsening.  
Proprietary of MD Anderson Cancer Center
  60/106 
  • The total infusion time for M7824 should not 
exceed 120 minutes  
Grade 2 – moderate  
• Therapy or infusion interruption indicated but 
responds promptly to symptomatic treatment 
(for example, antihis tamines, NSAIDs, 
narcotics, IV fluids); prophylactic medications 
indicated for ≤ 24 hours.  • Stop M7824 infusion. 
• Resume infusion at 50% of previous rate once 
infusion -related reaction has resolved or 
decreased to at least Grade 1 in severity, and monitor cl osely for any worsening 
Grade 3 or Grade 4 – severe or life -threatening  
• Grade 3: Prolonged (for example, not rapidly responsive to symptomatic medication and / or 
brief interruption of infusion); recurrence of 
symptoms following initial improvement; 
hospi talization indicated for clinical sequelae.  
• Grade 4: Life -threatening consequences; 
urgent intervention indicated.  • Stop the M7824 infusion immediately and 
disconnect infusion tubing from the subject.  
• Subjects have to be withdrawn immediately 
form M7824 tr eatment and must not receive 
any further M7824 treatment 
IV = intravenous; NCI- CTCAE = National Cancer Institute – Common Terminology Criteria for Adverse Event; 
NSAIDs = nonsteroidal anti- inflammatory drugs  
Additional Modifications for Subjects with Grad e 2 Infusion -related Reactions  
If, in the event of a Grade 2 infusion- related reaction that does not improve or worsens after 
implementation of the modifications indicated in Table 7 (including reducing the infusion rate by 
50%), the Investigator may consider treatment with corticosteroids and the infusion of IMP should be stopped for that day. At the next infusion, the Investigator may consider the addition of H2-blocker antihistamines (for example, famotidine or ranitidine), in addition to premedication, for select subjects. However, prophylactic steroids are NOT permitted. If the subject has a second infusion- related reaction Grade ≥ 2 on the slower infusion rate, with or without the addition of 
further medication to premedication, the infusion should be stopped and the subject removed from M7824 treatment. 
5.5.3.2  Severe Hypersensitivity Reactions and Flu- like Symptoms  
If a hypersensitivity reaction occurs, the subject must be treated according to the best available medical practice. A complete guideline for the emergency treatment of anaphylactic reactions according to the Working Group of the Resuscitation Council (United Kingdom) and can be found at https://www.resus.org.uk/pages/reaction.pdf. Subjects should be instructed to report any delayed reactions to  the Investigator immediately.  
A. Symptoms 
• Impaired airway  
• Decreased oxygen saturation (< 92%)  
Proprietary of MD Anderson Cancer Center
  61/106 
  • Confusion 
• Lethargy 
• Hypotension 
• Pale / clammy skin  
• Cyanosis 
B. Management  
1. Epinephrine injection and IV dexamethasone 
2. Patient should be placed on cardiac, blood pressure, heart rate, and oxygen saturation 
monitor immediately  
3. Alert intensive care unit for possible transfer if required  
For prophylaxis of flu- like symptoms, a NSAID, for example, ibuprofen 400 mg or comparable 
NSAID dose, may be administered 2 hours before and 8 hours after the start of each dose of M7824 IV infusion. 
5.5.3.3  Immune- Related Adverse Events  
For reporting irAE severity/toxicity grading, refer to CTCAE v4.03 toxicity grading system. 
For treatment management of irAE per CTCAE v4.03 criteria, refer to American Society of 
Clinical Oncology (ASCO) Clinical Practice Guidelines and National Comprehensive Cancer 
Network  irAE Management Guidelines.  
Treatment of irAEs is mainly dependent upon severity as defined by NCI -CTCAE v4.03. In 
general, management by CTCAE v4.03 grading, as per ASCO, is listed below: 
• Grade 1: study treatment should be continued with close monitoring, with the exception of some 
neurologic, hematologic, and cardiac toxicit ies.  
• Grade 2: study treatment may be suspended for most Grade 2 toxicities, with consideration of resuming when symptoms revert to Grade 1 or less. Corticosteroids may be administered (initial dose of 0.5 to 1 mg/kg/day of prednisone or equivalent).  
• Grad e 3: study treatment is generally suspended and the high -dose corticosteroids (prednisone 
1 to 2 mg/kg/day or methylprednisolone 1 to 2 mg/kg/day) treatment should be initiated. Corticosteroids should be tapered over the course of at least 4 to 6 weeks. So me refractory cases 
may require infliximab or other immunosuppressive therapy.  
• Grade 4: in general, permanent discontinuation of study treatment is recommended, with the exception of endocrinopathies that have been controlled by hormone replacement. 
Proprietary of MD Anderson Cancer Center
  62/106 
  Since  inhibition of PD -L1 stimulates the immune system, irAEs may occur. Treatment of irAEs is 
mainly dependent upon severity (NCI- CTCAE grade):  
• Grade 1 to 2: treat symptomatically or with moderate dose steroids, more frequent 
monitoring 
• Grade 1 to 2 (persistent): manage similar to high grade AE (Grade 3 to 4)  
• Grade 3 to 4: treat with high dose corticosteroids  
Treatment of irAEs should follow guidelines set forth in the ASCO/NCCN Management of 
Immunotherapy- Related Toxicities 
(https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf ). 
5.5.3.4  Anemia  
Anemia is considered a potential risk based on toxicological findings with M7824 in cynomolgus monkey indicating a  decrease in Hgb, RBCs, and hematocrit that was fully reversible or showed a 
substantial trend toward recovery. 
Notably, there are many reasons for anemia in patients with advanced 
cancer, which is why a thorough investigation of new anemia cases of unspecified etiology is requested.  
 Risk management measures in addition to routine laboratory tests will include:  
• Subjects must enter the study with Hgb values at least 9 g/dL , independent of recent (≤ 28 
days) packed red blood cell transfusion and/or use of an erythropoietin- stimulating agent.  
• Routine monitoring of Hgb will be performed every 2 weeks (prior to treatment). 
o Instructions for study treatment discontinuation or modification in case of anemia will be provided, briefly described here: In  case of any Hgb < 8 g/dL, the 
Investigator should use discretion to initiate anemia work up, including Coombs, haptoglobin, indirect bilirubin and peripheral smear, and prothrombin time (PT), 
activated partial thromboplastin time (aPTT), international normalized ratio  
(INR); Hgb  and hematocrit are to be closely monitored. 
 
• For new anemia events assessed as treatment-related, items queried may include but are not 
limited to detailed relevant past medical and treatment history, bruising tendency, history of 
blood transfusions and/or dependency, and a request for an updated eCRF including details such 
as concomitant medications, all laboratory data, updated dosing information and recent tumor 
evaluation scans.  
• If a subject experiences significant anemia, then the amount of  blood to be drawn may be 
reduced by not taking blood at selected time points for PD-L1 target occupancy, 
immunomonitoring, soluble factors, and TGFβ. The decision to reduce the time points for 
these biomarkers will be taken by the Investigator in consulta tion with the principal 
investigator .  
Proprietary of MD Anderson Cancer Center
  63/106 
  • Evaluation Guidance of  baseline anemia and Suspected Treatment -related Anemia AEs  
Baseline anemia evaluation (prior to transfusion, if feasible)  
Hb and CBC with differential (e.g. MCV, RDW, ANC, hematocrit, reticulocytes counts)  
Peripheral blood smear for cell morphological assessment  
Complete metabolic panel including liver panel -LFTs, bilirubin, LDH, renal function, and serum folate, B12 
values and other chemistries  
Coagulation factors (PT, PTT, INR) 
Urinalysis including culture  
Iron panel (TIBC, ferritin, Fe) 
TSH/hormonal panel  
Fecal -occult blood testing  
Peripheral blood smear  
haptoglobin  
Further recommendation based on suspected etiology (in addition to baseline anemia testing)  
Unknown etiology, 
suspect possible hemolysis Coombs test, fibrinogen, d- dimer  
Consider hematology consultation.  
Consider blood transfusion at clinical discretion.  
Unknown etiology, suspect possible bleeding  Consider blood transfusion at clinical discretion.  
Consider surgical/interventional radiology consultation.  
Consider imaging, as clinically indicated (e.g. FAST scan, CT scan, MRI, angiography).  
Consider endoscopy (upper/lower)   
Unknown etiology despite above work-up  Hematology consultation  
Consider bone marrow aspiration/morphologic evaluation  
•  
5.5.3.5  Rash with Hyperkeratosis / Keratoacanthoma / Squamous 
Cell Carcinoma of the Skin  
Treatment -related skin lesions with hyperkeratosis, keratoacanthoma, cutaneous squamous cell 
carcinoma possibly due to TGFβ inhibiti on as important identified risks (adverse reactions) for 
M7824. T hey have been manageable and did not lead to permanent discontinuations in M7824 
studies. Patients with known Lynch Syndrome who develop keratoacanthomas on study are 
encouraged to be evaluated for Muir Torre syndrome.  Monitoring will include skin assessments 
as defined in the Schedules of Assessments ( Tables  1-3) , with biopsy of suspicious lesions. 
Management should be discussed with the p rincipal investigator on a case -by-case basis. 
Dermatological consults should be requested as needed  in the event that possible drug -related skin 
toxicity is suspected by the investigator. 
5.5.3.6  Alterations in Wound Healing or Tissue Damage Repair 
Due to the involvement of TGFβ in repair of skin and other tissue injuries, alterations in wound healing or repair of tissue damage is considered a potential risk. No AEs have been reported in 
Proprietary of MD Anderson Cancer Center
  64/106 
  Phase I studi es. For any surgeries conducted post -treatment initiation, surgical wound healing will 
be closely monitored. Management should be discussed with the principal investigator  on a case -
by-case basis. Dermatological consults should be requested as needed.  
5.5.3.7  Dose Interruptions for Adverse Events not related  to Study 
Drug  
In case of Grade 3 and Grade 4 AEs not study drug- related, the study treatment may be interrupted 
based on the Investigator assessment and the subject will be medically treated for the event.  
If the AE reduces to a lower tolerable grade the study treatment might be resumed in th e subsequent 
cycle. If the AE remains the same in spite of medical treatment until the next treatment (second 
cycle after the AE occurred) a discussion with the principal investigator should occur and 
consideration of a possible extension of the dose interruption for up to 1 additional cycle or a permanent withdrawal from the study treatment should be considered. 
If upon the resumed study treatment the subject experiences the same AE this should be re -
discussed with the principal investigator  to assess perm anent withdrawal from the study treatment.  
Grade 3 and 4 laboratory abnormalities that do not have clinical significance do not require dose 
interruption. 
5.6 Packaging and Labeling of the Investigational Medicinal 
Product  
M7824 drug product is a sterile freez e-dried formulation presented at a concentration of 600 
mg/vial in USP type I glass vial closed with a rubber stopper and sealed with an aluminum plastic 
crimping cap. 
Packaging and labeling will be in accordance with applicable local regulatory requirements and 
applicable Good Manufacturing Practice guidelines. M7824 will be packed in boxes containing a suitable number of vials. The information on the medication will be in accordance with approved submission documents. 
M7824 will be shipped in transport cool containers (2°C to 8°C) that are monitored with 
temperature control devices.  
All IMPs will be packaged and labeled in accordance with all applicable regulatory requirements and Good Manufacturing Practice Guidelines.  
5.7 Preparation, Handling, and Storage of the Investigational Medicinal Product  
M7824 drug product must be stored at 2°C to 8°C until use. The storage condition is based on data from ongoing long term stability studies with M7824. 
Proprietary of MD Anderson Cancer Center
  65/106 
  M7824 drug product stored at room (23°C to 27°C) or higher temper atures for extended periods 
of time might be subject to degradation. M7824 must not be frozen. Rough shaking of the 
reconstituted solution must be avoided. 
For application in clinical trials, M7824 drug product must be reconstituted with 4.5 mL of Water 
for Injection and diluted with 0.9% saline solution (sodium chloride injection). The chemical and 
physical in- use stability for the infusion solution of M7824 in 0.9% saline solution has been 
demonstrated for a total of 72 hours at room temperature; however, from a microbiological point 
of view, the diluted solution should be used immediately and is not intended to be stored unless dilution has taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and condit ions prior to administration are the responsibility of the user. No 
other drugs should be added to the infusion containers containing M7824. 
Detailed information on infusion bags and medical devices to be used for the preparation of the 
dilutions and subsequent administration will be provided in the manual of preparation. 
M7824 must not be used for any purpose other than the study. The administration of IMPs to 
subjects who have not been enrolled into the study is not covered by the study insurance. 
The contents of the M7824 vials are sterile and nonpyrogenic, and do not contain bacteriostatic 
preservatives. Any spills that occur should be cleaned up using the facility’s standard cleanup procedures for biologic products. 
Any unused portion of the solution should be discarded in biohazard waste disposal with final 
disposal by accepted local and national standards of incineration. 
5.8 Investigational Medicinal Product Accountability  
The Investigational Pharmacy  is responsible for ensuring IMP accountability, includ ing 
reconciliation of drugs and maintenance of records. 
• Upon receipt of IMP, the responsible person will check for accurate delivery and acknowledge receipt by signing or initialing and dating the appropriate documentation and returning it to the location specified. A copy will be archived for the Investigator Site File.  
• IMP dispensing will be recorded on the appropriate drug accountability forms so that accurate records will be available for verification at each monitoring visit.  
• IMP accountability records will include the following: 
o Confirmation of IMP receipt, in good condition and in the defined temperature range. 
o The inventory of IMP provided for the clinical trial and prepared at the site. 
o The use of each dose by each subject.  
o The disposition (including return, if applicable) of any unused IMP. 
Proprietary of MD Anderson Cancer Center
  66/106 
  o  
o Dates, quantities, batch numbers, vial numbers, expiry dates, formulation (for IMP 
prepared at the site), and the individual subject trial numbers. 
The Investigator site should maintain records, which adequately document that subjects were provided the doses specified in this protocol, and all IMPs provided were fully reconciled. 
Unused IMP must not be used for any purpose other than the present trial. No IMP that is dispensed 
to a subject may be redispensed to a different subject.  
The clinical trial monitor will periodically collect and review the IMP accountability forms and 
where applicable, will check all returns (both unused and used containers) before arranging for their return or authorizing their destruction by the trial site.  
At the conclusion or termination of this trial, trial site personnel and the IND Office  will conduct 
a final product supply inventory on the Investigational Drug Accountability Forms and all unused containers will be destroy ed. Instructions for destruction of product will be provided to the site. 
The Clinical Trial Monitor will be supplied with a copy for filing of the Investigational Drug Accountability Forms. This documentation must contain a record of clinical supplies used, unused, and destroyed and shall include information on 
• all administered units,  
• all unused units, 
• all destroyed units (during the trial),  
• all destroyed units at the end of the trial,  
• date of destruction(s),  
• name and signature of the Investigator / pharma cist. 
It must be ensured at each trial site that the IMP is not used  
• after the expir ation  date, and 
• after the retest date unless the IMP is reanalyzed and its retest date extended.  
 This is to be closely monitored by the Clinical Trial Monitor.  
5.9 Assessment of Investigational Medicinal Product Compliance 
In this trial, subjects will receive M7824 IV infusions at the investigational site. Well -trained 
medical staff will monitor and perform the IMP administration. The information of each IMP administration including the date, time, and dose of IMP will be recorded in  Prometheus . The 
Proprietary of MD Anderson Cancer Center
  67/106 
  Investigator will make sure that the information entered into Prometheus regarding IMP 
administration is accurate for each subject. Any reason for noncompliance should be documented.  
Noncompliance is defined as a subject missing > 1 administration of trial treatment for nonmedical 
reasons. If 1 treatment administration was missed and the interval between the subsequent treatment and the last administered treatment is longer than 4 weeks for nonmedical reasons, the criteria of insufficient compliance are met as well. Continuation of treatment should be discussed with the p rincipal investigator. 
5.10 Medical Care of Subjects after End of Trial  
After a subject has completed the trial or has wi thdrawn early, usual treatment will be 
administered, if required, in accordance with the trial site’s standard of care and generally accepted medical practice and depending on the subject’s individual medical needs. 
Upon withdrawal from the trial, subjects  may receive whatever care they and their physicians agree 
upon. Subjects will be followed for survival and AEs as specified in Section 6.1.4. 
6 Trial Procedures and Assessments  
6.1 Schedule of Assessments 
A complete schedule of assessments is provided in Tables  1-3, including sample  collection for 
tumor biopsies and plasma samples.   
Prior to performing any trial assessments not part of the subject’s routine medical care, the 
Investigator will ensure that the subject or the subject’s  legal representative has provided written 
informed consent according to the procedure described in Section 7.2. 
6.1.1 Screening and Baseline Procedures and Assessments  
There is a 28-day washout / recovery period for prior anticancer treatment (for example, 
cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ- spearing technique], immune therapy, or cytokine therapy except for erythropoietin) 
and major surgery before the start of trial treatment (Section 4.3.2). Hematology and chemistry laboratory samples must be drawn and reviewed within 72 hours prior to dose administration.  
During the screening period and before any trial related investigations and assessments are started, the subjects will be asked to sign the relevant ICFs. The subjects’ information that will be documented during screening includes the demographic information (birth date, sex, ethnicity, and race) and the complete medical history, including the history of the tumor disease and prior anticancer therapies, previous medications (prior 30 days to signing of ICF), concomitant medications, and baseline medical con dition (the information of concomitant medications and AEs 
will be monitored throughout the trial treatment period).  
During screening, subjects will undergo a complete physical examination, dermatological assessments (assessments for skin lesions or rash with biopsy of suspicious lesions), recording 
Proprietary of MD Anderson Cancer Center
  68/106 
  vital signs, including body weight and height (height only at screening), 12- lead electrocardiogram 
(EKG), and a determination of the ECOG PS (Appendix 1).The screening laboratory e xamination 
includes hematology, full serum chemistry and full urinalysis. Antinuclear antibody (ANAs), 
rheumatoid factor (RF), free thyroxine (T4), and TSH will also be assessed at screening.  
During screening, a serum β -human chorionic gonadotropin (β -HCG) pregnancy test will be 
perfo rmed for females of child bearing potential and blood.  HIV, HBV, and HCV testing will be 
performed for all screening subjects as these conditions are trial entry exclusion criteria. A female is considered of childbearing potential (that is fertile) follow ing menarche and until becoming 
postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an al ternative medical cause. A high follicle-
stimulating hormone (FSH) level (> 40 mIU/mL) in the postmenopausal range may be used to confirm a postmenopausal state in females not using hormonal contraception or hormonal replacement therapy.  
For Cohort D, pati ents will be screened for the presence or absence of ctDNA in the screening 
period prior to treatment initiation.  
Additional blood will be collected  during screening for  exploratory blood biomarkers including 
circulating cytokines and leukocyte subpopulations (Section 6.4.5). 
The tumor evaluation (type / staging, etc.) will be performed using CT scan or MRI (if MRI is 
used, CT of chest is mandatory.  
Collection of tumor biopsies or archived surgical specimen will also be done during this period, if 
applicable and at 4 weeks into the study (prior to dose 3)  for cohort A -C. For cohort B, tumor 
biopsies will be collected pretreatment, prior to dose 2, and prior to dose 4.  ] Pretreatment and /or 
post- treatment biopsies will be subjected to assessment of immune infiltration, expression of PD -
L1, and CMS classification by FFPE RNA analysis.  
6.1.2 Treatment period  
For this protocol, a cycle is defined as 28 days. M7824 will be given until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from t he trial  or IMP occurs (see Section 
4.5). Subjects who have experienced a PR or CR should continue treatment through the end of 12 months, although additional treatment is possible. If the Investigator believes that a subject may benefit from treatment bey ond 12 months, it may be permissible after discussion with the p rincipal 
investigator . In the case of PD, subjects should continue treatment through their next tumor 
assessment, if they meet the criteria described in Section 4.5.1. 
For subjects who achieve a PR or CR on M7824 therapy and then subsequently develop disease 
progression after stopping therapy, but prior to the end of the trial, a re-initiation course of 
treatment at the same dose and schedule and treatment duration up to 12 months is allowed at the discretion of the Investigator and agreement of the trial principal investigator. In order to be eligible for retreatment, the subject must not have experienced any toxicity that led to treatment discontinuation of the initial M7824 therapy. Prior to re -initiation of the study treatment, malignant 
Proprietary of MD Anderson Cancer Center
  69/106 
  disease needs to be radiologically re -staged to assess all known sites of the disease and to establish 
a new baseline for subsequent tumor measurements. Relevant safety laboratory samples must be 
drawn and results available and verified prior to re- initiating of treatment.  
Subjects will be a sked to visit the investigational site according to the Schedules of Assessments 
(see Tables  1-3) . In addition, the tumor evaluation (see Section 6.3) has a tumor assessment 
visiting time window of 5 days prior to dosing ( -5 days). Furthermore, if any Screening procedures 
are conducted within 3 days prior to Day 1 of trial treatment ( Cycle 1, Day 1), the assessments 
scheduled on Cycle 1 , Day 1 do not need to be repeated except for the evaluation of AEs and 
concomitant medicatio ns. 
During the treatment period, the following assessments will be performed (see Tables  1-3 for the 
detailed schedule):  
• AEs and concomitant medications will be documented in each study visit 
• ECOG PS will be assessed prior to trial treatment on Day 1 (unless the Screening ECOG PS was performed within 3 days prior to Day 1) 
• Physical examination will be performed prior to trial treatment on Day 1 (Cycle  1) and 
then prior to trial treatment according to Tables  1-3 
• Eye signs and symptoms should be checked. If clinically relevant findings then an appropriate ophthalmology examination including slit lamp evaluation inclusive of the anterior segment and with visual acuity should be obtained within 2 days 
• Dermatological assessments (assessments for skin lesions or rash with biopsy of suspicious lesions according to Tables  1-3) 
• Vital signs, including body weight, will be assessed prior to trial treatment according to 
Tables  1-3. 
• The 12- lead E KG will be assessed according to Tables  1-3. 
• The laboratory hematology tests will be assessed prior to trial treatment according to 
Tables  1-3. Complete  blood count results must be drawn and reviewed within 72 hours 
prior to dose administration. 
• Full serum chemistry will be assessed prior to trial treatment according to Tables  1-3. 
Samples for full  chemistry results must be drawn and reviewed within 72 hours prior to 
dose administration . 
• A basic urinalysis will be performed prior to trial treatment every according to Tables  1-
3. 
• Samples for ANAs and RF according to Tables  1-3. 
Proprietary of MD Anderson Cancer Center
  70/106 
  • A serum HCG pregnancy test will be required at Screening, urine or serum β -HCG 
pregnancy test will be performed prior to each administration of the study drug (if 
applicable). 
• The tumor evaluation (see Section 6.3) will be performed prior to treatment at week 8 , and 
then once every 8 weeks, with a tumor assessment visiting time window of 5 days prior to dosing. For subjects continuing treatment beyond 12 months (in consultation with the principal investigator ), tumor evaluations should take place every 12 weeks. 
• Tumor biopsies at Week 4, prior to the third treatment dose ( -7 day window permitted).  
Archival tissue may be used in place of a fresh pretreatment biopsy if adequate tum or is 
available for analysis.  If insufficient tissue is available for analysis for pretreatment tumor, then a mandatory fresh  biopsy must be obtained. In cohort A, the site of tumor tissue for 
the pretreatment sample, whether archival or fresh, may be fro m the primary tumor or the 
metastasis. In cohort B, the site of tumor for the pretreatment sample, in order to classify the CMS subtype, must come from the primary tumor.  The week 4, on- treatment biopsy 
for both cohorts may come from the primary tumor or from a metastatic site.  
• Free T4, and TSH will be measured prior to trial treatment according to Tables  1-3. 
• The exploratory blood biomarkers including circulating cytokines and leukocyte 
subpopulations will be performed as det ailed in Tables  1-3 as described in Section 6.4.5.2 
• Samples for TGFβ determination will be drawn as detailed in Tables  1-3. 
6.1.3 End of Treatment 
6.1.3.1  End of Treatment Visit 
All subjects must undergo an End-of- Treatment visit after discontinuation of M7824 for any 
reason. This visit should be performed on the day of or within 7 days after the decision to discontinue trial treatment but before any new antineoplastic therapy is started (if possible), whichever occurs earlier (see Tables  1-3). If it is known to the Investigator at the time of the End 
of- Treatment visit that the subject will start new treatment within 28 days of last treatment or they  
will be unable to return within 28 days of last treatment, assessments associated with the 28 -Day 
Safety Follow-up visit may be conducted at the End-of- Treatment visit. For all these subjects, the 
discontinuation visit consists of: 
• Documentation of AEs and concomitant medication. 
• Physical examination including vital signs and body weight. 
• Eye signs and symptoms should be checked. If clinically relevant findings then an appropriate ophthalmology examination including slit lamp evaluation inclusive of the anterior segment and with visual acuity should be obtained within 2 days. 
Proprietary of MD Anderson Cancer Center
  71/106 
  • Dermatological assessments (assessments for skin lesions or rash with biopsy of suspicious 
lesions). 
• Laboratory hematology, full serum chemistry, and basic urinalysis. 
• ECOG performance  status will be assessed . 
6.1.4 Post Treatment Follow Up  
6.1.4.1  28-Day Safety Follow Up  
A Safety Follow -up visit is scheduled 4 weeks (28 ± 5 days) after the last administration of M7824 
but before any new therapy is started, if possible, whichever occurs earlier. If it is known to the Investigator at the time of the End of -Treatment visit that the subject will start new treatment 
within 28 days of last treatment or they will be unable to return within 28 days of last treatment, assessments associated with the 28 -Day Sa fety Follow -up visit may be conducted at the End-of-
Treatment visit. The 28 -Day Safety Follow -up visit will comprise a full assessment for safety, 
immunogenicity, and tumor response as appropriate, which will include the following (refer to Tables  1-3):  
• AEs, concomitant medications. 
• Vital signs and body weight. 
• Physical examinations . 
• Eye signs and symptoms should be checked  by the treating investigator . If clinically 
relevant findings then an appropriate ophthalmology examination including slit lamp evaluation inclusive of the anterior segment and with visual acuity should be obtained within 2 days. 
• Dermatological assessments (assessments for skin lesions or rash with biopsy of suspicious lesions) by the treating investigator. 
• The 12- lead E KG. 
• Complete blood count , full serum chemistry . 
• Full urinalysis . 
• ECOG performance status will be assessed . 
• The β -HCG pregnancy test (in females of childbearing potential). 
• The tumor evaluation (only to be performed, if no disease progression was documented previously). 
Proprietary of MD Anderson Cancer Center
  72/106 
  • Free T4, and TSH . 
• Samples for ANAs and RF .  
• The exploratory blood biomarkers including circulating cytokines and leukocyte 
subpopulations will be performed as detailed in Tables  1-3 as described in Section 6.4.5.2. 
• Samples for TGFβ determination. 
• Blood samples for gene expression evaluation for subjects with PD. 
• An optional tumor biopsy following progression may be offered to the patient. 
6.1.4.2  Long- term Follow -up / Trial Termination  
All SAEs ongoing at the 28- Day Safety Follow -up visit must be monitored and followed up by the 
Investigator until stabilization or until the outcome is known, unless the subject is documented as 
“lost to follow -up.” In addition, all trial drug- related SAEs occurring after 28- Day Safety Follow -
up visit and ongoing at the Safety Follow-up visit have to be followed up in the same manner. 
Subjects without PD at the 28- Day Safety Follow -up visit will be followed up for disease 
progression (CT / MRI scans every 12 weeks) until PD. After the 28 -Day Safety Follow -up visit, subjects will be followed quarterly (± 14 days) for 
survival (including assessment of any further anticancer therapy). The survival follow -up will 
continue until 1 year after the last subject receives  the last dose of M7824. 
6.1.5 Blood Consumption for Clinical Assessments 
The overall amount of blood to be drawn from a single subject must not exceed 120 mL/day and 
550 mL in an 8- week period for safety laboratory testing, pregnancy testing, exploratory biomar ker 
investigation, and antibody evaluation. 
6.2 Demographic and Other Baseline Characteristics  
The assessments and procedures described in this section must be performed during the Screening period. 
6.2.1 Demographic Data 
The following demographic data will be recor ded: 
• Subject identifier  
• Date of birth  
• Sex 
Proprietary of MD Anderson Cancer Center
  73/106 
  • Ethnicity  
• Race 
6.2.2 Diagnosis of Tumor 
The tumor disease information that will be documented and verified at the Screening visit for each 
subject includes: 
• Detailed history of the tumor, including histopathological diagnosis, grading and staging in accordance with the American Joint Cancer Committee  (7
th Edition) Tumor Node 
Metastasis Classification at diagnosis (AJCC TNM).  
o The M category (M0 or M1) of the tumor at the time of study entry, based on screening assessments. 
• All therapy used for prior treatment of the tumor (including surgery, radiotherapy and 
chemotherapy, immunotherapy, etc. ). 
• Any other conditions that were treated with chemotherapy, radiation therapy, or 
immunotherapy. 
• Current cancer signs and symptoms and side effects from current and / or previous anticancer treatments.  
• Current cancer disease status.  
6.2.3 Medical History  
In order to determine the subject’s eligibility to the trial, a complete medic al history of each subject 
will be collected and documented during Screening, which will include, but may not be limited to, the following: 
• Past and concomitant non- malignant diseases and treatments.  
• All medications taken and procedures carried out within 30 days prior to Screening. 
For the trial entry, all the subjects must fulfill all inclusion criteria described in Section 4.3.1, and 
none of the subjects should have any exclusion criterion from the list described in Section 4.3.2. 
6.2.4 Vital Signs and Physical Examination  
Vital signs including body temperature, respiratory rate, heart rate (after 5 -minute rest), and arterial 
blood pressure (after 5 -minute rest), body weight and height will be recorded at study entry. 
Physical examinations will be performed according to Tables  1-3. An ophthalmology examination 
including slit lamp evaluation inclusive of the anterior segment and with visual acuity should be conducted. 
Proprietary of MD Anderson Cancer Center
  74/106 
  The ECOG PS will be documented during the Screening phase. 
6.2.5 CT or M RI Scans for Tumor Assessment at Baseline 
A CT scan or MRI (if MRI is used, CT of chest is mandatory ) of the chest, abdomen, and pelvis 
will be performed within 28 days prior to trial treatment start in order to document the baseline 
status of the tumor di sease using i RECIST 1.1 target and non- target lesions. However, if the results 
of a CT scan or MRI performed within 4 weeks prior to first treatment are available, the Screening CT / MRI does not need to be performed. 
A bone scan should be done at Screening as clinically indicated. 
6.2.6 Cardiac Assessments  
A 12 -lead E KG will be recorded at Screening. The E KG will be recorded after the subject has been 
in a supine position breathing quietly for 5 minutes. The E KG results will be used to evaluate the 
heart rate, atrial -ventricular conduction, QR, QT, and corrected QT intervals, and possible 
arrhythmias.  
The EK Gs will be documented by recording date and time of collection. All E KG results must be 
reviewed at the site by the Investigator or a medically qualified desi gnee for clinical management 
of the subject. E KGs are to be performed according to local procedures and will NOT be digitally 
uploaded. The Investigator will judge the overall interpretation as normal or abnormal. If abnormal, it will 
be decided if the abnormality is clinically significant or not clinically significant and the reason for the abnormality will be recorded on the eCRF  (Prometheus) . Abnormal values will not be 
recorded as AEs unless they are the reason for discontinuation of the trial IMP due to AEs or are SAEs.  
6.2.7 Clinical Laboratory Tests 
Blood samples will be collected at screening for clinical laboratory parameter evaluations. These clinical laboratory test results will serve not only as the baseline values for subsequent safety 
clinical labora tory evaluations during the trial, but also help to make sure that each enrolled subject 
fulfills all the trial entry criteria as listed in Section 4.3.1 and does not meet any of the trial 
exclusion criteria for laboratory parameters as listed in Section 4.3.2. Detailed description of laboratory assessments is provided in Section 4.4.3. 
6.2.8 ctDNA testing  
Guardant360 is a next -generation sequencing (NGS) panel of 70 clinically actionable onco- and 
tumor suppressor genes utilizing digital sequencing of cell -free circulating tumor DNA (cfDNA) 
isolated from a simple, non- invasive blood draw. It is medically in dicated for the prevention of a 
repeat invasive biopsy in advanced cancer patients when the initial biopsy is insufficient (QNS) or unavailable/unobtainable as well as when cancer has progressed or recurred despite treatment. The test detects single nucleo tide variants via complete exon sequencing in 70 genes, copy number 
Proprietary of MD Anderson Cancer Center
  75/106 
  amplifications in 16 genes, small indels in EGFR, ERBB2 and MET exon 14 skipping, and fusions 
in ALK, FGFR2, FGFR3, RET, ROS1 and NTRK1. The genes are selected because mutations in these g enes have FDA -approved matched therapies or are eligible for late phase clinical trials, as 
well as non- druggable genes with high prevalence alterations that may be helpful in monitoring 
for molecular response/non-response such as TP53.  
Guardant360 is an advanced diagnostic laboratory test (ADLT) offered by a sole source laboratory 
certified by the Clinical Laboratory Improvement Amendments (CLIA) for high complexity (molecular pathology) testing and accredited by the College of American Pathology (CAP). D ue 
to high rates of false positives with traditional NGS assays when tumor DNA is in low concentrations, the majority of “liquid biopsy” methods interrogating cell -free DNA have been 
limited to hotspot analyses. In contrast, the ultra -high specificity (> 9 9.9999%) of the digital 
sequencing method enables the sequencing of long, targeted regions (146,000 base pairs) without false positives. Complete exons are sequenced for all exons in 30 genes and the critical exons (those reported as having a somatic mutat ion in COSMIC) in 40 additional genes. Thus, its key 
differentiating characteristic from other “liquid biopsy” methods is the ability to sequence complete exons in many genes, in contrast to gene hotspot testing. 
Advantages of  the Guardant360 cell -free DNA NGS methodology versus solid tumor tissue -based 
NGS are:  
1. An invasive needle or surgical biopsy is avoided with ctDNA, reducing 
costs and complications.  
2. CtDNA provides a quantitative measure (concentration or mutant allele 
frequency) of mutations pre sent whereas solid tumor biopsy typically 
provides a qualitative result (mutation either present or not detected). The quantitative cfDNA result may be followed over time to monitor response to treatment and evolution of acquired resistance. 
3. Ct DNA seque ncing identifies both germline and somatic mutations in the 
same sample.  
4. The assay failure rate is for ct DNA is less than 0.5% (in the first 9,000+ 
samples) compared to 15% -25% failure rates of tissue -based NGS related 
to insufficient quantity of tissue (QNS).  
 
Guardant360 utilizes algorithmic methods to encode and ultimately decode inputs and outputs 
from massively parallel deep sequencing analysis. By leveraging signal transduction processing technology where voice or image data is digitally encoded before transmission and then decoded post- transmission, this NGS method, known as Digital SequencingTM, enables signal interference 
to be reduced by two orders of magnitude or more 
(88).  Four validation studies have been published 
with concordance to tissue  biopsy- based genomic testing (88-91). With high enough sensitivity and 
specificity to robustly quantitate ctDNA from blood, this approach has the potential to evaluate the multiple genomic targets required in NCCN guidelines, to act as a “summary” of the different tumor clones in patients with intra -tumor and inter -tumor heterogeneity, and to prevent the time 
Proprietary of MD Anderson Cancer Center
  76/106 
  delays, costs and complications inherent in invasive biopsies. The analytical and clinical validation 
of Guardant360 is conducted in conformance with evidentiary standards established by the 
Standards for Reporting of Diagnostic Accuracy (STARD), REporting of tumor MARKer Studies (REMARK), Evaluation of Genomic Applications in Practice and Prevention (EGAPP), and the recent Next -generation Sequencing: Standardization of Clinical Testing (Nex -StoCT) biomarker 
guidelines 
(92-95). 
Methodology 
The gene panel was selected to focus on those genomic alterations that are currently actionable 
defined as being targets of sensitivity or resistance to an FDA -approved matched therapy and/or a 
targeted therapy in clinical trials. The test simultaneously sequences the 70 cancer -related genes 
to an average depth of coverage of greater than 8,000X. To summarize, cell -free DNA is extracted 
from plasma and genomic alterati ons are analyzed by massively parallel paired end synthesis -by-
sequencing of amplified target genes utilizing an Illumina Next -Seq platform complemented by 
systematic end -to-end process optimization including conversion of cell -free DNA fragments into 
digital sequences, improvements in the Illumina next generation sequencing process itself, 
followed by bioinformatics algorithms which enable ctDNA to be measured as a quantitative percentage of total cell -free DNA.  
Two 10mls of whole blood are collected in S treck Cell -Free DNA Blood Collection (Streck) tubes, 
which contain a proprietary formaldehyde -free preservative in that stabilizes white blood cells, 
preventing the release of genomic DNA and allowing shipping and stability for seven days without need for refrigeration, cold bricks or preliminary centrifugation prior to shipping.  
After digital libraries are produced, the sample is sequenced and post -sequencing data is processed 
using bioinformatics algorithms to quantify the absolute number of unique DNA f ragments at a 
given nucleotide position. This proprietary process is referred to as Digital SequencingTM and 
enables reporting of the fractional concentration (mutant allele frequency) of a given SNV. 
Circulating cell -free DNA is mostly derived from leukocyte lysis (germline) and generally a much 
smaller amount of tumor DNA is derived from cancer cell apoptosis/necrosis. All of the cell -free 
DNA fragments, including leukocyte -derived and tumor -derived, are simultaneously sequenced 
with up to single molecule  sensitivity. In other words, both tumor DNA and “normal”/germline 
DNA are sequenced and measured in the same sequencing assay. The fractional concentration or 
mutant allele frequency for a given mutation is calculated as the fraction of circulating tumor DNA harboring that mutation in a background of wild- type cell -free DNA fragments. The analytic 
sensitivity reaches detection of 1 -2 single mutant cell -free DNA molecules from a 10 ml blood 
sample.  
 
Gene list and genomic alterations in the Guardant360 Panel 
Proprietary of MD Anderson Cancer Center
  77/106 
  6.3 
Efficacy Assessments  
For all subjects, tumor response assessment will be performed by CT scan or MRI (if MRI is used, 
CT of chest is mandatory . All the scans performed at baseline and other imaging performed as 
clinically required (other supportive imaging) need to be repeated at subsequent visits. In general, lesions detected at baseline need to be followed using the same imaging methodology and preferably the same imaging equipment at subsequent tumor evaluation visits. 
Skin metastasis can be used as target lesions according to i RECIST 1.1 using measurements by 
caliper, if they fulfill i RECIST 1.1 for target lesions as described below. The presence of new 
cutaneous lesions will be considered diagnostic of progression for iRECIST 1.1, even if not 
imaged. For each subject, the Investigator will designate 1 or more of the following measures of 
tumor status to follow for determining response: CT or MRI images of primary and / or metastatic 
tumor masses, physical examination findings, and the results of other assessments. All available images collected during the trial period will be considered. The most appropriate measures to evaluate the tumor status of a subject should be used. The measure(s) to be chosen for sequential evaluation during the trial have to correspond to the measures used to document the progressive tumor status that qualifies the subject for enrollment. The tumor response assessment will be assessed and listed according to the Schedule of Assessments (refer to Ta bles 1-3).  
The foreseen treatment duration is until documentation of PD, unacceptable toxicity, or any criterion for withdrawal from the trial or IMP occurs (see Section 4.5).  
Proprietary of MD Anderson Cancer Center
  78/106 
  The treatment should be stopped immediately, if the subject does not tolerate M7824 anymore or 
if therapeutic failure occurs, which requires urgent treatment with an additional drug or results in clinically significant progression / deterioration.  
Tumor responses to treatment will be assigned based on the evaluation of the response o f target, 
non-target, and new lesions according to iRECIST 1.1 (all measurements should be recorded in 
metric notation).  
• To assess objective response, the tumor burden at baseline will be estimated and used for comparison with subsequent measurements. At baseline, tumor lesions will be categorized in target and non-target lesions according to iRECIST 1.1  
Results for these evaluations will be recorded with as much specificity as possible so that pre- and 
post- treatment results will provide the best opportun ity for evaluating tumor response. 
Any CR or PR should be confirmed according to iRECIST 1.1.  
The Investigator may perform scans in addition to a scheduled trial scan for medical reasons or if 
the Investigator suspects PD.  
As outlined in Section 4.1, treatment should continue with M7824 if the patient has PD provided: 
• There are no new Grade 2 or greater symptoms or significant worsening of existing symptoms.  
• There is no decrease in ECOG PS.  
• In the opinion of the Investigator, the subject does not require new anticancer therapy. 
PD and any of the above conditions not satisfied results in study discontinuation.  
Subjects who have experienced a confirmed PR or CR should continue  treatment through the end 
of 12 months , although additional treatment is possible. If the Investigator believes that a subject 
may benefit from treatment beyond 12 months, it may be permissible after discussion with the 
principal investigator.  
6.4 Assessment of Safety  
The safety profile of the IMP will be assessed through the recording, reporting and analysis of 
baseline medical conditions, AEs, physical examination findings including vital signs and eyes signs and symptoms, and laboratory tests. 
Comprehensive assessment of any apparent toxicity experienced by each subject will be performed 
from the time of giving informed consent and throughout the trial. The Investigator will report any AEs, whether observed by the Investigator or reported by the subject (see Section 6.4.1.2). Given the intended MoA, particular attention will be given to AEs that may follow the enhanced T -cell 
activation such as persistent rash, diarrhea and colitis, autoimmune hepatitis, arthritis, glomerulonephritis, cardiomyopathy, uveitis and other inflammatory eye conditions, or other 
immune -related reactions. Ophthalmologic examinations should be considered, when clinically 
indicated, for signs or symptoms of uveitis. Furthermore, due to the anti -TGFβ activity, particular 
Proprietary of MD Anderson Cancer Center
  79/106 
  attention will also be given to events associated with , anemia, and rash with hyperkeratosis / 
keratoacanthoma and squamous cell carcinoma of the skin.  
The reporting period for AEs is described in Section 6.4.1.3. 
The safety assessments will be performed according to the Schedules of Assessments (see Tables  
1-3).  
6.4.1 Adverse Events 
6.4.1.1  Adverse Event Definitions  
Adverse Event  
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
For surgical or diagnostic procedures, the condition / illness leading to such a procedure is 
considered as the AE rather than the procedure itself.  
In case of a fatality, the cause of death is considered as an AE, and the death is considered as its OUTCOME.  
The investigator (or physician designee) is responsible for verifying and providing source documentation, grading the severity and assigning the attribution for all adverse events. 
Investigators will reference the NCI -CTCAE v4.03 (publication date: 17 November 2017), a 
descriptive terminology that can be used for AE reporting. A general grading (severity / intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event Grades are also provided. 
If a particular AE’s severity is not specifically graded by the guidance document, the Investigator 
is to use the general NCI -CTCAE definitions of Grade 1 through Grade 5 following his or her best 
medical judgment. 
Grade 1 : Mild  
Grade 2 :  Moderate  
Grade 3 : Severe  
Grade 4 : Life-threatening  
Grade 5 :  Death  
Proprietary of MD Anderson Cancer Center
  80/106 
   
Recommended Adverse Event Recording Guidelines  
Attribution  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Unrelated  Phase I  Phase I  Phase I  
Phase II   
 Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Unlikely  Phase I  Phase I  Phase I  
Phase II   Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Possible  Phase I  
Phase II   Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Probable  Phase I  
Phase II  
 Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Definitive  Phase I  
Phase II  
  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II  
Phase III  Phase I  
Phase II   
Phase III  
 
Any clinical AE with severity of Grade 4 or 5 must also be reported as an SAE as per Section 
6.4.1.4; however, a laboratory abnormality of Grade 4, such as anemia or neutropenia, is considered serious only if the condition meets one of the serious criteria described below. 
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as an SAE. “Fatal” will be recorded as the outcome of this specific event and death will not be recorded as separate event. Only, if no cause of death can be reported (for example, sudden death, unexplained death), the death per se might then be reported as an SAE. 
Investigators must also systematically assess the causal relationship of AEs to the IMP using the 
following definitions. Decisive factors for the assessment of causal relationship of an AE to the 
Proprietary of MD Anderson Cancer Center
  81/106 
  M7824 include, but may not be limited to, temporal relationship between the AE and the M7824, 
the known safety profile of M7824, medical history, concomitant medication, course of the 
underlying disease, trial procedures.  
Unrelated : Not reasonably related to the IMP. The AE could not medically (pharmacologically / 
clinically) be attributed to the IMP  under study in this clinical trial protocol.  A reasonable 
alternative explanation must be available. 
Related : Reasonably related to the IMP. The AE could medically (pharmacologically / clinically) 
be attributed to the IMP under study in this clinical trial protocol.  
Abnormal Laboratory Findings and Other Abnormal Investigational Findings  
Abnormal laboratory findings and other abnormal investigational findings (for example, on an 
EKG trace) should not be reported as AEs unless they are associated with clinical signs and 
symptoms, lead to treatment discontinuation or are considered otherwise medically important by the Investigator. If a laboratory abnormality fulfills these criteria, the identified medical condition (for example, anemia, increased ALT) must be reported as the AE rather than the abnormal value itself.  
6.4.1.1.1  Serious Adverse Event (SAE) Reporting 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the investigator or Merck/EMD Serono , it results in any of the following outcomes: 
• Death  
• A life -threatening adverse drug experience – any adverse experience that places the patient, 
in the view of the initial reporter, at immediate risk of death from the adverse experience as it occurred. It does not include an adverse experience that, had it occurred in a more severe form, might have caused death. 
• Inpatient hospitalization or prolongation of existing hospitalization • A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions.  
• A congenital anomaly/birth defect. Important medical events that may not result in death, be life -threatening, or require hospitalization 
may be considered a serious adverse drug experience when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an  emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse (21 CFR 312.32). 
Proprietary of MD Anderson Cancer Center
  82/106 
  • Important medical events as defined above, may also be considered serious adverse events. 
Any important medical event can and should be reported as an SAE if deemed appropriate by the 
Principal Investigator or the IND Office.  
• All events occurring during the conduct of a protocol and meeting the definition of a SAE 
must be report ed to the IRB in accordance with the timeframes and procedures outlined in “The 
University of Texas M. D. Anderson Cancer Center Institutional Review Board Policy for Investigators on Reporting Serious Unanticipated Adverse Events for Drugs and Devices”.  Unless stated otherwise in the protocol, all SAEs, expected or unexpected, must be reported to the IND Office, regardless of attribution (within 5 working days of knowledge of the event). 
• All life -threatening or fatal events, that are unexpected, and rel ated to the study drug, must 
have a written report submitted within 24 hours (next working day) of knowledge of the event to 
the Safety Project Manager in the IND Office.   
• Unless otherwise noted, the electronic SAE application (eSAE) will be utilized fo r safety 
reporting to the IND Office and MDACC IRB.  • Serious adverse events will be captured from the time of the first protocol -specific 
intervention, until 90 days after the last dose of drug, unless the participant withdraws consent. 
Serious adverse events must be followed until clinical recovery is complete and laboratory tests 
have returned to baseline, progression of the event has stabilized, or there has been acceptable resolution of the event. 
• Additionally, any serious adverse events that occur after the 90  day time period that are 
related to the study treatment must be reported to the IND Office. This may include the 
development of a secondary malignancy. 
 Reporting to FDA : 
• Serious adverse events will be forwarded to FDA by the IND Office (Safety Project Manager 
IND Office) according to 21 CFR 312.32.  It is the responsibility of the PI and the research team to ensure serious adverse events are 
reported according to the Code of Federal Regulations, Good Clinical Practices, the protocol guidelin es, Merck/EMD Serono ’s guidelines, and Institutional Review Board policy.  
6.4.1.1.2  Events Not to Be Considered as AEs / SAEs  
Medical conditions present at the initial trial visit that do not worsen in severity or frequency during the trial are defined as Baseline Medical Conditions, and are not to be considered AEs. 
AE / SAEs Observed in Association with Disease Progression  
Proprietary of MD Anderson Cancer Center
  83/106 
  Progression of the disease / disorder being studied assessed by measurement of lesions on 
radiographs or other methods as well as associated cli nical signs or symptoms (including 
laboratory abnormalities) should not be reported as an AE / SAE, unless the subject’s general condition is more severe than expected and / or unless the outcome is fatal within the AE reporting period (as defined in Section 6.4.1.3). 
6.4.1.1.3  Pre-defined AEs of Special Interest (AESI) for Safety 
Monitoring  
Any AE that is suspicious to be a potential irAE (see Section 5.5.3.3), including ophthalmologic 
findings, has to be reported in an expeditious manner and will be considered an A E of special 
interest (AESI).  
Infusion- related reactions / hypersensitivity, regardless of grade, must be reported as AESIs.  
In addition, rash with hyperkeratosis / keratoacanthoma / squamous cell cancer of the skin are 
regarded as AESIs. Please note that squamous cell cancer of the skin should be considered as medically important condition and thus as a serious AESI, which has to be reported in an expedited manner as a SAE.  
Anemia when considered related to M7824 will be reported as AESI reg ardless of  grade. 
 The reporting of AESI is defined in Section 6.4.1.4. 
6.4.1.2  Methods of Recording and Assessing Adverse Events 
At each trial visit, the subject will be queried on changes in his or her condition. During the reporting period, any unfavorable changes in the  subject’s condition will be recorded as AEs, 
whether reported by the subject or observed by the Investigator. 
Complete, accurate and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the eCRF  
(Prometheus) . All SAEs and all non- serious AEs of special interest must be additionally 
documented and reported using the e SAE database. 
It is important that each AE report include a description of the event, its duration (onset and resolution dates and times to be co mpleted when it is important to assess the time of AE onset 
relative to the recorded treatment administration time), its severity, its causal relationship with the trial treatment, any other potential causal factors, any treatment given or other action tak en, 
including dose modification or discontinuation of the IMP, and its outcome. In addition, serious cases should be identified and the appropriate seriousness criteria documented.  
6.4.1.2.1  Investigator Communications with Merck/EMD Serono 
• In addition to the regular reporting obligations, the following reportable events must be submitted to EMD Serono within 48 hours for fatal/life -threatening SAEs and 5 business days  
for all other SAEs.  
Proprietary of MD Anderson Cancer Center
  84/106 
  • Exposure during pregnancy or breastfeeding (even if not associated with an adverse event) and 
occupational exposure (even if not associated with an adverse event) shall also be reported.  
 
Contact information for submission of reportable events and monthly extracts to EMD Serono: E-mail: GlobalDrugSafety@merckgroup.com  or Fax: +49 6151 72 6914 
Specifying:  
• PROTOCOL Number  
• SUBJECT Number  
• SITE Number/PI Name  
• SAE/ONSET DATE  
 
6.4.1.3  Definition of the Adverse Event Reporting Period 
The AE reporting period for safety surveillance from the firs t protocol intervention to 90 days after 
last study drug administration and continues through the trial’s 28 -Day Safety Follow -up visit, 
defined as 28 days (± 5 days) after last trial drug administration. After the 28- Day Safety Follow -
up visit only AEs that are deemed attributable to trial drug by the Investigator should be 
documented until the Safety Follow -up visit, defined as 28 days (+/ - 7 days)  after the last trial drug 
administration. 
Any SAE assessed as related to M7824 must be reported whenever it occurs, irrespective of the 
time elapsed since the last administration of M7824.  
6.4.1.4  Procedure for Reporting Serious Adverse Events, Adverse Events of Special Interest  
Serious Adverse Events 
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum 24 hours after becoming aware of the event) inform the IND Office and/or Merck/EMD Serono  using the SAE Report Form following specific completion 
instructions.  
In exceptional circumstances, a SAE (or follow -up information) may be reported by telephone; in 
these cases SAE Report Form must be provided immediately thereafter.  
Reporting procedures and timelines are the same for any new information on a previously reported SAE (= follow -up). 
Proprietary of MD Anderson Cancer Center
  85/106 
  Relevant pages from the eCRF (Prometheus) may be provided in parallel (for example, medical 
history, concomitant drugs). Additional documents may be provided by the Investigator, if 
available (for example, laboratory results, hospital report, and autopsy report). In all cases, the information provided on the SAE Report Form must be consistent with the data about the event recorded in the eCRF  (Prometheus). 
The Investigator must respond to any request for follow- up information (for example, additional 
information, outcome final evaluation, other records where needed) or to any question the IND Office and/or Merck/EMD Serono  may have on the AE within the same timelines as those noted 
above for initial reports. This is necessary to ensure a prompt assessment of the event by the IND 
Office and/or Merck/EMD Serono and (as applicable) to allow the IND Office to meet strict 
regula tory timelines associated with expedited safety reporting obligations.  
Adverse Events of Special Interest  
In the event of a non- serious Grade ≥ 3 AESI, the Investigator must report the AESI using the 
eSAE database within 5 days, and the logs should be provided to Merck/EMD Serono every 3 
months. Serious AESIs have to be reported in an expedited manner as SAEs within 24 hours a s 
outlined above, and reported to EMD Safety. For Grade 1 and Grade 2 non- serious AESIs, results 
from  the eSAE database should be forwarded to Merck/EMD Serono every 3 months.  
Safety Report to Health Authorities, Independent Ethics Committees / Institutional Review Boards and Investigators 
The IND Office will send appropriate safety notifications to Health Authorities in accordance wit h 
applicable laws and regulations. The Investigator must comply with any applicable site -specific requirements related to the 
reporting of SAEs (particularly deaths) involving trial subjects to the IEC / IRB that approved the 
trial. 
In accordance with ICH GCP guidelines, Merck/EMD Serono  will inform the Investigator of 
“findings that could adversely affect the safety of subjects, impact the conduct of the trial, or alter the IEC’s / IRB’s approval / favorable opinion to continue the trial.” In particular and in line with respective regulations, Merck/EMD Serono will inform the Investigator of AEs that are both serious and unexpected and are considered to be related to the administered product (suspected unexpected serious adverse reactions [SUSARs]). The Inv estigator should place copies of Safety 
Reports in the Investigator Site File. National regulations with regard to Safety Report notifications to Investigators will be taken into account. 
When specifically required by regulations and guidelines, Merck/EMD Serono will provide 
appropriate Safety Reports directly to the concerned lead IEC / IRB and will maintain records of 
these notifications. When direct reporting is not clearly defined by national or site -specific 
regulations, the Investigator will be respon sible for promptly notifying the concerned IEC / IRB 
of any Safety Reports provided by Merck/EMD Serono and of filing copies of all related correspondence in the Investigator Site File.  
Proprietary of MD Anderson Cancer Center
  86/106 
  6.4.1.5  Monitoring of Subjects with Adverse Events  
Adverse events are recorded  and assessed continuously throughout the trial (see Section 6.4.1.3) 
and are assessed for final outcome at the End of Treatment visit. After the End of Treatment visit 
only AEs that are deemed attributable to trial drug by the Investigator should be documented until the Safety Follow-up visit. 
All SAEs ongoing at the 28- Day Safety Follow -up visit must be monitored and followed up by the 
Investigator until stabilization or until the outcome is known, unless the subject is documented as 
“lost to follow -up”. In addition, all trial drug related SAEs occurring after 28 -Day Safety Follow-
up visit and ongoing at the Safety Follow-up visit must be followed up in the same manner. 
Reasonable attempts to obtain this information must be made and documented. It is also the 
responsibility of the Investigator to ensure that any necessary additional therapeutic measures and follow-up procedures are performed. 
6.4.2 Pregnancy and In Utero Drug Exposure 
Only pregnancies considered by the Investigator to be related to trial treatment (for example, resulting from a drug interaction with a contraceptive medication) are considered to be AEs; however, all pregnancies with an estimated conception date during the period defined in Section 6.4.1.3 must be recorded by convention in the AE pa ge / section of the eCRF  (Prometheus) . The 
same rule applies to pregnancies in female subjects and to pregnancies in female partners of male subjects. The Investigator must also notify the IND Office  in an expedited manner of any 
pregnancy using the Paper Pregnancy Report Form, which must be transmitted according to the same timelines as described for SAE reporting in Section 6.4.1.4. 
Investigators must actively follow up, document and report on the outcome of all these 
pregnancies, even if the subjects are withdrawn from the trial.  
The Investigator must notify the IND Office  of these outcomes using the Pregnancy Report Form. 
If an abnormal outcome occurs, the SAE Report Form will be used if the subject sustains an event and the Parent-Child / Fetus Adverse Event Report Form if the child / fetus sustains an event. 
Any abnormal outcome must be reported in an expedited manner as described in Section 6.4.1.4, 
while normal outcomes must be reported within 45 days after delivery. 
In the event of a pregnancy in a subject occurring during the course of the trial, the subject must 
be discontinued from trial medication immediately. The IND Office  must be notified without delay 
and the subject must be followed as mentioned above. 
6.4.3 Clinical Laboratory Assessments  
It is es sential that the IND Office be provided with a list of laboratory normal ranges before 
shipment of IMP. Any change in laboratory normal ranges during the trial will additionally be forwarded to  the IND Office . 
Proprietary of MD Anderson Cancer Center
  87/106 
  Blood samples will be taken from non- fasted subjects. All routine laboratory analyses will be 
performed at a laboratory facility local to the investigational site and relevant results must be drawn 
and checked before administration of M7824. The report of the results must be retained as a part of the subject’s medical record or source documents. Complete blood count and full  serum 
chemistry must be checked within 72 hours prior to each dose administration. 
ANA, RF, T4, TSH, and urinalysis will be assessed at the time points defined in the Schedules of 
Assessments ( Tables  1-3). 
If confirmation of a subject’s postmenopausal status is necessary, a FSH level will also be performed at Screening, see Section 6.1.1. 
Table 7: Required Laboratory Panel Tests  
Full Chemistry  Hematology 
Albumin  Absolute lymphocyte count  
Alkaline  phosphatase  Absolute neutrophil  count  
Alanine aminotransferase  Hematocrit  
Amylase+ Hemoglobin 
Aspartate aminotransferase   Platelet count  
Bicarbonate RBC count  
Blood urea nitrogen / total  urea White blood cell count and differential  count 
Calcium  Red blood cell  morphology**  
Chloride  Reticulocytes  
 Mean corpuscular  hemoglobin  
Creatine kinase  Mean corpuscular volume 
Creatinine Mean corpuscular hemoglobin concentration  
C-reactive protein 
 Glucose   
Lactate dehydrogenase  
Lipase+  
Phosphorus /  phosphates  
 Magnesium Basic Urinalysis (dipstick, including macroscopic  appearance, 
bilirubin, blood, color, glucose, ketones, leukocyte esterase, 
nitrite, pH, protein, specific gravity, urobilinogen)  
Full urinalysis (dipstick plus microscopic evaluation) to be 
performed only at the Screening and 28-Day Safety  Follow-up 
visits and a basic urinalysis prior to Day 1 of every cycle. Potassium  
Sodium 
Total bilirubin / direct bilirubin/ indirect  
bilirubin* 
Total protein  
 Uric acid  
  
 ANA***, RF ***, TSH, and T4 
 
 
 
Proprietary of MD Anderson Cancer Center
  88/106 
   Hepatitis  Screeninga 
Hepatitis B surface antigen, hepatitis B core  antibody  
Hepatitis C Antibody  
 
ACTH=adrenocorticotropic hormone; ANA=antinuclear antibody; IMP=Investigational Medicinal Product; PCR = 
polymerase chain  reaction; RF=rheumatoid factor; TSH=thyroid-stimulating  hormone; T4=free thyroxine. 
** Only in case of anemia onset assessed as related to study  treatment  
+Only day 1 of every cycle  
***Only at pre -screening evaluation (see schedule of assessments)  
a If hepatitis  B surface antigen  positive and hepatitis  B core antibody positive, then reflex  to 
quantitative  HBV DNA (PCR); if hepatitis B core antibody positive alone, then reflex to quantitative 
hepatitis B  DNA (PCR); if hepatitis  C antibody positive,  then reflex  to quantitative hepatitis  C RNA 
(PCR).  
If a subject has a clinically significant abnormal laboratory test value that is not present at Baseline, 
the test will be repeated weekly and the subject will be followed until the test value has returned to the normal range or the Investigator has determined that the abnormality is c hronic or stable.  
For pharmacokinetic assessment of M7824 , a blood sample should be collected prior to infusion 
of M7824 and following completion (within 30 minutes) of infusion of M7824 (doses 1 and 3), 
prior to dose 2, and prior to dose 6/end of treatment visit (whichever of these two comes first) .  
Samples should be processed as follows: 
1.  Collect 3.5 mL of blood in an SST tube with silica clot activator and polymer gel. 2. Gently invert the tube 5 times to mix the clot activator with the blood.  
3. Allow blood to clot for 30 minutes at room temperature in a vertical position.  
4.  After allowing clot to form, centrifuge the tube for 15 minutes at 1100- 1300x g at 25°C.   
     If refrigerated centrifuge is available, set the temperature at 25°C in order to  prevent  
     heating during centrifugation and to optimize flow of the barrier material.  Flow may  
     be impeded if chilled before or during centrifugation. 5. Carefully collect and aliquot the serum equally into 2 separate Micronics tubes. 
6. Place t he tubes immediately into the freezer in an upright position at -80°C. 
7.  Samples will be analyzed as a batch with EMD Serono at a later date.  
6.4.4 Vital Signs, Physical Examinations, and Other Assessments 
The ECOG PS will be assessed at Screening and at subsequent visits as indicated in the Schedules of Assessments ( Tables  1-3) and documented in the eCRF (Prometheus). 
Body weight will be measured at Screening and at subsequent visits as indicated in the Schedules of Assessments ( Tables  1-3) and documented in the eCRF  (Prometheus) . Body height will be 
measured at screening only.  
A physical examination will be conducted at Screening and at subsequent visits as indicated in the Schedules of Assessments ( Tables  1-3) and documented in the eCRF  (detailed description in 
Section 6.1). Any abnormalities arising or worsening after the signing of the ICF should be 
Proprietary of MD Anderson Cancer Center
  89/106 
  documented in the eCRF  (Prometheus) Adverse Event section (see Section 6.4.1). Abnormal 
findings are to be reassessed at subsequent visits.  
Physical examination should include a dermatological examination.  If abnormal skin findings are 
observed, the  patient should be referred to a dermatologist for biopsy of suspicious lesions. 
An ophthalmology examination including slit lamp evaluation inclusive of the anterior segment and with visual acuity should be conducted at Screening. At subsequent visits, eye signs and symptoms should be checked. If there are any clinically relevant findings then an appropriate ophthalmology examination including slit lamp evaluation inclusive of the anterior segment and with visual acuity should be obtained within 2 days. 
Digital 12 -lead E KGs will be recorded as a single recording  at the screening visit.  Subsequent 
EKGs will likewise be obtained as single recordings.  
All newly diagnosed or worsening conditions, signs and symptoms observed since Screening, 
whether related to trial treatment or not, are to be reported as AEs.  
For female subjects of childbearing potential, serum β -HCG pregnancy test will be carried out 
during the Screening phase. A urine β -HCG test may be performed prior to schedule on treatment 
assessments. Results of the most recent pregnancy test should be available prior to the next dosing of IMP. Subjects who are postmenopausal (age -related amenorrhea ≥ 12 consecutive months and 
if needed FSH > 40 mIU/mL [in the postmenopausal range] as outlined in Section 6.1.1), or who have undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing. If necessary to confirm postmenopausal status, an FSH will be drawn at Screening. 
6.4.5 Biomarkers  
Due to limited understanding of the biological activities induced by M7824 in cancer subjects, there can be no certainty t hat the doses examined will be associated with relevant antitumor 
immune activities. Further details regarding translational studies are listed in Appendix 3.  As the consequence, the trial will serve to  
1. Evaluate MSI -H status with CMS subtype 
a. MSI will be assessed by MSI-H CRC either by IHC for loss of protein expression 
in one of 4 mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) or by detection of micro satellites within the tumor DNA  (as per institutional practices ) 
b. External MSI testing  in a CLIA certified laboratory with a documentation of MSI -
H status performed pr ior to screening  is acceptable for inclusion in cohort A- C.  
2. Evaluate PD -L1 expression as a predictor of response 
a. Primary tumor will be stained for PD -L1 expression by IHC 
b. PD-L1 staining will be semi -quantitatively scored by absence, weak, moderate,  
strong by a pathologist 
Proprietary of MD Anderson Cancer Center
  90/106 
  c. The above will be performed on the mandatory fresh on-treatment biopsy. 
3. Evaluate the effect o n TGFβ concentrations in plasma.  
4. Evaluate potential predictive / prognostic biomarker candidates related to the drug and / or 
the cancer (such as the CMS, immune infiltrating populations, systemic cytokine profiles) 
a. CMS wi ll be assessed using a 75 gene FFPE based assay using t he Nanostring 
technology in a CLIA -certified laboratory at MD Anderson .  
i. Current discovery of 74 samples run in 18 batches with random duplicate samples to assess technical validity demonstrate accuracies compared to 
gold standard gene expression by Affymetrix hybridization: 
1. A 75 gene model had 4 group CMS accuracy of 87.1% with very high accuracies (>90%) in CMS1 and CMS2 groups which were over-represented in this small cohort 
2. The CMS4 versus other subgroups demonstrated accuracy of 90.6%  
3. The Nanostring technology on FF PE has been successfully applied 
to breast cancer
67 and lymphoma68 cohorts 
4. The Nanostring codesets utilized for the CMS classification are now being assessed for technical  validity in MDA’s CLIA  molecular 
pathology laboratory  
 
b. Immune infiltrating populations will be analyzed by immunohistoch emistry (IHC), 
and Multiplex IF analyses. 
1. IHC markers will include, but are not limited to, PD -L1, CD3, 
Foxp3, CD25, CD8, CD68, CD56, CD20, CD45RO and granzyme 
B. We may also include PD -L2, B7- H3, B7 -x/H4, galectin 9, 
HVEM and CD48 to measure in tumors and PD-1, 2B4, LAG -3, 
Tim-3 and BTLA in TILs. These studies will be conducted at TMP -
IL. 
2. Multiplex IF Analysis. Up to 10 immune markers, 2 panels may be 
utilized. Currently, there are 2 Vectra panels optimized: Panel#1, 
CD3, CD8, CD68, PD -L1, PD -1 pan-cytoker atin and DAPI; Panel 
#2, CD20, CD45RO, FOXP3, Granzyme B, CD57, pan-cytokeratin 
and DAPI.  A third myeloid panel will be developed. For multiplex 
IF analysis, we will use the Opal chemistry and multispectral 
microscopy Vectra system (Perkin -Elmer) which in cludes the 
Nuance software; analysis will be performed using the InForm software. Additional markers will be selected according the results of the gene expression analysis and may include other 
Proprietary of MD Anderson Cancer Center
  91/106 
  immunotherapy targets (e.g., OX -40, Vista, GITR, TIM -3, LAG -3, 
NKp46/CD16, etc.) and proliferation markers (e.g., Ki67).  
3. RNAscope.  TGF -β and other additional markers may be analyzed 
by RNA scope.  
c. Immune infiltrating populations and systemic cytokine profiles 
i. Blood collections and biopsies prior to week 8 treatment will be collected for 
immune studies under the supervision of the Translational Molecular Pathology Immunoprofiling Lab (TMP -IL) at MD Anderson. 
ii. In tumor tissue, IHC studies will be performed to evaluate CD3
+, CD4+ and 
CD8+ T cells, T reg, NK cells, macrophage [M1/2 profile] infiltrating populations. 
Fresh tissue will be available for flow cytometry analysis on larger tumor samples only. We will assess the proportion of MDSC, macrophage, DC and NK cell subsets within the Live CD45+ cells in pan el 3. The expression of checkpoint 
ligands will be explored using panel 4. Live cells will be sub- gated as CD45 -
negative to exclude immune cells. EPCAM will be used as a marker of tumor cells and CD90 as a fibroblast marker. The expression of CD80, CD86, G ITR-
L, ICOS -L, MIC A/B, B7 -H3, B7 -H4, CD73, PD -L2, OX40L and other relevant 
immune cells will be assessed.  
iii. In peripheral blood, evaluation by circulating immune populations will include, but not be limited to, CD4
+, CD8+, NK, T reg, monocytes and neutr ophils 
as outlined by the Schedules of Assessments ( Tables  1-3). High order flow 
cytometry panels will be designed. The panels will focus on 1) delineation of major immune cell types (T cells, B cells, NK cells, DC), 2) determ ination of T 
cell differentiation status and limited functionality (
IFNγ, TNFα , GB ) and 3) 
defining the expression level of costimulatory and coinhibitory molecules on T cells. The proposed studies will be conducted retrospectively on cryopreserved PBMCs.  
iv. Serum  Cytokine Analyses.  Cytokines (IFN -γ, IL -1α, IL -2, IL -4, IL -5, IL -8, 
IL-10, IL -12p70, IL -13, and TNF -α) will be measured in the serum using the 
Meso Scale Discovery Platform (Rockville, MD). This technology allows for the detection of up to 40 analytes per well and uses a very low sample volume. This method has a sensitivity up to 1000 fold higher than traditional ELISA assays with a large linear range of 3 -4 logs. The instrument performs immunoassays 
utilizing electrochemiluminescense to detect the signal in a 96 well plate format. This technology can be utilized for either single agent detection or in multiplex format. A wide menu of validated single or multiplex kits for the detection of 1 to 40 analytes are available from the manufacturer and can be customized.  
d. Mutational profiling  
Proprietary of MD Anderson Cancer Center
  92/106 
  i. KRAS, NRAS and BRAF will be assessed via next generation sequencing 
in a panel of 409 genes that sequences known hotspot s to a coverage of at 
least x250 coverage depth performed in the Molecular Diagnostic 
Laboratory (MDL) at MD Anderson. The lab is CAP accredited and CLIA 
certified to perform high complexity molecular testing for clinical purposes.  
ii. Tumor DNA analysis for KRAS, NRAS and BRAF performed in another CLIA ce rtified molecular diagnostics laboratory do not need to be tested 
again  
iii. TGFβ signaling pathway mutations will also be assessed via this panel which will include , but not limited to, TGFβR2, ACVR2A, SMAD2 and 
SMAD4.  
iv. RNA- seq and WES. This analysis will be performed using fresh frozen 
tissue specimens from CNB at MD Anderson Sequencing Facilities.  
v. Optionally, using plasma specimens, genotyping analysis of circulating free DNA (cfDNA), circulating tumor cells (CTCs), and exosome (exo) -DNA 
may be performed  to mo nitor tumor response and progression.  
5.   Microbiome analyses of buccal and fecal biospecimens 
i. Buccal and fecal specimens may be collected at defined time points for microbiome studies. Buccal swab (buccal smear or cheek swab) will be collected firmly ru bbing the entire inner surface of both cheeks for 10 sec 
each side using a sterile polyester swab using standard SOPs.  Stools for enteric microbiome analysis will be collected using the OMNIgene kit (DNA Genotek, Ottawa, Ontario, Canada). The collection w ill allow 
obtaining high quality DNA suitable for microbiome profiling and sequencing. 
ii. Analysis: Bacterial identification and classification is achieved by profiling the 16S rRNA gene, which is present in all bacteria but has sufficient sequence level diversity for classification purposes. 16S deep sequencing is cost-effective and technically and computationally robust, and can be 
utilized as a primary assay to initially characterize fecal samples. Briefly, the bacterial 16S rRNA V3 -V4 region from each samp le will be amplified 
and amplicons sequenced using a MiSeq 2x250 bps protocol. An internal pipeline will be utilized for read processing and analysis. Operational taxonomic unit (OTU) classification will be achieved by mapping the UPARSE OTU table to an op timized version of the SILVA database. 
Abundances will be recovered by mapping the de -multiplexed reads to the 
UPARSE OTUs and a custom script will construct an OTU table from the output files generated in the previous two steps. This OTU table will be use d 
to calculate diversity, 2- dimensional visualization, and taxonomic 
summaries.  
Proprietary of MD Anderson Cancer Center
  93/106 
   
Details of time points and sampling are provided in the Schedules of Assessments ( Tables  1-3).  
All proposed biomarker analyses are exploratory and dependent on the quality and availability of 
sufficient materials. The panel of biomarkers might be adjusted based on results from ongoing research related to anti -PD-1 / PD -L1 therapies and / or safety, therefore, each subject will also be 
asked whether any remaining tumor tissue and blood- derived samples can be stored at a central 
repository (until such time as these samples cannot support any further analysis) and can be used for future exploratory research on the drug and / or disease- related aspects. A subject’s consent to 
the use of any remaining samples for such future exploratory research shall be optional and shall not affect the subject’s participation in the current trial.  
6.4.5.1  Target -related Biomarkers  
Blood will be collected to analyze PD -L1 targe t occupancy, TGFβ 1, 2, 3 concentrations, and 
circulating cytokine levels according to the Schedule of Assessments ( Tables  1-3).  
6.4.5.2  Immunomonitoring 
As biomarker research is constantly evolving, the selection of markers with the highest specificity 
and relevance to treatment effect may change.  
Leukocyte subpopulations and immune activation status will be assessed by flow cytometry (fluorescence- activated cell sorter [FACS]) on PBMC from heparinized blood samples (10 mL, 
tubes) dr awn at the time points outlined in the Schedule of Assessments ( Tables  1-3). 
Soluble factors (for example, cytokines profile, soluble PD -1, and soluble PD -L1) will be assessed 
on blood (plasma / serum) samples collected as outlined in the Schedule of Assessments ( Tables  
1-3).  
Plasma will be stored at -80 degrees and sent for immunoprofiling for interleukin (IL) IL -1α, IL-
1β, IL-2, IL-5, IL -6, IL -8, IL-13, TNF -α, MCP, MIP -1β, G-CSF, GM -CSF, IFN -γ via a cytokine 
assay .  
6.4.5.3  Predictive and Prognostic Biomarkers  
It is important to identify biomarkers that help to predict and / or evaluate the efficacy of the therapy, in order to achieve the optimal benefit from targeted therapies. No thoroughly validated biomarkers are available to date for anti -PD-1 / PD -L1 and anti -TGFβ therapies; therefore, this 
trial plans to evaluate biomarkers from pre -treatment and post -treatment tumor biopsies of primary 
tissue and blood samples that might be predictive of therapy outcome for all indications. Of note, availability of a tumor sample will be a prerequisite for all subjects.  
The following requirements apply to the tissue samples collected during the trial: 
Tissue collection : Endoscopic biopsies, core needle biopsies, excisional biopsies and surgical 
specimens are acceptable. Fine needle aspiration biopsies are not acceptable.  
Proprietary of MD Anderson Cancer Center
  94/106 
  Additionally, a mandatory on- treatment  biopsy will be performed in cohort A -C prior to cycle 2, 
day 1 of M7824 administration. A mandatory on- treatment biopsy pri or to cycle 1, day 11 and 
cycle 2, day 1 for cohort B will also be performed.  Resected tissue from metastatic resection will 
serve as the baseline, pretreatment specimen for Cohort D.  
Microbiome sample collection : Collection of stool samples for microbiome analyses can be done 
using OMNIgene -Gut kits. OMNIgene -Gut is an all- in-one system for easy self -collections and 
stabilization of microbial DNA from feces. It allows easily self -collection at home. Sam ples are 
rapidly homogenized and stabilized at the point -of-collection and shipped to the laboratory for 
aliquoting and freezing at - 80C prior DNA extraction. This kit allows the collection of high-quality 
DNA suitable for 16 rRNA microbiome profiling, sequencing and other assays. Buccal swab 
(buccal smear or cheek swab) will be collected firmly rubbing the entire inner surface of both cheeks for 10 sec each cheek side using a sterile polyester swab and storing in Eppendorf tube at -
80°C until DNA extractio n and analyses.  Tissue processing : The cancer tissues should be fixed 
in 10% neutral buffered formalin (NBF), paraffin- embedded and routinely processed for 
histological evaluation. Formalin substitutes are not suited as fixative.  
Tissue storage: Fresh tum or tissue obtained from subjects for the evaluation of efficacy should be 
stored in defined cryopreservation medium containing 10% dimethyl sulfoxide [CryoStor® CS10].  
Provision of samples : 1. priority: tumor -containing formalin fixed, paraffin embedded (F FPE) 
tissue block; 2. Priority : if the tumor containing FFPE tissue block cannot be provided in total, 
sections from this block should be provided which are freshly cut, 4 μm thick and mounted on positively -charged microscope slides. SuperFrost Plus glass slides are recommended. Preferably, 
25 slides should be provided; if not possible a minimum of 10 slides is required. Tumor tissues suitable for biomarker analysis are required. Suitable means that the central laboratory can confirm that the tissue is eval uable (enough viable tumor cells are present).  
Sample storage : At the central laboratory the FFPE tissue blocks shall be stored at room 
temperature and the  fresh -frozen  tumor slides shall be frozen in sealed containers at -20°C. 
A panel of putative marker s including molecular, soluble and cellular markers will be analyzed at 
baseline from archived tumor tissue (or fresh tumor biopsy, preferred when available), and from serum / plasma samples/microbiome  to investigate a possible correlation between clinical  efficacy 
and analyzed markers. 
The following assessment will be considered:  
• CMS classification based on FFPE based RNA expression.  
• Level of PD -L1 expression in fresh biopsy by IHC staining. Of note, further techniques to 
evaluate the expression of PD -L1 and / or marker candidates impacting the targeting or 
contributing to improve its expression may be also investigated if needed. 
• Level of circulating TGFβ. 
• Frequency and localization of tumor -infiltrated leukocytes (for example, CD3, CD8, CD4 
T-cells, Treg , NK cells, macrophage [M1/2 profile]) by IHC. 
Proprietary of MD Anderson Cancer Center
  95/106 
  • If quantity of tissue permits, genomic characterization of TGFβ signaling components (for 
example, SMAD4) 
• Further exploratory markers related to the MoA) of the drug such as soluble PD -L1 sera 
level, intratumo ral cytokine profile, and auto-antigen proteomic arrays may be explored. 
• Further cellular and / or molecular markers specific to the cancer may be also investigated according to the indication. 
• Microbiome sequencing analyses of buccal and fecal samples wil l be conducted. 
7 Statistics  
7.1 Sample Size Calculations  
7.1.1 Cohort A -C 
7.1.2 The total sample size of this cohort is 15 patients.  With this 
sample size, the half- width of the 95% confidence interval for 
the estimated response rate will be at most 0.253.  Cohort B  
For this cohort, the Simon’s Optimum two -stage design will be implemented. A historical response 
rate of 5% and a target response rate of 25% are assumed under the null and the alternative hypotheses, respectively. In the first stage, we will enroll 15 patients; if 1 or fewer achieves a best 
response of CR/PR, we will stop enrolling patients. Otherwise, we will continue to enroll all 29 patients and the treatment is deemed as promising if there are 4 or more responders out of these 29 
patients. The design has a type I error rate of 0.042, a 90% power and a probability of early termination of 82.9% under the null hypothesis. P atient enrollment will be temporarily suspended 
when the enrollment for the first stage patients has been completed yet not enough responders have been observed to trigger the start of second stage. 
7.1.3 Cohort D  
The total sample size of this cohort is 15 patients. With this sample size, the half -width of the 95% 
confidence interval for the estimated response rate will be at most 0.253. 
 
7.2 Randomization 
Not applicable. 
Proprietary of MD Anderson Cancer Center
  96/106 
  7.3 Endpoints 
7.3.1 Primary Endpoints 
The primary endpoints are objective  response (i.e. CR+PR) according to i RECIST 1.1  criteria  for 
cohorts A- C and  B, and clearance of ctDNA for cohort D.  
 
7.3.2 Secondary Endpoints  
The secondary endpoints to this study are: 
• PFS according to i RECIST 1.1  criteria.  
• DFS (cohort D) 
• OS  
• Number, severity, and duration of treatment related AEs according to NCI- CTCAE v4.03 
7.3.3 Exploratory Endpoints  
The exploratory endpoints for this study are: 
• Changes in intratumoral immune populations, gene expression and proteomic profiles pre 
and post-treatment with M7824 where paired biopsies are available  
• Changes in circulating immune cell populations and cytokine profiles pre and post -
treatment with M7824 
• Circulating levels of TGF -β collected from serial plasma samples.  
7.4 Analysis sets 
The following analysis sets will be defined: 
Safety  Analysis Set : All subjects who receive at least 1 dose of trial treatment.  
7.5 Description of Statistical Analyses  
7.5.1 General Considerations  
All data recorded during the study will be presented in individual data listings performed on the 
Safety Analysis Set. All  data will be evaluated as observed, and no imputation method for missing 
values will be used. All data will be presented in a descriptive manner. Each cohort will be analyzed separately, and no multiplicity adjustment across cohorts will be performed. 
Descriptive statistics will be used to summarize the trial results, that is, statistics for continuous 
variables may include means, medians, ranges, and appropriate measures of variability. 
Categorical variables will be summarized by counts and percentages. The uncertainty of estimates 
will be assessed by confidence intervals. Unless otherwise specified, the calculation of proportions 
Proprietary of MD Anderson Cancer Center
  97/106 
  will be based on the sample size of the analysis set of interest. Counts of missing observations will 
be included in the denomi nator and presented as a separate category.  
All other statistical analyses will be performed using SAS® Version 9.1.3 or higher, or R, Version 2.10.1 or higher. 
7.5.2 Analysis of Primary Endpoint  
7.5.2.1  Response Rate  
7.5.2.1.1  Cohorts A -C and B 
Patient  response will be determined using i RECIST 1.1. Unconfirmed responses will not be used 
in the final analysis. O RR is defined by the number of (PR + CR)/ (total number of treated 
patients) in the safety analysis set . For all cohorts, we will estimate the response rate along with 
the two -sided exact 95% confidence interval. Also for Cohort B, if the trial continues to the full 
enrollment of 29 patients, we will declare M7824 with radiation promising and worthy of further 
investigation if there are at least 4 responders out of these 29 patients.  
7.5.2.1.2  Cohort D  
Identification of somatic mutations in the blood will be confirmed by sequencing of the resected tumor using a CLIA -certified next -generation sequencing panel at MD Anderson.  Clearance  of 
ctDNA will be characterized by the disappearance of all somatic mutations identified in the blood, as well as no appearance of any additional new somatic mutations following 6 doses of M7824.  For this cohort, we will estimate the response rate as the percentage of patients whose ctDNA status converts from “positive” to “negative” after twelve weeks of therapy with M7824 relative to the total number of patients treated.  
7.5.3 Analysis of  Endpoints  
7.5.3.1  Secondary Endpoints  
The secondary endpoints of PFS (cohorts A -C and  B) and DFS (cohort D) according to i RECIST 
1.1 and OS time will be presented using the Kaplan- Meier method.  PFS will be measured in 
months from the date of first administration of M7824 to the date of documented progression by 
RECIST 1.1 or death by any cause, whichever is earlier. For Cohort D , DFS will be measured in 
months from the date of documented recurrence or development of distant metastasis by i RECIST 
1.1 criteria.  Median PFS and DFS and 95% confidence intervals will be estimated using the  
Kaplan -Meier method. 
OS will be measured in months from the date of first administration of M7824 to the date of death 
by any cause. Median OS with 95% confidence interval will be estimated using the Kaplan -Meier 
method. Severity of AEs will be graded usi ng the NCI-CTCAE v4.03 toxicity grading scale. 
Safety will be assessed by descriptive statistics and summarized in tabular format. This data will be separated based on organ class, immune-relation, severity and relation to M7824.  
Proprietary of MD Anderson Cancer Center
  98/106 
  Adverse events (serious and  non- serious)  will be considered treatment emergent adverse events 
when emerging during the  on- treatment  period defi ned as the time from f irst trial drug  
administration  to  the  last  drug  administration date + 30 days or the earliest date of subsequent 
anticancer dr ug therapy minus 1 day, whichever occurs first, unless otherwise stated. All 
premature terminations will be summarized by  primary reason for treatment withdrawal.   
7.5.3.2  Exploratory Endpoints  
Summary statistics will be tabulated for microsatellite instability , CMS1, CIMP, KRAS and BRAF 
status. Paired t -test or Wilcoxon signed rank test will be used to assess the changes in biomarkers 
pre- and post -treatment. The differences in biomarker levels between responders and non -
responders will be assessed using X2 or Fis her’s exact test as appropriate. Similar analysis will be 
used to assess the correlation between biomarker mutation statuses .  
Statistical analyses will be conducted by MDACC statisticians. Tabulations will be produced for 
appropriate demographic, baseline, efficacy and safety parameters.  For categorical variables, 
summary tabulations of the number and percentage of subjects within each category (with a category for missing data) of the parameter will be presented, as well as two -sided  95% confidence 
intervals, unless otherwise stated. For continuous variables, the number of subjects, mean, median, standard deviation (SD), minimum, and maximum values will be presented.  Time -to-event data 
will be summarized using Kaplan -Meier methodology using 25th, 50th (median), and 75th 
percentiles with associated 2 -sided 95% confidence intervals, as well as percentage of censored 
observations. 
7.5.3.3  Adverse Events 
Severity of AEs will be graded using the NCI-CTCAE v4.03 toxicity grading scale. Safety will 
be assessed by descriptive statistics and summarized in tabular format. This data will be separated based on organ class, immune-relation, severity and relation to M7824.  
Adverse events (serious and non- serious)  will be considered treatment emergent adverse events 
when emerging in the on- treatment  period defined as the time from the first  trial  drug  
administration  to  the  last  drug  administration date + 30 days or the earliest date of subsequent 
anticancer drug therapy minus 1 day, whichever occurs first, unless otherwise stated. All 
premature terminations will be summarized by  primary reason for treatment withdrawal.  
7.5.3.4  Laboratory Variables  
Laboratory results will be classified by grade according to NCI -CTCAE v4.03. The worst  on-trial 
grades after the first trial treatment will be summarized.  Shifts  in toxicity  grading from  first 
treatment to highest grade  will be displayed. Results  for variables  that are not part of NCI-CTCAE 
will be presented as within or above normal limits. Only subjects with post -Baseline laboratory 
values will be included in these analyses.  
Proprietary of MD Anderson Cancer Center
  99/106 
  7.5.3.5  Physical Examination, Including Vital Signs and 12 -Lead 
Electrocardiogram  
Vital signs (body temperature,  respiratory  rate, heart  rate, and blood pressure),  eye signs and 
symptoms  based  on System  Organ  Class of “eye disorders”,  and 12-lead EKG recorded according 
to the Schedules of Assessments (refer to Tables  1-3) will be  presented.  
7.6  Interim safety monitoring  
For each cohort, we will implement Bayesian toxicity monitoring69 such that we will all stop 
patient enrollment into a cohort if there is a high probability that the AE rate of M78 24 is greater 
than 20%. For each cohort separately, we will apply the toxicity monitoring rule in cohort size of 
5, starting from the 5th patient. For cohort  A-C, the toxicity stopping rule to be applied is as 
follows: Stop patient enrollment in a cohort if Prob(p>0.20 |data ) > .75, where p denotes the probability of toxicity.  
 
Assuming a beta(.4, 1.6) priori for p, the above decision criterion implies that we will stop cohort 
A or cohort C according to table 8 below.  
Table 8: Toxicity stopping boundaries for Cohort A -C and D  
Number of evaluable 
patients  Number of patients with 
toxicities is at least  
5 2 
10 4 
15 5 
The operating characteristics for toxicity monitoring in cohort A- C are illustrated in Table 9.   
Table 9: Operating Characteristics for Toxicity Monitoring in Cohort A -C and D  
True toxicity rate  Prob (stop early)  Average Sample Size  
0.10 0.086  14.2 
0.20 0.284  12.3 
0.30 0.532  10.0 
0.40 0.750  8.0 
0.50 0.894  6.5 
 
Similarly for cohort B, the toxicity stopping rule to be applied is as follows: Stop patient enrollment 
if Prob(p>0.20 |data ) > .85, where p denotes the probability of toxicity. Assuming a beta(.4, 1,6) priori for p, the above decision criterion implies that we will stop cohort B according to table 10 
below.   
Proprietary of MD Anderson Cancer Center
  100/106 
  Table 10: Toxicity stopping boundaries for Cohort B 
Number of evaluable 
patients  Number of patients with 
toxicities is at least  
5 3 
10 4 
15 5 
20 7 
25 8 
29 9 
The operating characteristics for toxicity monitoring in cohort B are illustrated in Table 11.  
Table 11: Operating Characteristics for Toxicity Monitoring in Cohort B 
True toxicity rate  Prob (stop early)  Average Sample Size  
0.10 0.25 28.5 
0.20 0.238  24.9 
0.30 0.623  18.4 
0.40 0.900  12.3 
0.50 0.989  8.7 
The stopping boundaries and the operating characteristics for cohorts A -C and  B were generated 
using Shiny application for Bayesian toxicity monitoring ( http://qctrlshiny/postprobtoxicity ). 
AEs of 3 or greater and deemed related to M7824 (section  6.4.1.1.1) will count towards toxic ity 
calculations with respect to interim safety monitoring. AEs of 3 or greater deemed unrelated to 
M7824 are not included towards safety decision making. Th ese include  AEs attributable to disease 
progression (section 6.4.1.1.2) and abnormal laboratory or investigational values that are 
asymptomatic or do not result in treatment discontinuation (section 6.4.1.1.1). 
The time period that grade 3 AEs attributable to M7824 are counted towards  interim safety 
monitoring decisions is  defined from their onset  to 90 days after the last dose of study drug (section 
6.4.1.1.3).  
Any grade 5 event on- study will require suspension of the study pending review of the safety 
data regarding the death. The Investigator is responsible for completing an efficacy/safety sum mary report, and submitting 
it to the IND Office Medical Affairs and Safety Group, for review and approval.  This should be 
submitted after the first 5 evaluable patients per cohort, complete 1 cycle of study treatment, and 
every 5 evaluable patients per cohort, thereafter. On every report submission, the information 
from previous reported patients will need to be updated. 
Proprietary of MD Anderson Cancer Center
  101/106 
  A copy of the cohort summary should be placed in the Investigator’s Regulatory Binder under 
“IND Office correspondence”.  
8 References Cited in the Text 
1. Donkor MK, Sarkar A, Li MO. Tgf- β1 produced by activated CD4(+) T Cells 
Antagonizes T Cell Surveillance of Tumor Development. Oncoimmunology. 2012;1(2):162-171. 
2. Topalian SL, Drake CG, Pardoll DM. Targeting the PD- 1/B7 -H1(PD-L1) pathway to 
activate anti -tumor immunity. Current Opinion in Immunology. 2012;24(2):207-212. 
3. Song S, Yuan P, Wu H, et al. Dendritic cells with an increased PD -L1 by TGF- β induce 
T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. International immunopharmacology. 2014;20(1):117-123. 
4. Weber JS, Kudchadkar RR, Gibney GT, et al. Updated survival, toxicity, and biomarkers 
of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI). Journal of Clinical Oncology. 2014;32(15_suppl):3009-3009. 
5. Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (Fresolimumab): A 
human anti-transforming growth factor- beta (TGFβ) monoclonal antibody in patients 
with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9(3).  
6. Van Aarsen LAK, Leone DR, Ho S, et al. Antibody-mediated blockade of integrin alpha 
v beta 6 inhibits tumor progression in vivo by a transforming growth factor- beta-
regulated mechanism. Cancer research. 2008;68(2):561-570. 
7. Dolan DE, Gupta S. PD-1 pathway inhibitors: Changing the landscape of cancer 
immunotherapy. Cancer Control. 2014;21(3):231-237. 
8. Sznol M, Longo DL. Release the Hounds! Activating the T- Cell Response to Cancer. 
New England Journal of Medicine. 2015;372(4):374-375. 
9. Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF- beta in cancer 
patients. Curr Pharm Biotechnol. 2011;12(12):2176-2189. 
10. Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single- dose study of 
fresolimumab, an anti- TGF -β antibody, in treatment -resistant primary focal segmental 
glomerulosclerosis. Kidney International. 2011;79(11):1236-1243. 
11. Cohn A, Lahn MM, Williams KE, et al. A phase I dose-escalation study to a predefined 
dose of a transforming growth factor- β1 monoclonal antibody (TβM1) in patients with 
metastatic cancer. International journal of oncology. 2014;45(6):2221-2231. 
12. Goudie DR, D'Alessandro M, Merriman B, et al. Multiple self -healing squamous 
epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nature Genetics. 2011;43(4):365-369. 
Proprietary of MD Anderson Cancer Center
  102/106 
  13. Oettle H, Hilbig A, Seufferlein T, et al. Phase I/II study with trabedersen (AP 12009) 
monotherapy for the treatment of patients with advanced pancreatic cancer, malignant 
melanoma, and colorectal carcinoma. Journal of Clini cal Oncology. 
2011;29(15_suppl):2513-2513. 
14. Leask A, Abraham DJ. TGF -beta signaling and the fibrotic response. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology. 2004;18(7):816-827. 
15. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or 
Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015;373(1):23-34. 
16. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced 
Melanoma. The New England journal of medicine. 2015;372(26):2521-2532. 
17. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced 
Nonsquamous Non- Small -Cell Lung Cancer. The New England journal of medicine. 
2015;373(17):1627-1639. 
18. Herbst  RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously 
treated, PD -L1-positive, advanced non- small -cell lung cancer (KEYNOTE -010): a 
randomised controlled trial. Lancet (London, England). 2016;387(10027):1540-1550. 
19. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the Treatment of Non–Small -Cell 
Lung Cancer. New England Journal of Medicine. 2015;372(21):2018-2028. 
20. Le DT, Uram JN, Wang H, et al. Programmed death -1 blockade in mismatch repair 
deficient colorectal cancer. Journal of Clinical Oncology. 2016;34(15_suppl):103-103. 
21. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and 
Hyde of c ancer. Nature reviews Cancer. 2006;6(7):506-520. 
22. Menter DG, Tucker SC, Kopetz S, et al. Platelets and cancer: A casual or causal 
relationship: Revisited. Cancer and Metastasis Reviews. 2014;33(1):231-269. 
23. Rybinski B, Franco- Barraza J, Cukierman E. The wound healing, chronic fibrosis, and 
cancer progression triad. Physiol Genomics. 2014;46(7):223-244. 
24. Cantelli G, Crosas-Molist E, Georgouli M, Sanz- Moreno V. TGFΒ -induced transcription 
in cancer. Seminars in cancer biology. 2017;42:60-69. 
25. Kallu ri R, Weinberg Ra. Review series The basics of epithelial -mesenchymal transition. 
Journal of Clinical Investigation. 2009;119(6):1420-1428. 
26. Gabrilovich DI, Ostrand -R S, Bronte V. Coordinated regulation of myeloid cells by 
tumours. Nature reviews Immuno logy. 2012;12(4):253-268. 
Proprietary of MD Anderson Cancer Center
  103/106 
  27. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype 
by TGF- beta: "N1" versus "N2" TAN. Cancer cell. 2009;16(3):183-194. 
28. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived 
Suppressor Cells in the Tumor Microenvironment. Trends in Immunology. 
2016;37(3):208-220. 
29. Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor 
cell nomenclature and characterization standards. Nature communications. 2016;7:12150-
12150. 
30. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural 
killer cells in mice is impeded by platelets. Cancer research. 1999;59(6):1295-1300. 
31. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell- mediated elimination of tumo r cells. 
Blood. 2005;105(1):178-185. 
32. Kopp H- G, Placke T, Salih HR. Platelet -derived transforming growth factor-beta down-
regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer research. 2009;69(19):7775-7783. 
33. Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nature Publishing Group. 2016;17(1):38-53. 
34. Khan Z, Marshall JF. The role of integrins in TGFβ activation in the tumour stroma. Cell and tissue research. 2016;365(3):657-673. 
35. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and 
disease. Nature Reviews Molecular Cell Biology. 2014;15(12):786-801. 
36. Hawinkels LJaC, Paauwe M, Verspaget HW, et al. Interaction with colon cancer cells hyperactivates TGF -β signaling in cancer -associated fibroblasts. Oncogene. 
2014;33(1):97-107. 
37. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in 
the classification of malignant tumours. The Journal of pathology. 2014;232(2):199-209. 
38. Le DT, Uram JN, Wang H, et al. PD -1 Blockade in Tumors with Mismatch- Repair 
Deficiency. N Engl J Med. 2015;372(26):2509-2520. 
39. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mism atch Repair -Deficient/Microsatellite Instability -High 
Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779. 
40. O'Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 
checkpoint inhibition. Cancer treatment reviews. 2017;52:71 -81. 
Proprietary of MD Anderson Cancer Center
  104/106 
  41. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of 
colorectal cancer. Nature Medicine. 2015;21(11):1350-1356. 
42. Becht E, de Reyniès A, Giraldo NA, et al. Immune and Stromal Classification of 
Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research. 2016;22(16):4057-4066. 
43. Calon A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-
prognosis subtypes in colorectal cancer. Nature genetics. 2015;47(4):320-329. 
44. Calon A, Espinet E, Palomo- Ponce S, et al. Dependency of colorectal cancer on a TGF -
beta- driven program in stromal cells for metastasis initiation. Cancer Cell. 
2012;22(5):571-584. 
45. Kopetz S. M7824 (MSB0011359C), a bif unctional fusion protein targeting PD -L1 and 
TGF -β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. J 
Clin Oncol. 2018;36(4):suppl 764. 
46. Demaria S, Kawashima N, Yang AM, et al. Immune -mediated inhibition of metastases 
after treatment with local radiation and CTLA -4 blockade in a mouse model of breast 
cancer. Clin Cancer Res. 2005;11(2 Pt 1):728-734. 
47. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated 
tumors (abscopal effect) is immu ne mediated. Int J Radiat Oncol Biol Phys. 
2004;58(3):862-870. 
48. Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990-1993. 
49. Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation 
therapy. Curr Probl Cancer. 2016;40(1):10-24. 
50. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after 
radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409-
425. 
51. Nikitina EY, Gabrilovich DI. Combination of gamma -irradiation and dendritic cell 
administration induces a potent antitumor response in tumor-bearing mice: approach to 
treatment of advanced stage cancer. Int J Cancer. 2001;94(6):825-833. 
52. Deng L, Liang H, Burnette B, et al. Irradiation and anti- PD-L1 treatment synergistically 
promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-695. 
53. Rodriguez- Ruiz ME, Rodriguez I, Barbes B, et al. Brachytherapy attains abscopal effects 
when combined with immunostimulatory monoclonal antibodies. Brachytherapy. 2017;16(6):1246-1251. 
Proprietary of MD Anderson Cancer Center
  105/106 
  54. Yasuda K, Nirei T, Tsuno NH, Nagawa H, Kitayama J. Intratumoral injection of 
interleukin -2 augments the local and abscopal effects of radiotherapy in murine rectal 
cancer. Cancer Sci. 2011;102(7):1257-1263. 
55. Tauriello DVF, Palomo -Ponce S, Stork D, et al. TGFbeta drives immune evasion in 
genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538-543. 
56. Overman MJ VJ, Aloia TA, Conrad C, Chun YS, Pereir a AAL, Jiang ZQ, Crosby S, Wei 
S, Raghav KPS, Morris VK, Tan M, Maslan A, Talasaz AA, Mortimer S, Kopetz S. Circulating tumor DNA (ctDNA) utilizing a high -sensitivity panel to detect minimal 
residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol. 2017:(suppl; abstr 3522). 
57. Diehn M AH, Lee JJ, Klassen S, Palma JF, Hinzman B, Lovejoy AF, Newman AM, Yao L, Yaung S, Balasubramanyam A,  Rohr UP, Rosenthal A, Kube R, Steinmüller T, Marusch F, Mantke R, Heise M, Pross M. Early prediction of clinical outcomes in resected stage II an d III colorectal cancer (CRC) through deep sequencing of circulating 
tumor DNA (ctDNA). J Clin Oncol. 2017;35:(suppl; abstr 3591). 
58. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra392. 
59. Le DT, Durham JN, Smith KN, et al. Mismatch -repair deficiency predicts response of 
solid tumors to PD-1 blockade. Science (New York, NY). 2017;6733(June):1-11. 
60. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA 
mismatch repair -deficient or microsatellite instability -high colorectal cancer (CheckMate 
142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191. 
61. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor- infiltrating lymphocytes are a marker 
for microsatellite instability in colorectal carcinoma. Cancer. 2001;91(12):2417-2422. 
62. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological 
ident ification of colon cancer with microsatellite instability. The American journal of 
pathology. 2001;158(2):527-535. 
63. Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell  apoptosis in colorectal carcinomas 
with microsatellite instability. The American journal of pathology. 1999;154(6):1805-1813. 
64. Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial -to-mesenchymal 
transition. International journal of cancer. 2014;134(3):552-562. 
Proprietary of MD Anderson Cancer Center
  106/106 
  65. De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by 
a molecularly distinct subtype and develops from serrated precursor lesions. Nature 
medicine. 2013;19(5):614-618. 
66. Chen W, Ten Dijke P. Immunoregulation by members of the TGFβ superfamily. Nature 
reviews Immunology. 2016;16(12):723-740. 
67. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(22):2783-2790. 
68. Veldman -Jones MH, Lai Z, Wappett M, et al. Reproducible, quantitative, and flexible 
molecular subtyping of clinical DLBCL samples using the NanoString nCounter system. Clinical Cancer Research. 2015;21(10):2367-2378. 
69. Thall PF, Simon RM, Estey EH. New s tatistical strategy for monitoring safety and 
efficacy in single- arm clinical trials. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 1996;14(1):296-303. 
 
Proprietary of MD Anderson Cancer Center